The morphological, biological and genetic characteristics of low nuclear grade breast carcinoma and their putative precursor lesions by Abdel-Fatah, Tarek Mohamed A.
Abdel-Fatah, Tarek Mohamed A. (2010) The 
morphological, biological and genetic characteristics of 
low nuclear grade breast carcinoma and their putative 
precursor lesions. PhD thesis, University of Nottingham. 
Access from the University of Nottingham repository: 
http://eprints.nottingham.ac.uk/30458/1/522996.pdf
Copyright and reuse: 
The Nottingham ePrints service makes this work by researchers of the University of 
Nottingham available open access under the following conditions.
· Copyright and all moral rights to the version of the paper presented here belong to 
the individual author(s) and/or other copyright owners.
· To the extent reasonable and practicable the material made available in Nottingham 
ePrints has been checked for eligibility before being made available.
· Copies of full items can be used for personal research or study, educational, or not-
for-profit purposes without prior permission or charge provided that the authors, title 
and full bibliographic details are credited, a hyperlink and/or URL is given for the 
original metadata page and the content is not changed in any way.
· Quotations or similar reproductions must be sufficiently acknowledged.
Please see our full end user licence at: 
http://eprints.nottingham.ac.uk/end_user_agreement.pdf 
A note on versions: 
The version presented here may differ from the published version or from the version of 
record. If you wish to cite this item you are advised to consult the publisher’s version. Please 
see the repository url above for details on accessing the published version and note that 
access may require a subscription.
For more information, please contact eprints@nottingham.ac.uk
The University of 
Nottingham 
THE MORPHOLOGICAL, BIOLOGICAL AND GENETIC 
CHARACTERISTICS OF LOW NUCLEAR GRADE BREAST 
CARCINOMA AND THEIR PUTATIVE PRECURSOR LESIONS 
MEDICAL LIBRARY 
QUEENS MEDICAL CENTRE 
TAREK MOHAMED A. ABDEL-FATAH, MD 
Thesis submitted to the University of Nottingham for 
the degree of Doctor of Philosophy 
October 2009 
IMAGING SERVICES NORTH 
Boston Spa, Wetherby 
West Yorkshire, LS23 7BQ 
www.bl.uk 
BEST COpy AVAILABLE. 
VARIABLE PRINT QUALITY 
"In recent times, liowever, fEgypt and' )Ira 6 Worta; wliicli gave to Science I6n-Sina 
()J:Clicenna) I6n-CJ(uslia Ol'CleTToes) I6n-J(ayan (qe6er) 16n-J(aytliam OlC-J(azen) ana 
otliers, fiave fiaa no prizes in science or medicine. I sincereCy liope tliat tliis first one wi£[ 
inspire tlie young generations of aeClefoping countries witfz k,nowfecfge tfiat it is possi6fe to 





There is evidence to suggest that some special types of breast cancer including tubular and 
lobular carcinoma and their putative precursor lesions including atypical ductal hypetplasia 
(ADH), low grade ductal carcinoma in-situ (DOS) and lobular neoplasia (LN) may consist 
in a family of interrelated lesions. Recently, an attention has been focused on the columnar 
cell lesion as an early non-obligate precursor lesion of breast cancer. 
In this study we examined this hypothesis by identifying the morphological and biological 
characteristics of these lesions. In addition, we used high resolution array comparative 
genomic hybridization to identify the molecular genetic profiles of invasive lobular and 
tubular carcinoma and their matched coexisting precursor lesions to investigate their 
relationship and to provide insight into some of the earliest events leading to invasive breast 
cancer. Moreover, by validating aspects of our immunohistochemical and in situ 
hybridization expression data with high throughput tissue microarrays, we identified 
potential oncogenes and tumour suppressor genes that could potentially drive the 
progression of BC and have clinicopathological implications on BC Subsequently, 
di.'lgnostic, predictive and genetic classifications of breast cancer and their putative 
precursor lesions were developed 
In sUIIl1l1<ll}', our results suggest that 1) Tubular and lobular breast carcinoma arise as 
members of a low nuclear grade breast neoplasia (LNGBN) family, 2) CCLs are early 
non-obligate precursor components of the LNGBN family, 3) The common cell of origin 
of the LNGBN family may be the oestrogen receptor-alpha (ER ex) positive luminal 
restricted progenitor cell (ER +/MUC1 + cells) of the terminal duct lobular unit that might 
acquire stochastic genetic and epigenetic changes that eventually lead to activation of the 
luminal "A" pathway, 4) C ~ l i n n D1 and MDM4 are oncogenes that potentially lead to 
l11 
activation of the lwninal pathway and progression of the LNGBN family, 5) An alteration 
of E-cadherin (CDHl) appears to be a second.-uy event resulting in the characteristic 
morphology of both in situ and invasive lobular lesions, 6) A biological grading system 
dependent on the balance between Bcll protein expression and mitotic figures could 
accurately reclassify patients with intennediately differentiated, small early stage or ER IX 
negative breast cancers into two groups of low versus high risk of death and recurrence, 
and 7) The functional status of p53 transcriptional pathways can be assessed using 
immunohistochemistry protein expression of p53 downstream! regulator genes to 
accurately discriminate between low and high grade breast carcinoma and to assist routine 
clinical decision-making. 
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Breast cancer (Bq is the third most common tlUllOur in the world, representing 9% of the 
global cancer burden, and is the second most common cause of death from cancer in 
women 1-3, Globally, there are more than 4.4 million women living with Be and annually 
there are 410,712 BGreL'lted deaths 1-3, According to American Cancer Society 2009 
estimates 1 there will be 192,370 new cases of Be diagnosed as well as 62,380 additional 
cases of in situ. In developing countries, there are 514,072 incident cases and 220,648 Be 
deaths 3, In Europe, 2006 estimates indicated 429,900 new cases of Be diagnosed and 
131,900 BGrelated deaths 4, In the UK, annually there are 37,000 new cases diagnosed >8 
and 11,000 deaths recorded each year 9, 
Be is considered as a diverse group of diseases in terms of presentation, morphology and 
molecular profile, Be taxonomy divides BCs into tlUllOurs of special types; lobular (lLq, 
tubulolobular (ILq, tubular erq, mucinous, papillary, cribrifonn (lc:q, medullary, 
adenoid cystic, metaplastic, adenosquamous and squamous and ductal carcinoma of no 
special type (lDGNS1) 10, It is now believed that the morphological difference between 
'lobular' and 'ductal' 'carcinoma' results from secondary genetic! epigenetic changes rather 
than a difference in cell of origin as the current view is that most breast cancers arise from 
the tenninal duct lobular unit (IDLUs) 11, 
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1.1 Nonnal breast tissue 
The female breasts are modified sweat glands composed of lobes and lobules interspersed 
with adipose tissue and connective tissue. The mammary gland is organized into a tree-like 
structure composed of hollow branches which are started with 6-10 large ducts and ended 
by the TDLUs 12. TDLUs have an inner "epithelial cell layer" that face the lumen and an 
outer "myoepithelial cell layer" which produces the basal lamina separating the manunary 





T&rminal ductal-lobular unit 
luminal c.lIs 
Figure 1-1: Structure of the normal breast tissue. 





1.1.1 Developmental stages of the female breast 
Intra-uterine development 
IntrrxIuaion 
During foetal development, the mammary gland epithelium is derived from the embryonic 
basal cells of the epidennis (the ectodenn) which from 28 weeks of intrauterine life, are 
rearranged into two cell layers - an inner luminal and a distinct outer basal cell layer 14. The 
outer basal and inner luminal cell layers within the mammary epithelium express well 
defined immWlophenotypes in vitro and vivo through the different stage of development of 
the breast 14. All the epithelial cells of the breast bud retain the expression of cytokeratin 19 
(CX 19), but lose ex 14 which is normally expressed in the epidennal basal cells 14. The 
specialized stromal cells together with the outer basal cell layer of foetal breast between 16 
and 23 weeks of age are strongly positive for Bc12 protein 15. From 28 weeks of intrauterine 
life, Bc12 protein is expressed by the inner luminal epithelial cell layer while; outer basal 
myoepithelial cell layer becomes generally negative 16. The vimentin is first expressed 
between 23 and 28 weeks in foetal breast and its expression is restricted to a few isolated 
suprabasal cells l4• None of the outer basal myoepithelial cells is positive for vimentin 14. 
None of the inner luminal epithelial cells is positive for CX18 or CX8. The proliferation 
index (MIB 1), oestrogen receptor-alpha (ER 0:) and progesterone receptor (PR) are almost 
absent (<I.%) in foetal breasts and their expression (if an0 restricted to the inner luminal 
epithelial cell layer 15. The stromal cells show no expression of ER 0: or PR and display 
heterogeneous expression of both MIB 1 and Bc1215• 
During infancy 
Within the infant breast, CX 14 and SMA are expressed in' the myoepithelial cells 
throughout the mammary tree from birth to 2 years. The epithelial cell layer is negative for 
both SMA and CX14. CX19 is uniformly expressed in the epithelial cell layer of infant 
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breast throughout the mammary tree. The epithelial cells show heterogeneous expression of 
ex 18 and Bel2. The proliferation rate, ER-ex and PR are very low in infant breasts until 
puberty 13-15. 
Adult breast 
At the onset of puberty and under control of oestrogen and growth hormone, the immature 
mamrnaty ghnd undergoes rapid growth and differentiation at the tip of the terminal end 
buds (TEBs) which are composed of outer cap cell layer and inner body cells (Figure 1-2) 
16. The cap cells have a phenotype that is intermediate between luminal and rnyoepitheli.-u 
cells, as indicated by low expression of markers associated with both lineages (e.g. vimentin, 
smooth muscle actin (SMA) and MUC1 16• Subsequently, the cap cell layer can differentiate 
into myoepithelial or epithelial cells 16. The TEBs are transient niche structures that 
disappear once the duct reaches the end of the fat pad 13-16. In fact, the balance between the 
proliferation and apoptosis controls the development of TEBs which are characterised by 
high expressions of MIB 1, ER, PR and Bcl2 13-16. Interestingly, in vitro and cell line culture 
studies have demonstrated that most of the proliferating cells (MIB 1 positive cells) are ER-
/PR- suggesting that the oestrogen honnone may stimuhte the proliferation of ER negative 
cells by indirect mechanisms. For instance, estrogens by binding to ER + cells might 
stimulate proliferation of the StuTOunding ER- cells through the induction of certain growth 
factors (para-crine mechanism) 17-18. 
4 
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Lumina l epithelial cells t Cap cells 
B 
i I\I'yoeplthella l cells 
Du etal' eplth e II a I c lis Alveolar epitheli a l ce lls 
Figure 1-2: The terminal end bud (TEB). 
The TEB appears at the onset of pubeny, undergoing rapid growth and differentiation. (A): the 
structure of TEB: a cap cell layer surrounds the body cells. (B): The structure of fully differentiated 
terminal duct lobular unit (IDLU) during mid pregnancy. (Adopted from Wood et al200S 16) 
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1.1.2 Heterogeneity of Tenninal Ductal Lobular Units 
(TDLUs) 
The IDLU is heterogeneous morphologically, phenotypically and functionally. 
Morphologically, the luminal epithelial cell layer and myoepithelial cells may be either 
spindle in shape, cuboidal or low colwnnar depending on their location on the branching 
structure of the breast duct system and on the hormonal or menopausal status of the tissue 
19, Functionally, there are three epithelial cell t}pes: a) the ductal cells are those that line the 
ducts of the mammary gland, b) the lobular cells are those that form secretory acinar 
structures at the end of each duct and c) alveolar cells are those that line the acinar 
structures during late pregnancy and produce milk proteins during the lactation period 16, 
The structure of normalIDLUs varies considerably as a function of the hormonal status 
and they are grouped into four histological categories on a continuum of differentiation 
towards lactation 20,21, 
Pre-menopausal TDLUs 
TDLU TYPE t (LOBt) 
IDLU t}pe 1 (lob!) is the least differentiated structure of IDLU (fEB) and is more 
numerous in the breast of post-pubertal nulliparous women 20,21, It is noteworthy that in 
contrast to the overlapping myoepithelial cells of mammary ducts, the myoepithelial cell 
layer of IDLUs is a basket-like L'1yerthat allows some of the luminal epithelial cells to be in 
direct contact with the basement membrane and the surrounding stroma. Lob 1 shows a 
relatively high proliferative rate and high expression of ER and PR 20, 21,but shows the 
lowest level of Bcl2 \4 .. 15, There is specu1'1tion that lob! is the origin of atypical ductal 
hyperplasia and ductal carcinoma in situ 20 
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TDL U TYPE 2 (LOB2) 
IDLU type 2 is composed of more nwnerous ductules per lobule and exhibit a more 
complex mOlphology20. There is some specubtion that atypicallobuL1.r hypetplasia (ALH) 
appears to arise directly within rebtivelywell differentiated type 2IDLU20. 
TDLU TYPE 3 (LOB3) 
During the mid-C)de and lSI and 2nd trimesters of pregnancy, lob 1 and lob 2 rapidly 
progress to a more differentiated IDLU; lob 3 which is composed of more nwnerous and 
smaller alveoli per lobule 20. 
TDLU TYPE 4 (LOB4) 
During the last trimester of pregnancy the alveoli become distended and are fully 
differentiated structures and persist during bctation period. After weaning, all lob 4 
structures regress reverting to lob 3 and lob 220. 
There is a progressive decrease in the percentage of proliferating cells (MIB 1 expressing 
cells) with the progressive maturation of lob 1 to lob 2, lob 3 and lob 4 20-21. The 
percentage of ER + and PR + cells is highest in lob I and progressively decreases in an 
inverse rebtionship to the degree of 10buL1.r differentiation 21. The undifferentiated lobI 
shows the lowest expression of Bc12 but the fully differentiated lob 4 exhibits the highest 
expression of Bc1215. 16, 22. In addition, the Bc12 shows a marked c}Clic variation with 




Postmenopausal TDLUs (lobI) 
After the menopause all remaining differentiated lobular structures (lob3 and lob2) regress, 
acquiring the appearance of the lob 1 of nulliparous women from which they seem 
morphologically indistinguishable 20-21, However, the proliferative activity and ER+ 
expression of lob 1 nulliparous women at menopause is at least 2-fold greater than of the 
lob 1 of parous women's breast 20-21, LobI is more common in cancerous breast 
suggesting that it may preferentially give rise to early growth alterations with pre-malignant 
potential 20-21 such as columnar cell lesions, 
Phenotypically, the mature differentiated epithelial and myoepithelial cells constitute )90% 
of the cells present in the IDLUs, A small number of small light undifferentiated electron-
lucent cells have also been recognized in the suprabasal compartment of the epithelial cell 
layer and considered as candidate cells with stem and progenitor activities 23, The fully 
differentiated myoepithelial cell exhibits many features of smooth muscle and expresses: 
myosin, smooth muscle actin (SMA), vimentin, neutral endopeptidase (m10), p63, CK.S/6 
and CX 14 23-25, The immunohistochemistry profiles of the epithelial and myoepithelial cells 
of the liDU are summarized in (Table 1-1) 17-25 
It is noteworthy that in the breast pathology, the terms "basal" and "luminal" has acquired 
different meanings for each 19, In one context, basal and luminal have become synonymous 
with breast myoepithelium and epithelial cell layer; respectively, In another context, luminal 
and basal define a specific subpopulation of "basal" cytokeratins (CXS/6 and CK.14) and 
"luminal" cytokeratins (CX 19 and CK.18) expressing cells; respectively and are perceived to 
reside in the luminal epithelial cell layer of IDLUs 23-25, Regarding breast cancer, "luminal" 
Be usually refers to ER + positive cancer 26, 
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Table 1·1: Immunohistochemistry profile of the cells lining the luminal and myoepithelial 
cell layer of terminal duct lobular unit 
Epithelial cells lining TDLUs 
MaIkeD ER+ ER· ER· Stem/ 
Differentiated Differentiated Differentiated progenitor cells Differentiated 
luminal luminal basal epithelial myoepithelial 
epithelial ceO epithelial ceO cells ceO 
ER-rx + - · +/- -
CDUJ + · · - · 
P61 + · · - · 
PgR + +/- - +/- -
Bcl2 + +/- · +/-
ESA + + + + · 
MUCl + + · -
CD24 + + + +/- · 
CKI9 + + - +/- -
CKI8 + + · +/- -
CKS/6 
- · + +/- + 
CKI4 









- - + . + 
P63 - · + +/- + 
MIBI - +/- +/- + -
9 
Oupter 1 
1.2 Stem and progenitor cell concepts 
1.2.1 Adult progenitor and stem cells 
[rtraluaion 
Adult stem cells are long-lived, generally quiescent cells that generate both new stem cells 
(self-renewal), and the different cell types of the tissue in which they exist (differentiation) 
27. The self-renewal of stem cells can be either asymmetric or symmetric. In asymmetric 
stem cell self-renewal, one of the two progeny is identical to the initial stem cell, whereas 
the other cell is a committed progenitor cell, which undergoes celluL'll" differentiation 27. The 
processes that regulate the balance between asymmetric and symmetric divisions of stem 
cells are poorly defined, but recent evidence indicates a role for p53 27·28. 
1.2.2 Mammary stem and progenitor cells 
The ability of the mammary gland to regenerate through cycles of pregnancy, lactation and 
involution is attributed to nonna! breast stem cells 16. Under the regulation of the systemic 
honnones, as well as local stromal epithelial interactions, these cells proliferate extensively 
differenti.'1te during each pregnancy and lactation, and undergo apoptosis during mammary 
involution in pre-menopausal and post-menopausal periods 16-22. 
By using different approaches, techniques and immunohistochemical marker.;, several 
models for breast progenitor and stem cells were proposed 16, 17, 23-40 however, these studies 
lack an in vivo validated xenotransplant assay38. As aforementioned, the earliest progenitor 
cells in the epithelial bud are CK19+, Bcl-2+, and ER- which differentiates into three 
pathways; one lineage acquiring basal marker.; (CK14, CK5/6) and the other acquiring 
lwninal cell specific marker.; (CK18) or myoepithelial specific maker.; (SMA) 13-17. These 
observations are consistent with the reports that considered CK 19 and! or ER as marker.; 
for stem/progenitor cells 31, 33-36. However, some investigator.; 27,32, 40 identified 
stem/progenitor cell populations by their expression of CK18 and CK14 (CK18 +/004-, 
10 
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CK.18-/CK.14+, CK.18-/CK.14- and CK.18+/CK.14+) while Backer et al 23, 25 generated a 
different model in which the CK.5 +/ CK.18 + cells are adult stem! progenitor cells. 
Stingl and colleagues 24, 37, 38 characterized the multipotent epithelial cells in the nonnal 
human adult breast. In their model, two distinct types of human breast epithelial cell 
progenitor population could be distinguished on the basis of their differential expression of 
the MUC1, Q)10 and epithelial-specific antigen (ESA). MUC1 +/Q)lO-/ESA+ 
progenitors (huninal restricted progenitors) expressed typical luminal epitopes (CK.8/18+ 
and CK.19+) and showed low levels of expression of myoepithelial/basal epitopes (CK14, 
CK.5/6 and Q)44v6). The second progenitor cell was MUC1-/Q)10+/ESA+ (bipotent 
progenitor, or ductal progenitor) which generated mixed colonies of both luminal, basal, 
myoepithelial cells when seeded in two-dimensional and three-dimensional cultures 24,37,38. 
1.2.3 Breast tumour stem cells 
Cancer cells and nonnal stem! progenitor cells share the capacity for self-renewal, the ability 
to differentiate, active telomerase and anti-apoptotic pathways, increased membrane 
transport activity, anchorage independence and ability to migrate and form metastasis 27. 
A subpopulation of highly tumorigenic breast cancer cells (CD44+ CD24-) was isolated 
from the bulk of human breast tumour cells 41,42 and it was claimed that this subpopulation 
possesses stem cell characteristics. Analysis of gene expression profiles 42-44 showed that 
CD44 + CD24-cells from nonnal breast and breast cancers were more similar to each other 
than to CD24+ cells of the same tissue 17. However, gene expression profiling of 
Q)44+CD24- breast cancer cells compared to normal breast epithelium identified 186-
genes which had a significant association with the invasiveness, poor outcome and basal-
like tumour phenotype 42-44. 
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Taken togetherthe published dataI7-44 regarding breast stem/progenitor cells (Figure 1-3), 
we can postulate that: 
1. There is a common breast stem cell that is perceived to reside in the suprabasal 
companment of the epithelial cell layer. However, its nature and molecubr 
characteristic remain elusive. This stem cell could be those cells which are ESA +, 
CD44+, CD24- and ER-17,24, 27, 29, 30,38,41-#. 
2. There are at least 4 progenitor cells: one multilineage progenitor, 2 restricted 
luminal progenitors and one basaV myoepithelial progenitor cell and all of them are 
perceived to reside in the suprabasal companment of the epithelial celllayerl7, 24, 27, 
29,30,38. 
The multilineage progenitor cells are characterized by the expression of: ESA +, 
0<19+,0)10+,0<14+,0<5/6+,0<18/8-, MUCl-, ER-, 0)133-, 0)61- and 
could give rise to both luminal, basal and myoepithelial cells. 
According to the level of ER, CD133 and p61 expressions 17,24,27,29,30,38, there are 
two luminal restricted progenitor cells that differentiate into ER + and ER- luminal 
epithelial cells. ER+ luminal restricted progenitor cells have an ESA+, 0<19+, 
0)24+,0<18/8+, MUC1+, ER+, 0)133+, C061+, 0)10- ,0<14-, and 
0<5/6- urummohistochemical profile. The ER- luminal restricted progenitor cell 
(alveol'U" progenitor cells) are ESA+, 0<19+, 0)24+, 0<18/8+, MUCl +, ER-, 
C0133-, 0)61-, COlO- ,0<14-, and 0<5/6- expressing cells. T 
he basaVmyoepithelial restricted progenitor cells have an ESA-, CX19-, CD24-, 
0<18/8-, MUC1-, ER-, C0133-, C061-, 0)14+, 0)10+ and CXs/6+ 
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Figure 1-3: Stem cell and progenitor cells model of breast and cell of origin theory of breast 
tumour subtypes. 
Adapted with modification from {StinglJ and Carlos C 2007} 38. 
1.3 Breast cancer evolution and progression 
Gene expression array studies have shown the existence of at least five different Be 
subtypes, each with different clinical outcomes 45,46 (Figure 1-4). These include luminal (A 
and B), basal, HER-2 and normal-like Be The luminal subtype 'N have higher levels of 
ER and a better survival outcome compared with luminal subtypes 'B'. The basal and 
HER2 subtypes are generally of higher grade than that of the luminal subtypes. According 
to Nielsen et al 26 the immunohistochemistry profile of basal like tumour (ER-, HER-2-, 
and either CKS/6+, CK14+ or EGFR+) is very similar to the immunohistochemistry 
profile of stem cell and basal cell of TDLUs of normal breast 17, 24, 26, 38 . Moreover, the 
immunohistochemistry profile of luminal "N' tumours was very similar to that of ER + 
luminal restricted differentiated cells 17, 24, 26, 38. These observations raise the following 
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question: 'Do different breast carcinoma subtypes as defined by gene expression arise from 
the normal cell equivalent like luminal, basal and possibly stem cell compartments that 
reside in the epithelial cell layer of TDLUs?' 17,24,26,38 (Figure 1-3) 
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Figure 1·4: Oassification of breast carcinoma according to gene expression signature. 
(Adapted from Sorlie et al2001 46) 
Interestingly, it has been demonstrated that the morphological and molecular patterns of 
Be were strongly related to the histological grade of breast cancer more than any other 
clinicopathological parameter or tumour intrinsic characteristic 47·52. For instance, the 
evolutionary pathways of breast carcinoma can broadly be classified into a low and high 
grade route 52. Low grade tumours have favourable prognosis, low proliferation rate, low 
apoptosis, glandular differentiation and fewer genetic changes compared to their high grade 
counterpartsS2.S3• They are characterized by ER+, PR+, Bcl2+, wild type p53 and no 
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HER2-overexpressionl amplification inununophenotype 52-55. Moreover, they frequently 
show gain of lq and loss of 16q52-55. In contrast, high grade twnours show a higher degree 
of nuclear atypia, and are more frequently negative for hormone receptors. Moreover, high 
grade tumours more commonly showed pS3 mutation, triple negative (ER-/PR-/HER-2-) 
and basal like phenotypes52-55• They are genetically advanced lesions, showing a 
combination of recurrent genomic changes including loss of 8p, llq, 13q, 14q; gain of lq, 
Sp,8q, 17q; and amplifications on 6q22, 8q22, llq13, 17q12, 17q22-24, and 20q13 52,55-61. 
It is known that the fate of any tumour reflects the molecu11r events acquired during its 
development. Accordingly, the morphological and clinical heterogeneity of any twnour 
including breast carcinoma is likely to derive from stochastic genetic and epigenetic events 
resulting in oncogenes activation and loss of tumour suppressor gene (fSG) function 27-30. 
However, in contrast to the 'stochastic' model of ontogenesis 62, 63 where transformation 
results from random mutations and subsequent clonal selection, tumours nowadays are 
considered as a multi-step clonal disease and its progression is dependent on acquiring 
further genetic and epigenetic changes in the stem or progenitor cells 62. In this model, 
cancer originates in tissue stem or progenitor cells probably through dysregulation of self-
renewal pathways and this leads to expansion of these cell populations that may undergo 
additional genetic and epigenetic changes 27-30,62-65. The nature of the genetic and epigenetic 
changes, and the type of progenitor they target, probably contribute to the cellular/lesional 
heterogeneity found in BC62• 
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1.4 Precursor lesions of breast carcinoma 
The development of breast cancer involves a multi-step progression spanning from the 
normal IDLU, precursor lesions to invasive and metastatic disease. Frequently, 
pathologists observe a collection of co-existing subtle pathological changes representing 
'precursor' lesions. These are challenging to identify, classify and manage and currently, we 
cannot predict which precursors will progress into cancer but studies suggest that between 
1-30% lesions develop a subsequent tumour event within a decade 66, 67. Moreover, 
autopsy studies have demonstrated that almost 20% of women with no overt symptoms 
are, in fact, harbouring pre-malignant lesions within their breast tissue that are not yet 
detected by mammograms or other techniques 68. These clata indicate that pre-malignant 
lesions are more common than originally appreciated but only a fraction of these women 
will ultimately develop invasive disease. Atypical ductal hyperplasia (ADH), atypical lobular 
hyperplasia (AL11), lobular carcinoma in situ (LOS) and ductal carcinoma in situ (DOS) 
have been proposed as precursor lesions of Be 66-67. More recently, attention has been paid 
to a group of lesions called columnar cell lesions (cx:::Ls) 69-71, The frequent co-existence of 
CX1s with ALHiLOS and low grade DOS as well as overlapping morphological and 
immunohistochemical features with DOS and low grade tumours suggest CCLs could be 
an early candidate precursor for the progression to low grade DOS and invasive carcinoma 




1.4.1 Columnar cenles ions (CCLs) 
c::x:::Ls represent a spectrum of lesions in the IDLUs of the breast which are characterized 
by dilatation of IDLUs and are lined by tall columnar cells with prominent apical 
cytoplasmic snouts (Figure 1-5), intraluminal secretion and calcification (Figure 1-6) and a 
varying degree of nuclear atypia and architecture complexity as described by Schnitt and 
Vincent-Salomon 69-71 . CCLs are increasingly recognised as a result of the widespread use of 
screening mammography and extensive investigation of radiological calcification 76. They 
are considered as one of the most conflicting issues in breast pathology because there is no 
internationally accepted classification or terminology for this range of lesions, a limited 
number of cases that have been studied in a systemic fashion and the limited available data 
about these lesions 69. 
Figure 1-5: Columnar cell lesion showing apical snouts and intraluminal secretion 
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Figure 1-6: Columnar cell lesion showing complex architecture and intraluminal calcification 
The CCLs have long been reported by pathologists under several names 69 including blunt 
duct adenosis, columnar cell metaplasia, atypical lobule, type A, hyperplastic tenninal 
groupings, clinging carcinoma, columnar alteration of lobules, metaplasia cylindrique, 
columnar alteration with apical snouts and secretions, small ecstatic ducts lined by atypical 
ductal cells with apocrine snouts, atypical cystic duct, pretubular hyperplasia, atypical cystic 
lobules, ductal intraepithelial neoplasia of flat monomorphic type, unfolded lobules 69. 
CCLs represent a spectrum which range from bland columnar cell changes (ceq to 
columnar cell hyperplasia (CCH) with cytological atypia and architecture complexity. Based 
on recent classification of CCLs produced by Schnitt and colleagues 69, Simpson and 
colleagues 71 categorize CCLs as follows: 
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eee (categOlY 1) 
ax:. is the simplest fotnl of CCLs and is a very frequent finding and as such has often been 
considered to be of negligible clinical significance misinterpreted as nonna!, or as 
microcystic lesions because of subtle or absence of cytological atypia. This lesion is 
characterized by variable dilatation of the IDLUs which are lined by one or two layers of 
cuboidal to tall columnar epithelial cells distributed in a relatively unifotnl pattern (Figure 
1-7). The nuclei are unifotnl ovoid to elongated and oriented perpendicular to the basement 
membrane while the nucleoli are inconspicuous or absent. The nuclear cytoplasmic ratio is 
normal. Apical cytoplasmic snouts, luminal secretion and calcification may be present 
eeewith cytological atypia (Gtegory 6) 
In this less common lesion, the cells showed mild to moderate cyto-nuclear atypia of a 
degree to cause concern but not amounting to flat DOS (low grade atypia). This atypia 
may be extremely subtle. The nuclei are round to ovoid, mildly pleomorphic and 
hyperchromatic with inconspicuous basophilic nucleoli and increased nuclear cytoplasmic 
ratio. Sometimes the nuclei may show clumped chromatin or vesicular nuclei or prominent 
multiple nucleoli (Figure 1-8). 
ern (Gte gory 2) 
These comprise variably dilated IDLUs lined by columnar cells which have cytological 
features similar to those seen in ax:. but show cellular stratification of more than two cell 
layers (Figure 1-9). The proliferating columnar cells may fotnl small mounds, tufts or 
abortive micropapillations but true micropapillary structures lacking fibrovascular cores and 
epithelial bridges are not seen in this form. At present, this is considered to be equivalent 
to usual epithelial hypetplasia. 
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ern with architectural atypia (Gtteg01:Y 3) 
These lesions show more complex architectural pattern in the fonn of well developed tufts, 
fronds, bulbous micropapillary, rigid cellular bridges, bars and arcades or punched-out 
fenestration with at least some evidence of cellular polarization within the micropapillations 
and bars or around fenestrations (Figure 1-10). 
ern with cytological atypia (category 4) 
In these lesions the columnar cells show mild to moderate cytological atypia usually low 
grade but with no complex architecture. The degree of atypia is not sufficient to v.rarrant a 
diagnosis of ADHorDOS (Figure 1-11). 
ern with architectural and cytological atypia (Gttegory 5) 
These lesions show cytological and architecture atypia which are insufficient to warrant a 
diagnosis of ADH or DOS (Figure 1- U). 
Flat Epithelial Atypia (FEA) 
FEA are lesions of the lDLUs in which the native epithelium is replaced by one (ax: with 
atypia) to several layers (CCH with atypia) of cells that show low grade cytological atypia. 
The tenn flat denotes the absence of more complex architectural patterns. While Flat 
DOS is lDLUs which is lined by one or two cell layers with high grade cytological atypia 
and marked nuclear pleomorphism 77. 
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Figure 1-7: Columnar cell changes without cytological atypia 
Figure 1-8: Columnar cell changes with cytological atypia 
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Figure 1-9: Columnar cell hyperplasia with cytological atypia 
Figure 1-10: Columnar cell hyperplasia with complex architecture but without nuclear atypia 
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Figure 1·11: Colunmar cell hyperplasia with cytological atypia 
Figure 1·12: Colunmar cell hyperplasia with cytological atypia and architecture atypia 
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1.4.2 Ductal carcinoma in situ 
The cyto-motphologic and architectural criteria used to identify low grade DOS and ADH 
are similar and distinction is primarily quantitative, based mainly on the extent of 
involvement. The ADHiDOS results from a disruption in the architecture of the breast 
epitheliwn due to lwninal epithelial cell proliferation in IDLUs that occur due to cell cycle 
dysregulation and imbalance between apoptosis and proliferation 78. DOS was categorized 
by architectural description into six groups: comedo (neoplastic cells surrounding a central 
area of necrotic debris), cribriform (radially oriented neopl.1Stic cells forming glandular 
lumina), papillary (large papilhtions with fibrovascular stalks), solid (ductal filling with 
neoplastic cells), micropapillary (finger like papillaty projections into dilated ductal spaces) 
and fbt (absence of more complex architectural patterns) 77. Also DOS were categorized 
into three groups according to the nuclear grade (high, intermediate or low) 77. 
High nuclear grade DCIS 
Cells have pleomotphic, irregular spaced large nuclei exhibiting marked variation in size 
with irregular nuclear contours, coarse chromatin and prominent nucleoli. Nuclei are 
typically large and greater than three times the size of erythrocytes. Mitoses are usually 
frequent and abnormal forms may be seen 77. This form of DOS commonly shows 
negative expression of oestrogen r e c e p t o r ~ ~ (ER-O() and Bcl2 and exhibited overexpression 
of HER-2 and p53 mutation 79-80. Moreover, high grade DOS commonly shows genetic 
changes similar to high grade Be including gain 17q, llq 13, and 13q 81. Some forms of 
DOS showed basal like features 0<.5/6+, ex 14 + and! or E G F R ~ . .
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Intennediate nuclear grade OCIS 
The nuclei show moderate pleomorphism with L1Ck the monotony of the small cell t)pe and 
the nuclei are typically larger than those seen in low grade DOS i.e., 2-3 times the size of 
erythrocyte. The nuclear cytoplasmic ratio is often high with 1-2 nucleoli. Intermediate 
grade DOS showed combination of immunohistochemistry and genetic features of high 
and low DOS n-8!. 
ADH/Low nuclear grade OCIS 
ADHiLow grade DOS is composed of monomorphic evenly spaced cells with rounded, 
small centrally placed nuclei and inconspicuous nucleoli. Mitoses are few. ADHiLow 
DOS commonly shows strong positive expression of ER and Bc12 with absence of p53 
mutation and HER-2-overexpression n-8!. ADHiDOS is associated with simplex array 
CGH profile with broad or whole arm loss of 16q and gain of 1q and 16p with absence or 
occasional amplification events 8!. 
1.4.3 Lobular neoplasia 
For the pwpose of this study, ALH and LOS were grouped together as "lobular neoplasia" 
(LN). LN was characterized by round, cuboidal or polygonal with clear or light cytoplasm 
epithelial cell proliferation within terminal duct lobular units. The intraductal epithelial cells 
have small, round to oval nuclei with small inconspicuous nucleoli and bland cytology. The 
nuclear cytoplasmic ratio is high n, The cells similar to low DOS were monotonous and 
evenly distributed but with poor cell cohesion and loss of E-cadherin n, This proliferation 
of neoplastic cells above the basement membrane undermined the normal lining epithelial 




1.4.4 Usual epithelial hyperplasia (UEH) 
UEH is be used to describe any intralwninal proliferation of a mixed cell population 
comprising epithelial cells, basal! myoepitheli.'ll cells and metaplastic cells showing no or 
only mild atypia 77, 
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Morphological evidence for the existence of a low 
nuclear grade breast neoplasia family: matched 
precursor and invasive lesions 
2.1 Abstract 
TIlls study was \llldertaken to determine the motphological features and frequency of 
putative precursor lesions involved in the development of some pure forms of special type 
breast carcinoma. We reviewed 795 cases. comprising atypical ductal (ADH} and! or 
lobular hyperplasia (ALH} without coexisting invasive lesion (n=180); tubular carcinoma 
erG; pure type (n=135). invasive cribriform carcinoma OCX::; n=20). tubulolobular 
carcinoma (ILC; n=20).low grade invasive ductal carcinoma of no s p e c ~ - u u type (low grade 
IDGNST; n=60). invasive lobular carcinoma OLG; classical type (n=180) and high grade 
IDS-NST (n=200). The preinvasive cases were followed up for up to 20 years. The 
presence of pre-invasive lesions including columnar cell lesions (CXl..s). usual epithelial 
hyperplasia (UEH}. ductal carcinoma in situ (DOS). and lobular neoplasia (LN) was 
determined. Oestrogen receptor (ER) and E-cadherin imm\lllohistochemistty was 
performed. 
About 11% of ADH and!or ALH without invasive lesions developed DOS, LOS and! or 
invasive lesions within 5-15 years. Nmety-five percent (95%) of pure tubular carcinomas 
had associated CXl..s with the majority showing flat epithelial atypia (FEA). ADHilow 
grade DOS was present in 89% patients. Co-localization of c:a... ADHI low DOS and 
Ckpter2 MorpIxia;jml dunuteristUs cflaw11Jldmr grade breast mrJasia 
TC was seen in 85% of patients, all displaying the same cytologic-nuclear morphology in 
most cases. LN was seen in 16%. In ILC, 91% cases showed LN. CCL and DOS were 
seen in 60% and 42% cases, respectively. E-cadherin was positive in TLC but reduced in 
TC and completely absent in ILC In conclusion, our findings support the hypothesis that 
CCLs are associated with both tubular and lobular carcinoma, and that LN is involved in 
ILC development. Our observations suggest that these lesions represent family members 
of low nuclear grade precursor, in situ and invasive neoplastic lesions of the breast. 
2.2 Introduction 
Recent molecular studies in breast cancer have identified alterations associated with low and 
high grade tumours. Co-expression of the changes typically seen in low and in high grade 
carcinomas is rare, suggesting different evolutionary routes. The low grade tumours include 
tubular, cribriform, lobular and tubulolobular carcinoma and have a favourable prognosis, 
possibly a consequence of fewer genetic changes 71.82. The development of breast cancer is 
now believed to be a complex multi-step process originating in terminal duct lobular units 
(IDLUs) and progressing towards invasive cancer 11,81. Previously, four precursor lesions 
separating nonnal and malignant epithelium have been proposed: atypical ductal hyperplasia 
(ADH), atypical lobular hyperplasia (ALH), lobular carcinoma in situ (LOS) and ductal 
carcinoma in situ (DOS) 66-67. Recent attention has focused on a fifth group of TDLU 
lesions called columnar cell lesions (CCLs). These lesions are increasingly detected by 
screening mammography because of the associated calcification. CCLs are a controversial 
and topical issue in breast pathology because there is currently no internationally accepted 
classification or terminology, and a restricted evidence base resulting from only a limited 
number of systematically studied cases. The frequent coexistence of CCL with ADH 
and! or low grade DOS in the same breast (Figures 2-1 and 2-2) as well as overlapping 
morphological features with ADH and DOS provides evidence for CCL being a candidate 
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precursor in the progression to low grade DOS and invasive carcinoma 52, 71-73, 83-85. 
Simpson et al (2005) 71 found that the morphologic classification of cx::L closely mirrored 
the level of genetic instability seen with comparative genomic hybridization (CGH). To 
date, there have been no studies assessing and comparing the frequencies of putative 
precursor lesions found in association with different breast carcinomas. This study was 
undertaken to determine the morphological features and frequency of putative precursor 
lesions involved in the development of some pure forms of special types of breast 
carcmoma. 
Figure 2-1: Atypical ductal hyperplasia on background of columnar cell 
lesions 
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Figure 2-2: Atypical ductal hyperplasia partially lined by columnar epithelial cells showing apical 
snouts; high power (20X) 
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2.3 Material and Methods 
2.3.1 Morphologic review 
We accessed the Nottingham Tenovus Primary Breast Gtrcinoma Series data-base, 
Histopathology Department, City Hospital, for primary breast cancer cases diagnosed 
between 1986 and 2005. According to the WHO and UK. guidelines 19,20, we reviewed all 
the available haematoxylin and eosin (H&E) stained histological sections (average 20 slides/ 
case; range 12 to 46 slides/case) of 1) 180 successive pre-invasive cases not associated with 
invasive carcinoma including atypical ductal hyperplasia and! or atypical lobular hyperplasia, 
2) 355 successive low/moderate grade special types BC (135 cases: pure tubular carcinoma, 
180 cases; invasive classic lobular carcinoma, 20 cases; invasive cribriform carcinoma and 
20 cases of tubulolobular carcinoma) removed by simple mastectomy or wide local 
excision (WLE), 3) 60 successive cases of low grade invasive ductal carcinoma of no special 
type (IDGNS1) removed by simple mastectomy or WLE and 4) 200 successive cases of 
high grade (IDC NS1) cancer removed by simple mastectomy or WLE. As part of UK. 
NHS Breast Screening Programme (NHSBSP) introduced in 1988, all 180 pre-invasive 
cases without cancer (unknown malignant potential category? were regularly checked up for 
any further pathological changes (follow-up up to 20 years). 
In our study, pure TC was diagnosed with at least 90% tubule formation. The presence of 
invasive and pre-invasive lesions including columnar cell lesions (CX1.s), usual epithelial 
hyperplasia (UEH), atypical ductal hyperplasia (ADH), ductal carcinoma in situ (DOS), 
atypicallobuL1r hyperplasia (ALH), and lobular carcinoma in situ (LOS) was determined. 
For the purpose of our study ALH and Las were grouped together under lobuL1r 
neoplasia (LN). A comprehensive morphologic review of CXl.s was performed based 
upon an extended version 71 of the classification system outlined by Schnitt and Vincent-
Salmon 69. Subsequently, six categories were defined (Figure 2-3). Although simple cysts, 
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radial sclerosis, uncomplicated fibroadenomas, and sclerosing adenosis are common 
findings in breast biopsies, they have not been consistently linked to a clinically significant 
increased risk for breast cancer. For that reason, we will not include any of them in this 
study. 
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Figure 2-3: Oassification of columnar cell lesions. 
Columnar cell changes (cx:Q, columnar cell hyperplasia (CXl-Q, flat epithelial atypia (FEA). 
Cytologic atypia criteria include round to ovoid, mildly pleomorphic and hyperchromatic nuclei with 
inconspicuous basophilic nucleoli, increased nuclear/cytoplasmic ratio. Complex architectural: 
micropapillae, tufts, fonds, arcades, rigid bridges, and punched out spaces. 
2.3.2 Immunohistochemistry 
Oestrogen receptor (ER) and E-cadherin (CDHl) immunohistochemistry was perfonned 
according to the labelled streptvidin-biotin-peroxidase complex method with citrate pH6.0 
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antigen retrieval using a TechMate 500 inummostainer (DakoCytom.uion) as previously 
described 87. IHC was perfonned on 4wn sections of fonnalin fixed paraffin wax 
embedded tissue specimen pbced on TechM.lte glass slides (DakoCytomation, Cunbs, 
UK). The sections were melted on a hot plate (58-60 'q for 10 minutes, dewaxed in xylene 
for 20 minutes, and then re-hydrated in 3 chmges of descending graded alcohol for 1 
minute each. Sections were pre-treated with microwave antigen retrieval using 0.1% citrate 
buffer, pH6 for 23 minutes. Slides were then transferred to a DAKO autostainer. Staining 
was done at room temperature as folloM: 
Slides were first incubated in buffer 1 (GemMate) which contains goat senun for 20 
minutes, followed by quenching of endogenous peroxid'lSe activity by treatment with 0.1% 
HOz and then in the unconjugated primary antibody for 1 hour at room temperature. 
Therefore, slides were incubated in biotinybted seconduy antibodies for 30 minutes and in 
horseradish peroxidase (HRP) StreptAvidin (DakoCytomation LSAB2 kit) for mother 30 
minutes. After that, slides were incubated in Diaminobenzidine (DAB) solution for 10 
minutes. Then sections were counterstained in haematoxylin for 2 minutes, rinsed in tap 
water, dehydrated in ascending graded a l c o h o ~ ~ then cleared in xylene and mounted in DPX 
Evalu.'ltion of results 
Slides were evaluated under a light microscope with mediwn and high power magnification. 
Positive and negative controls were also evaluated to confinn the appropriate staining. 
Immunoreactivities were classified by estimating the percentage of cells showing 
characteristics staining, by estimating the intensity of staining and the location of staining 
cells either luminal or myoepithelial. 
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Negative and positive tissue controls 
Negative control tissue sections were generated by omitting the specific primary antibody 
from the staining process. Positive tissue controls were processed by the same method as 
the stained sections. 
Dilutions 
The primary antibody dilutions used for ER was (105, 1:100, DakoCytomation) and for E-
cadherin was (CDH1, 1:100, Zymed laboratories). These antibodies had previously been 
optimized in the Histopathology department, Oty Hospital, Nottingham. Only nuclear and 
membranous staining was considered for ER and E-cadherin scoring, respectively. For 
comparison with previous studies performed by Simpson et al200S 71, we evaluated the 
distribution of ER and E-cadherin in precursors lesions using a semi-quantitative five 
category score sy.;tem: negative (-), ~ ~ 5% of cells stained; weak positive or reduced ( +), 5% 
to 25% of cells stained; moderate positive (++), 25-50% of cells stained; strong positive 
(+++), ~ 5 0 % % of cells stained 
Data were analysed using the statistical software package SPSS, (SPSS, version15 Chicago, 
IL). A au square test was used to compare the presence of CX1..s, ADH, LN and DOS in 
pure and mixed TC, tubulolobular and ILC Results were considered significant if p < 0.05. 
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2.4 Results 
2.4.1 Preinvasive cases 
Eighty-two (46%), II (39%), and 27 (15%) patients were detennined to have ALH, ADH 
and co-existence ADH and ALB; respectively, on the histological review of cases originally 
diagnosed as lesion with lUlcertain malignant potential. Notably, all the initial biopsies, 
showed in addition to ADH and! or ALH backgrolUld of colwnnar cell lesions with and 
without atypia. The cx::Ls had morphological features and topographic distribution very 
similar to the associated ADH, and!or ALH Follow up of these cases revealed that 19 
cases (11%) subsequently developed invasive breast cancer (9 cases; 5%) and! or in-situ 
carcinoma (10 cases; 6%) within 5-15 years afterthe initial biopsy. The remaining 161 were 
followed up from 5-20 years and did not showed any significant pathological changes. 
Two cases of the coexisting ADH' ALH cases (2/27; 7%) developed invasive carcinomas 
within 10 years which had two separate f o c ~ ~ one of low grade tubular carcinoma (T1, P2, 
M1) and the other focus of invasive classic lobular carcinoma grade 2 (T3, P2, M1). Twelve 
cases of the initial ALH cases (12/46; 26%) progressed into: classic ILC grade 2 (2 cases), 
tubulolobular carcinoma grade 1 (one case), LOS with cribriforrnlmicropapillary 
ADHiDOS (5 cases) and exclusive LOS (4 cases). 
Five of the initial ADH cases (5/ll. 6%) developed: tubular carcinomas grade 2 (2 cases), 
IDGNST grade 2 (one case), IDGNST grade 3 (one case) and DOS grade 2 (one case) 
after 5 to 15 years. 
The average interval to the subsequent carcinoma was the same in the ADH (10 ~ a r s ) , ,
ALH (8.8 years) and ALHI ADH (9.5 years) cases. The average interval to the subsequent 
DOS and! or LOS after the diagnosis of ADH (71 years) and! or ALH (6.5 years) was 
similar too. Thus, ALH tended to progress to LOS which could progress to invasive 
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lobular carcinoma while ADH progressed into DOS and therefore into ductal lineage 
pathways. 
All subsequent carcinomas and their coexistent preinvasive lesions, except NST grade 3, 
showed cytoplasmic and nuclear morphological features very similar to the original 
preinvasive lesion. The initial preinvasive lesion of NST grade 3 was papillary ADH (ER +) 
which was detected in the subsequent biopsy adjacent and unrelated to the invasive 
carcinoma (ER-). While solid grade 3 DOS (ER-) with morphological and topographic 
distribution very similar to the coexistence invasive NST grade 3 was detected. 
Moreover, all ALH, LOS and ILC showed negative expression of E-Cadherin. While all 
CCLs, ADH, DOS, TC, IDGNST, and tubulolobuL1r lesions showed positive expression 
of E-cadherin. However, in three intraductal epithelial proliferative lesions lined by E-
cadherin positive columnar cells with apical snouts focal islands of E-cadherin negative 
luminal epithelial cells were seen (Figures 2-4 and 2-5). Furthermore, in another two 
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Figure 2-4: Duct lined by columnar cell epithelium with apical snouts spaces islands of pale lobular 
like cells. 
Figure 2-5: Duct lined by columnar cell epithelium showing positive expression for E-cadherin 
spaces islands of pale lobular like cells that showed no membranous expression of E-cadherin. 
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2.4.2 Tubular Carcinoma Pure type 
The patients' characteristics are summarized in (Table 2-1). About 67% of patients were 
postmenopausal. All cases were well differentiated (grade 1; Gl with low mitotic index 
(Ml). About 70% and 91% of cases showed moderate nuclear pleomotphism (P2) and 
~ O % % tubule fonnation (Tl), respectively. Most tubular carcinomas were small in size 
(mean whole tumour size: 1.3 cm, range 0.2-3.6 cm). Only 15% and 6% showed local 
lymph node metastases and distant metastases, respectively. About 94% of cases were 
ER+. All cases were positive for E-cadherin but the majority showed reduced expression. 
CXl.s were detected in 95% of cases (Table 2·2 and Figure 2·6). The CXl.s were 
stratified into six types comprising CXH with cytologic atypia (77%), o:::x:: with atypia 
(66%), o:::x:: without atypia (57%), CXH with complex and cytologic atypia (27%), CXH 
with complex architecture (9%), CXH without atypia (7%) (Figure 2-7 and Table 2-3). 
Collectively, FEA was seen in 84% of pure tubular carcinom.1S. ADHiDaS was present 
in 89% of patients; 65% low grade, 23% intermediate grade, 12% low to intermediate grade 
and none of high grade (Figure 2-S). ADHiDaS was extensive (extending> 1 mm 
beyond the invasive component) in 47% and minimal in 53% cases. A cribriform growth 
pattern was present in 88% of Das cases while rnicropapillary, solid and flat growth 
patterns were present in 31%,12% and 8% of ADHiDaS patients, respectively (Figure 
2·9). The triad of (XL, low/intermediate grade ADHiDOS and tubular carcinoma was 
seen in 85% of Cases. In most cases, the o::::Ls, DOS, and tubular carcinoma displayed the 
same cytologic· nuclear motphology and were intimately associated with the same 
geographical distribution. UEH was detected in 18% of cases and when present, was 
associated with both o::Ls and ADHiDOS. LN was detected in 9/56 of cases (16%) but 
in the majority was present away from the invasive component. The triad of LN, 
ADHiDOS and a:Ls was seen in 16% of cases. 
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Table 2·1: Clinicopathological features of low nuclear grade breast 
carcmomas. 
Parameter Tubular Tubular T ubulolobular 
Carcinoma carcinoma 
" Pure" "Mixed" 
Mean age (years) 57 56 60 
Mean tumoursize(cm) 1.6 1.3 1.8 
Histologic grade G1 G1 G1 
Lymph node involvement (%) 2% 10% 25% 
E·Cadherin protein expression 100% 100% 100% 
.(%) 
Estrogen receptor positive 96% 100% 100% 
express ion (%) 










ER; oestrogen receptor, NPIj Noningham Prognostic Index and ILC; invasive lobular carcinoma. 
Table 2·2: Comparison of the frequency for putative precursor lesions in tubular, cribriform 
tubulolobular and classical invasive lobular carcinoma (ILq. 
Lesions Tubular Inv.tSive T ubulolobuLtr ILC "Classical" Xl'" 
carcinoma cribrifonn carcinoma 
"Pure" carcinoma 
(n= 135) (n= 20) (0=20) (0=180) 
n % N % n % n % 
CCLs 128 95 18 90 17 86 108 60 . O O I ~ ~
DCIS 120 89 19 95 17 86 72 40 . O O l ~ ~
LN 22 16 4 20 11 57 162 90 .001'· 
HEU 24 18 6 30 3 14 45 25 0.568 
* Chi-square tests showed highly significant differences when comparing the presence of columnar 
cell lesions (CCLs), ductal carcinoma in situ (DOS) and lobular neoplasia (1.N) in different tumour 
types. Hyperplasia of usual type (HEll) did not significantly differ between different cancer types. 
** Statistical significant. 
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Table 2-3: Comparison of the frequency for different fOImS of ca..s in tubular, tubulolobular and 
invasive lobular carcinoma ~ L q q
Lesions Tubular Invasive T ubulolobular ILC Xl 
can:inoma cribrifonn can:inoma "Classical" 
"Pure" 
(n= 135) (n= 20) (n=20) (n=180) 
n % n % n % n % p 
ColumnarceU change 77 57 12 60 14 71 95 53 0.635 
ColumnarceU 9 7 4 20 8 42 97 54 .001-
hype_ll'las ia 
ColumnarceU 12 9 0 0 3 14 20 11 0.448 
hypetplas ia with 
complex an:hitecture 
ColumnarceU change 89 66 12 60 11 57 34 19 .001-
with cytologic atypia 
ColumnarceU 10 77 11 55 17 86 95 53 .013 
hypetplasia with 4 
cytologic atypia 
Flat epithelial atypia 11 84 14 70 17 86 97 54 .004-
3 
ColumnarceU 36 27 6 30 7 36 16 9 .029-
hWetplasia with 
complex and cytologic 
atypia 
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Figure 2-6: Frequency of columnar cell lesions (ca) , atypical ductal hyperplasia! ductal 
carcinoma in situ (ADHiDOS), lobular neoplasia (LN) and usual epithelial hyperplasia among 
tubular carcinoma, invasive classic lobular carcinoma and tubulobular carcinoma. 
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F igure 2-7: Frequency of different types of columnar cell lesions (CG.s) in tubular carcinoma, 
tubulolobular and invasive lobular carcinoma. 











G 1-2 WllllllI 
DOS . 
G2 
D O S ~ ~
G3 ~ ~
Figure 2-8: Frequency of different grades of DOS in tubular, tubulolobular, invas ive lobular 
carcinoma. 
(G 1; low grade, G2; intermediate grade, G3; high grade, co..s; columnar ceU lesions, DOS; ductal 
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Figure 2·9: Frequency of dtfferent growth patterns of DOS among tubular, tubulolobular, 
invasive lobular carcinoma. (ILq 
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2.4.3 Invasive lobular carcinoma classic type 
About 72% of patients were postmenopausal. About 95% were moderately differentiated 
(grade 2; G2) and 5% were well-differentiated (Gl) with low mitotic index (97%; Ml) and 
no tubule formation (T3; 96%). About 90% showed moderate nuclear pleomorphism. The 
mean whole tumour size was 2.1 cm (range; 0.13-5.5). Local lymph node metastases and 
distant metastases were detected in 41% and 24% of classic ILC All ILC and LN showed 
no E-cadherin expression and 95% were ER+. No pre-invasive lesions were detected in 
9% of cases while LN was seen in the remaining 91% of cases. ADHiDOS was detected 
in 42% of cases, and was extensive in 33%. About 46% ADHiDOS cases were of 
intermediate grade, 33% were low and 21% were high grade. Soud growth pattern 
ADHiDOS was seen in 79% while cribriform and micropapillary growth pattern were 
seen in 38% and 13% of cases, respectively. CCl..s were seen in 60% cases and all CX1s 
were associated with LN. ADHiDOS, CXl.. and LN were present altogether in 23% of 
cases. The CXl..s were stratified into six types including CCH without atypia (54%), a:t::-
(53%), CCH with cytologic atypia (53%), err. with atypia (19%), CCH with complex 
architecture (11%), CCH with complex and cytologic atypia (9%). UEH was diagnosed in 
25% of cases. 
2.4.4 Tubulolobular carcinoma 
The mean whole tumour size was 1.8 em. All cases were either well (75%) or moderately 
(25%) differentiated (G1) with low mitotic figure {Ml}. DOS was seen in 86% of cases; 
67% and 33% of low and intermediate grade respectively. A cribriform growth pattern was 
seen in 50% of DOS while solid and micropapillary were seen in 37% and 12.5% of DOS, 
respectively. CCl..s were detected in 86% of cases; 45% of cr:r. with atypia, 29% of CCH, 
14% of cr:r. and 14% of CCH with complex architecture. The triad of LN, DOS and 
CCl..s was seen in 56% of cases. UEH was diagnosed in 14% cases. 
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2.4.5 Cribrifonn carcinoma 
About 63% of patients were postmenopausal All cases were either well (81%) or 
moderately (19%) differentiated tumours with low mitotic index (M1). About 81% and 
88% of cases showed moderate nuclear pleomorphism (P2) and tubule f01mation (T2), 
respectively. Mean whole tumour size was 1.8cm; range 0.6-4.8 cm. No vascular invasion, 
local lymph node metastases or distant metastases was recorded. All cases were ER + and 
E-cadherin +. cx:::I...s were detected in 90% of cases. Collectively, FEA was seen in 80% of 
cases. ADHIDOS was present in 95% of patients; 85% of low grade/inte11l1ediate grade 
and 10% of high grade. A cribrifo11l1 growth pattern was present in 90% of DOS cases. 
In most cases, the CCLs, DOS, and rex::; displayed the same cytologic-nuclear morphology 
and were intimately associated with the same geographical distribution. UEH was detected 
in 20% of cases and when present, was assock'1ted with both CCLs and ADHIDOS. LN 
was detected in 30% of cases. 
2.4.6 IDe-NST low grade 
About 65% of patients were post-menopausal. The mean whole tumour size was 1.6 cm 
(range 003-3.0 cm). All cases showed low mitotic index (M1), while about 80% showed 
moderate pleomorphism and tubule f011l1ation. Local lymph node metastases and distant 
metastases were recorded for 21% and 18% of cases, respectively. cx:::I...s were detected in 
82% of patients. CCLs were stratified as cx:c with atypia (60%), cx:c (60%), cx:::H with 
cytologic atypia (55%), cx:::H with complex and cytologic atypia (27%) and cx:::H without 
atypia (20%). ADHiDOS was present in 87% of cases; 70% inte11l1ediate grade and 30% 
low grade. DOS was extensive in 40% of cases. A cribrifo11l1 growth pattern was present 
in 80% of DOS cases while solid growth pattern was present in 40% of DOS. UEH was 
detected in 42% of cases and all were associated with both CCLs and DOS and were in the 
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same geographic regions. LN was detected in 23% of cases and was frequently localized 
away from the invasive component. 
2.4.7 IDCNST high grade 
About 58% of patients were postmenopausal. About 90%,95% and 85% showed high 
mitotic index (M3), marked pleomorphism (P3) and no tubule fonnation CD), respectively. 
The mean whole tumour size was 22 cm (range; 0.16-6.5 cm). Local lymph node 
metastases, distant metastases and vascular invasion were detected in 41 %, 41% and 37% of 
cases, respectively. About 50% and 95% were ER + and E-Cadherin positive, respectively. 
No pre-invasive lesions were detected in 40% of cases while DOS, UEH, CCLs and LN 
were seen in 60%, 33%, 10% and 5% of cases, respectively. Comedo and solid growth 
pattern were present in (70%) and (36%) of Das associated with high grade IDe while 
micropapilL'U'Y and cribrifonn growth patterns were present in only 9% and 5% 
respectively. In most cases of high grade IDe the DOS lesions and invasive component 
displayed the same ER immunophenotype, cytologic-nuclear morphology and were 
intimately associated with the same geographical distribution. 
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2.5 Discussion 
With ADH and lobular neoplasia, there is a 4 to 10 fold increase in the risk for subsequent 
invasive breast cancer over 15 to 30 years 66,67. In our study, we found 11% of ADH 
and! or ALH progressed into either in situ or invasive carcinoma which had the same 
topographic and morphological features similar to the initial lesion supporting the concept 
of a direct precursor product rel'ltionship 66, 67. However this risk is spread over long 
periods, so that subsequent cancer can sometimes occur decades later as a result of the 
relatively low proliferative rate of ADH and LN. Interestingly, 10 cases of ADH and or 
ALH were associated with subsequent malignancy in other organ systems especially female 
genitourinary tract and gastrointestinal system which suggests that ADHI ALH could be a 
sign of a woman's increased risk for cancer either as a reflection of a genetic instability or as 
a part of common or general process that eventu.-illy lead to the development of particular 
form of human cancers e.g. ER sign.-illing dysregulation. 
To date, there has not been a comprehensive morphologic study comparing the association 
of different putative precursor lesions involved in the development of some special types of 
low grade and classical lobular breast carcinoma. Moreover, only a few studies have 
analysed the association of CCLs with tubular carcinoma 70, 72, 88. CCLs consistently 
harbour recurrent chromosomal abnormalities suggesting they are clonal and neoplastic 
rather than hyperplastic proliferative lesions 71. Some studies have shown that the sites and 
patterns of association of chromosomal alteration are similar to a range of precursor, in situ 
and invasive forms of breast cancer including ADH, ALH, low grade DOS, LOS, invasive 
low grade and lobular carcinoma 52, 67, 75, 76, 84, 89- 93 which led our group and others to 
speculate that these lesions form a family of related breast cancer and their precursor 
lesions (Figure 2-10). 
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Low Nuclear Grade Breast Neoplasia Family (LNGBN) 
CCl; columnar call lesions, IN; lobular neoplasia; ADH, atypical ductal hyperplasia; 
ICC; Invasive cribriform carcinoma, TC; tubular carcinoma; TlC; tubulolobular carcinoma; IDC; 
Invasive ductal carcinoma, ,llC; ; invasive lobular carcinoma 
Figure 2-10: Evolutionary pathways of low grade breast neoplasia, 
In tubular carcinoma, various names have been used synonymously to describe CXl.s 
including atypical lobules type A 1\, atypical cystic lobules 74, pre-tubular hyperplasia 85, 
small ectatic ducts lined by atypical ductal cells with apocrine snouts 72, monomorphic 
ductal neoplasia-flat type 75, columnar alteration with prominent apical snouts and 
secretions 70, clinging carcinoma 75 and flat epithelia atypia (PEA) 77. These lesions were 
often reported at the periphery of, or within, TC In our study of lesions associated with 
invasive carcinoma, we found a very high prevalence (95%) of CCLs in TC Also, our 
study indicated that FEA (ere with atypia and CCH with atypia) was the commonest 
fOlTIl of CCL (80% of cases) in accord with other studies, 70,72,88 while CCH with or 
without complex architecture was rare. This interesting finding suggests that not all folTIlS 
of CXl.s are directly associated with tubular carcinoma implying that the acquisition of 
nuclear atypia and the more complex folTIlS is a requirement for progression to invasive 
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carcmoma. Consequently, the type of CCLs could detennine the type of invasive 
carcinoma formed. It has been reported that the genetic profile patterns seen in different 
forms of CCLs closely reflect the degree of proliferation and atypia indicating some of 
these lesions represent a morphologic biological and molecularcontinuwn 71 • 
Previous studies have demonstrated a good correlation between the histological grade of 
DOS and the grade of associated infiltrative component 88,94. Also, some studies have 
shown that cribriform and micropapillary growth patterns are closely associated with 
tubular carcinoma 70, n. Our results concur with these studies as we found the majority of 
DOS lesions associated with low grade invasive carcinoma was low grade with a cribriform 
and! or micropapillary growth pattern, while the solid growth pattern was infrequent. We 
found the triad composed of <XLs, low grade DOS and invasive carcinoma was present in 
80% of tubular cases, showing simiL'lI', nuclear and cytoplasmic morphologic features and 
geographic location. We propose that FEA may develop into ADH and then low grade 
DOS, particularly cribriform and micropapillary types, with the eventual progression to 
tubular carcinoma. 
In agreement with other studies 7416,88,95 we demonstrated that LN was present in 
approximately 16% of tubular cases with all LN lesions being associ.'lted with CCL and 
DOS. This suggests DOS and LN may in this situation have a relationship and form part 
of the precursor pathway to invasive tubular carcinoma. We speculate that they share a 
developmental lineage pathway from a common cell of origin giving rise to both CCLs, 
LN, and low grade ductal neoplasia (ADH and DOS) dependant on acquisition of 
additional genetic alterations which influence morphological appearance and character such 
as E-cadherin loss. 
Invasive lobular carcinoma of classical type share the low mitotic frequency and growth 
fraction seen in tubular carcinoma and low grade ductal carcinoma46, 96 but are usually 
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moderately differentiated (histological grade 2) due to absence of tubule formation, brger in 
size, and have a higher tendency to metastasise to axilbry lymph nodes. In contrast to TC 
the overwhelming majority of LN and invasive lobular carcinoma are negative for the 
ttunour suppressor gene E-cadherin 81,97. In our study all LN and classical ILC lesions were 
negative for E-cadherin protein expression. Furthermore, mutation analysis of the E-
cadherin gene in adjacent in situ and ILC have revealed the same specific mutations in both 
lesions 97. This provides compelling evidence for the precursor role of LOS in ILC 97. LN 
was present in 91% of classical ILC in the same geographic localization. In addition, we 
found LN occurred in isob.tion without any other putative lesions in only 21% of ILG 
These findings further support the hypothesis that LN is a direct precursor for ILC in 
agreement with others 66, 97. Some investigators noted the higher co-existence of LN and 
FEA in the same surgical specimen, particularly in TC 76, 88, 95, but the co-existence of these 
precursors in ILC has not been reported. We found that cx:::Ls and LN co-exist in 60% of 
ILC cases and the majority of these cx:::Ls were CQ-I and FEA, particularly CQ-I with 
cytologic atypia. Also, we observed the combination of LN, <XLs, and DOS in 23% of 
ILG These observations when considered in the context of previous cytogenetic studies 
suggest that loss of normal E-cadherin gene expression is an early event and may switch on 
the development of lobular differentiation. We speculate that the particular evolutionary 
tumour pathway is dependent on the precise point when E-cadherin gene loss occurs; in 
ductal cancer, E-cadherin loss occurs at a later stage. 
We found that tubulolobular carcinoma (1Lq had similar characteristics to TC including 
low tumour grade, size, ER and E-cadherin expression and rebtively favourable prognosis. 
Compared to TC TLC also showed a high co-existence and distribution of DOS and 
<XLs shared with TG However, TLC differed from TC in showing a higher tendency to 
metastasize to axillary lymph node, and also resembled ILC with a higher frequency of LN, 
solid DOS and CXH lesions, all present in the same topographic regions as the invasive 
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component. Our findings support the hypothesis that lLCs are a distinct subtype of 
manunary carcinoma with motphologic and clinicopathological features overbpping those 
seen in tubular and invasive lobular carcinoma. The uniform positive expression of E-
cadherin protein in lLC supports an alternative molecular derivation to classical lobular 
carcinoma, despite a dominant lobular growth pattern 98. 
In sununaty, our findings support the hypothesis that CX1..s are associated with pure and 
mixed forms of tubular carcinoma, and that LN is involved in ILC development. C0-
existence of both LN and CX1..s with invasive tubular and with lobular carcinoma was 
common. Our obsetvations support the hypothesis that these lesions represent members of 
a family of low grade precursor, in situ and invasive neopL1Stic lesions of the breast. TIlls 
hypothesis will be tested (ClJ.apter 4) by performing molecular analr.;is of tubul'1r and 





Molecular evidence to support the concept of a 
low nuclear grade breast neoplasia family 
3.1. Abstract 
In chapter 2, we provided morphological evidence showing a link between some precursor 
lesions and low nuclear grade breast carcinomas (LNGBq especi.1lly tubular and classic 
lobular carcinoma. In this study, we aim to provide further immunophenotypic SUppOIt to 
our proposed route of pathogenesis of LNGBC and their precursor lesions. Precursor 
lesions including columnar cell lesions (CXl.s), atypical ductal hyperplasia (ADH), ductal 
carcinoma in situ (DaS), usual epithelial hyperplasia, and lobular neoplasia (LN) were 
immunohistochemically compared with matching 'morphologically norrn.ll' terminal lobular 
duct units (IDLUs) and matching invasive carcinoma. 
The epitheli.ll cells in the putative precursor cx:::Ls, flat epithelial at)pia (FEA), ADH, LN, 
Das lesions and their co-existing LNGBC were negative for basal and myoepithelial 
markers, but positive for CK19/18/8, ER-Q(, Bcl-2, and C)din Dl. The E R - Q ( / E R - ~ ~
expression ratio increased during carcinogenesis, as did expression of cydin Dl and Bcl-2. 
The p53 immunopositivity was found in 3% of LNGBC vs. 43% of high nuclear grade 
breast cancer (HNGBq, while ataxia telangiectasia mutated (ATM) expression was absent 
or reduced in 22% of LGNBC vs. 53% of (HNGBq cases. 
In summary, our findings SUppOIt the concept that FEA is the earliest morphologically 
identifiable non-obligate precursor lesion of LNGBC These may represent a family of 
precursor, in situ and invasive neoplastic lesions belonging to the luminal 'N subclass of 
breast cancer. The balance between ER-Q( and E R - ~ ~ expression may be important in driving 
cyclin D-1 and Bcl-2 expreSSlOn. ATM may be one of the alternative regulatory 
mechanisms to TP53 mutation or dy.;function in a subset of breast carcinoma. Our 
findings support the concept that progression of LNGBC "Luminal N' to HNGBC 
"Basal-like or HER-2+" phenotype is an unlikely biological phenomenon. Furthennore, 
we propose a model for the biological events that are associated with ER-C( in the 
development of LNGBC 
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3.2. Introduction 
Breast cancers (BCs) are heterogeneous in their morphology, response to therapy and 
clinical course 19, Molecular profiling studies have shown the existence at least five different 
BC subtypes, each with different clinical outcomes 45. 46, The lwninal subtype 'A' have 
higher levels of oestrogen receptor alpha (ER-Q() and a better survival outcome compared 
with ltuninal subtypes 'B' 45. 46, Moreover, there is convincing genetic evidence to suggest 
that the low grade (LGBq and high grade (HGBq breast cancers evolve through distinct 
evolutionary pathways 52.57, LGBCs are usually diploid! near-diploid and harbour recurrent 
loss of chromosome 16q and gains of chromosome 1q54.55, In contrast, HGBCs are usu.-illy 
aneuploid with complex genetic profiles and infrequent deletion of 16q 54, 55, In HGBCs, 
even when loss of 16q is present, the underlying genetic mechanism appears to be distinct 
from that seen in LGBCs 99, 
In chapter 2 we adopted the concept of low nuclear grade breast neoplastic (LNGBN) 
family based on: 
1) During follow up, some ADH and! or ALH progressed into invasive TC, TLC and! or 
classic ILC within 5-15 years of the initial diagnosis, 
2) The similarity of the nuclear and cytopl1smic morphological features between some 
putattve precursor lesions and their either co-exiting or consequent invasive 
carcmomas, 
3) The intimate topographic distribution of some putative precursor lesions and their 
either co-existing or consequent invasive carcinoma 
4) The significant coexistence of columnar cell lesions (CXLs), lobular neoplasia (LN) and 
atypical ductal hyperplasia/low grade ductal carcinoma in situ (ADH'low grade DOS) 
with invasive tubular carcinoma (Tq, tubulolobular carcinoma (TLq and classic 
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invasive lobular carcinoma (lLG. 
In this study, we expand our investigation to explore the immunohistochemical 
phenotype of the putative precursor lesions with both their related normalIDLUs and 
mvaslve cancers. 
3.3. Materials and Methods 
In this study, we included invasive TC (n=135), classic ILC (n=180), cribrifonn (lex:; 
n=20), TLC (n=20), mixed invasive tubular/classic lobular carcinoma (n=15) and 60 cases 
of invasive low grade ductal carcinomas of no special type (low grade IDGNS1) which 
were compared with high grade IDGNST (n=670). Phenotype was assessed using 
immunohistochemistry (lHG on tissue microarra)S (TMA) and full face sections. Two 
TMAs sets were prepared as previously described 87. Briefly, two representative areas from 
each lesion were carefully selected from haematoxylin-eosin stained sections of donor 
blocks. The H&E slide and its corresponding block were aligned then the selected marked 
area on the H&E slide was copied to the donor block using a marker pen. Blank paraffin 
blocks were used as recipient blocks for tissue cores. Paraffin wax was melted at 55-58'C 
and poured into a 5-10 mm thick moulds. A plastic cassette was pbced on the swface of 
the melted paraffin then all were cooled and the mould was removed Two core cylinders 
(0.6 mm diameter) were punched by using a tissue microarraying device (Beecher 
Instruments, Silver Spring, MD, USA) which was designed to make holes in the recipient 
blocks and to obtain cores from the donor blocks as previously described 87. Then the 
punched cores were deposited and arrayed into the recipient blocks with 1 mm spacing 
distance between the two adjacent cores. About 450 different components (preinvasive and 
matching invasive carcinoma) of 150 TC and classic ILC cases were arrayed in 1MA set 
57 
Oxtpter3 
number 1. A second set of 1MA containing W1Selected 2000 successive cases of invasive 
breast carcinoma was also used 87. 
Four-um thick sections of the resulting rnicroarray block were made and used for IHC 
analysis after transfer to glass slides. 
To validate the use of the microarrayfor immunophenotyping, full face sections of 10 cases 
of each tumour type were stained and the protein expression levels of the 15 antibodies 
were compared for each lesion on the full face sections and on 1MAs. 
By using hierarchical clustering methodology of a L-uge panel of well-characterized 
commen:iallyavailable biomarkers related to epithelial cell lineage, differentiation, honnone 
and growth factor receptors and gene products known to be altered in some forms of 
breast cancer, Abd EI-Rehim and her colleagues 87 identified 5 groups of breast cancer with 
distinct patterns of protein expression. In our study we have used the same panel of 
antibodies to immunophenotyping our lesions. In addition we explored the expression of 
selected proteins that are likely to play an important role in the pathogenesis of low grade 
breast cancer development such as Cydin D1 (cx:::ND1) 100, fragile histidine triad (FHI1)IOl, 
AlM10l-102 and ER- ~ ~ isoforms103• 
Subsequently, the 1MAs, as well as 40 full face sections of benign preinvasive lesions not 
associated with invasive lesions, were immunohistochernically profiled for basement 
membrane components (laminin and collagen type IV), cytokeratins (CKI9, CK18, CK8, 
CK 14, CK5.6), honnone receptors (ER-<x and ER- ~ ~ 1), putative tumour suppressor genes 
(FHIT, A 1M, BRCA1, p53 and E-cadherin), apoptosisl cell cycle regulator (Bc12 and cyclin 
Dl), and proliferation index (MIB1) markers to immunohistochemically phenotype the 
different lesion types (Tables 3-1 and 3-2). 
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In addition, nonn.'ll breast tissue comprising 40 biopsy specimens removed from patients 
(age range 25-60 years; 20 cases premenopausal and 20 cases postmenopausal) that 
underwent reduction mammoplasty, primarily for cosmetic reasons, were histologically 
examined and immunohistochemically profiled. All nonn.'ll control patients were free of 
breast cancer in both breasts and had no previous medical history of breast cancer. 
Immunostaining was performed as previously described in Cllapter 2 (section 2.32). 
Positive and negative (omission of the prim.-uy antibody and IgG-matched senun) controls 
were included in each run. 
Table 3·1: Types and number of breast lesions (n-160S) included in this study 
Type of lesions N w n b e r ~ l e s i o n s s
Invasive lesiQ!Y (n-1l85) 
• Tubular can:inoma 135 
• Classic invasive lobular can:inoma 180 
• T ubulolobular can:inoma 20 
• Mixed invasive tubular and classic lobular 15 
carcmoma 
• Invasive cribriform can:inoma 20 
· 
Invasive low grade ductal Carcinoma 60 
· 
Invasive High grade ductal Carcinoma 670 
Pre-invasive lesions adja_ent to invasive (n-255) 
· 
Columnar cell changes (a:q 49 
• Columnar cell hyperplasia (CXl-l) 43 
· 
Flat epithelial atypia (FE A) 40 
• At}-pical ductal hyperplasia/low grade 40 
ductal can:inoma in situ (ADI-Vlow OOS 
· 
Lobular neoplasia (LN) 39 
• Usual epithelial hwerplasia (UHf) 44 
Pre-invasive lesions not associated with invasive (n-110) 
· 
Columnar cell changes (a:q 20 
• Columnar cell hyperplasia (CXl-l) 20 
• Flat epithelial arwia (FEA) 40 
• At}-pical ductal hyperplasia/low grade ductal carcinoma in situ (ADI-Vlow OOS 20 
• lobular neoplasia (LN) 20 
• Usual epithelial hwerplasia (UEH) 20 
Normal Terminal Duct Lobular Units(1DLUs) adjacent to invasive (n- 65) 
Nonnal T D l U ~ ~ from r e d ~ t i o n n breast specimen (n- 40) 
· 
Premenopausal 20 
• Postmenopausal 20 
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Table 3·2: Primary antibodies, clone, source and optimal dilution used for immunohistochemistry. 
Antibody Oone Soun:e Dilution Pre- References 
treatment 
Mouse MAb anti p53 D07 Novocastra 1: 50 MAR 87, 102, 104, 
lOS, 106, 107 
Mouse MAb anti-Bcl2 124 Dako-C}tomation 1:100 MAR 87, 104 106, 107 
Mouse MAb anti-BRCAI MSllO Oncogen Research 1:150 MAR 87, 102, 104, 
106, 107 
Rabbit MAb anti-ATM Y170 Abeam 1:100 MAR 102,104 
Mouse MAb anti-vimentin Vim3B4 Dako-C}tomation 1:250 MAR 104,106 
Mouse MAb anti-CKl9 BCK 108 87,104 
Mouse MAB anti-CK7t8 CAM 5.2 87,104 
Mouse MAb anti-al8 OCI0 Dako-C}tomation 1:100 MAR 87,104 
Mouse MAb anti-ER-Q( 105 Dako-C}tomation 1:200 MAR 87,104,107 
Mouse MAb anti- PR PR Dako-C}tomation 1:150 MAR 87,104,107 
Mouse MAb anti-Ckl4 llO02 Novocastra 1:40 MAR 87,104,107 
Mouse MAb anti-Ck5t 6 DS/161B4 <11emicon 1:60 MAR 87,104,107 
Mouse MAb anti-1I2 57/3 Serotec 1:10 MAR 108 
Mouse MAb anti-Ill 14C8 Gene Tex 1:100 MAR 108 
Rabbit antihuman HER-2 pol}Clonal Dako-C}tomation 1:100 No treatment 104, 107, 109 
Mouse MAb anti-Ki-67 MIBI Dako-C}tomation 1:300 MAR 104, 107 
Mouse MAb anti-SMA 1M Dako-C}tomation 1:200 MAR 87 
Rabbit MAb anti-cyclin Dl SP4 Lab vision 1:200 MAR 100 
Mouse MAb anti-E-cadherin HERCD1 Zymed 1:100 MAR 87 
Laboratories 
Rabbit polyclonal ant-FHIT ZR44 Zymed 1:600 MAR 87 
Laboratories 
A1M: ataxia telangiectasia mutated; BRCA1: Breast cancer 1, ER: oestrogen receptor, PR; progesterone 
receptor, Oc cytokeratin, SMA; smooth muscle actin, MAb: Monoclonal antibody. 
60 
Oupter J 
3.3.1 IHe scoring and evaluation 
The immunohistochemistry staining was evaluated by estimating the percentage (%) of cells 
showing characteristic staining (from Wldetectable level or 0% to homogenous staining or 
100%), by estimating the intensity (I) of staining (1, weak staining; 2, moderate staining; or 
3, strong staining), and by determining topographical localization (membranous, nuclear, or 
cytoplasmic). The IHC staining was semi-quantitatively scored by 2 pathologists using both 
Allred and H-scores as previously described 86,87, 110. For H-score assessment, 10 fields 
were chosen at random at x 20 Ill.'lgnification and the staining intensity was scored as 0, 1,2, 
or 3 corresponding to the presence of negative, weak, intermediate, and strong brown 
staining, respectively. The total number of cells in each field and the number of cells stained 
at each intensity were counted. The average percentage positive was calculated and the 
following formula was applied: H-score = (% of cells stained at intensity category 1 x 1) + 
(% of cells stained at intensity category 2 x 2) + (% of cells stained at intensity category 3 x 
3). A score between 0 and 300 was obtained where 300 was equal to 100% of tumour cells 
stained strongly (3 +). For quick score, the percentage of cells stained at the most 
frequent intensity was counted and given a score (0 '"" 0%,1 < 1%, 2 ... 1-10%,3 = 11-
33%, 4 = 34-46%, 5 = 67-100%), as was their intensity (1 ... weak, 2 ... moderate, 3 = 
strong). The total of the two scores gives the overall Allred score between 2 to 8 (by 
definition, there is no Allred score of 1). The intensity of staining (0-3) and percentage of 
nunour cells with unequivocal nuclear staining for Ki-67 (MIB1), ATM and BRCAl was 
recorded semi-quantitatively (0, no staining; 1, :::10%; 2, 11-25%; 3,26-50%; 4, 51-75%, 
5; >9'5%) 102, 104. Cytoplasmic staining was scored for Bc12, cytokeratin (0<. 5/6, 0<.8/18, 
CK19 and, 0<.7/8), smooth muscle actin (SMA), and vimentin and the intensity of staining 
(0-3) and the percentage of positive cells were recorded 87,104,106,107. 
61 
OJapter 3 
Inuntmoreactivity for all antibodies was separately assessed in both epithelial and 
myoepithelial cells when present. 
The expression in twnours and putative precursor lesions was compared to those of the 
adjacent IDLUs. In normal IDLUs and precursor lesions the expression of different 
biological markers was quantified by estimating the percentage of positive cells as follow 
(0= none, 1=< 1%, 2=1% to 10%, 3=11% to 33%, 4=34% to 66%, 5=67% to 90%, 
6=91%-99% and 7=100%) 104. The expression of CK19, CK7/8, CK18, CK5/6, CK14, 
SMA, and vimentin was evaluated for cytopl1smic staining with a cut off point selected at 
10% determined by reference to the histogram. 
The H-score was used to categonse cytoplasmic FI-IIT staining using the following 
thresholds: strong expression (H-score= 210-300); moderate (H-score = 110-209); mild (H-
score of < 110) and complete loss (P <10%). H-scoring was selected because it had been 
shown previously to be an appropriate technique for assessing H-IIT to determine clinical 
outcome in breast cancer87• 
For invasive breast lesions, we used the H-score to assess membranous E-cadherin staining: 
complete loss was defined by staining in less than 10% of the cells while, positive 
expression was further categorised into reduced (H-score ~ 1 0 0 ) ) and normal (H-score 
>100). However, in Chapter 2 we used a different scoring system for E-Cadherin as 
proposed by Simpson et al 2005 71 to detect subtle changes among precursor lesions in 
breast tissue samples. 
Only nuclear reactivity was considered for ER-oc and E R - ~ ~ and both were scored as 
continuous variables (percentage of positive cells) and using the Allred score with positive 
expression defined as staining in ~ ~10% cells or Allred score > 2 as cut-offs as previously 
determined. 86, 108, 110. 
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For p53 and cyt:lin D1, nuclear expression was categorized as follo'WS: 0: no staining; 1: 
staining in <1% of cells; 2: staining in ~ ~ 1% and < 10% cells; 3: staining in ~ 1 0 % % and < 
50% cells; 4: staining in ~ ~ 50% 100. p53 positivity was fwther subdivided into negative 
(score 0 or 1), borderline positive (score 2) and definite positive (scores 3 or 4)100. For 
cyclin D1, positive expression was defined as staining in 10% or more of the cells 100. For 
MIB-l, the proliferation index (PI) was determined for each case by calculating the 
percentage of positive cell nuclei. PI was stratified into low: <10% cells stained; 
intermediate: 10-30% cells stained; high: ~ 3 0 % % cells stained 100. For AlM, we considered 
lesions with <75% positive cells 102 as showing reduced expression, while all others were 
classified as normal expression. 
HER-2 expression was assessed according to the new />Senl CAP guidelines 109 by using 
IHC and fluorescence in situ hybridisation (FISH). Membrane IHC expression of HER-2 
was scored according to the Herceptest guidelines 109 and FISH was performed using a 
HER-2 and a centromere 17 (CEPI7) specific probe (V}Sis, IL, USA), according to the 
supplier's instructions. A positive HER-2 result is IHC staining of 3 (uniform, intense 
membrane staining of 30% of invasive tumour cells) or FISH amplified (ratio of HER-2 to 
CEP17 of 21) and a negative HER-2 is an IHC staining of 0 or 1 (no or faint incomplete 
membrane staining) or FISH ratio of less than 1.8. Equivocal for HER-2 is defined as 
either IHC 2 or FISH ratio of 1.8-21. 
3.3.2 Statistical analysis 
Associations between clinicopathological variables were performed using either Pearson's 
Chi-square test, Fisher'S exact test or Mann-'Whitney U anal}Sis where appropriate, using 
SPSS software (SPSS, Chicago, IL). Where appropriate, X2 test for trend, Student's t test 
and mov As one way test were used. To assess intra-lesional differences for markers 
producing multiple outcomes, the Kruskal-Wallis test was used. The correbtion between 
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different target antibodies within each lesion type was determined using the Spearman test. 
All tests were two-sided unless otherwise stated, with a confidence interval of 95%. 
Significant p value was <0.05. 
3.4. Res ults 
3.4.1 Immunohistochemical profile of TDLUs 
IDLUs comprise two cell layers: an outer basal (myoepithelial cells) and inner luminal cell 
layers (epithelial cells) slUTOunded with complete intact basement membrane showing 
strong positive complete laminin and collagen IV staining. In the IDLUs (associated with 
and without invasive lesions), all epithelial cells showed staining for one or more of the 
luminal cytokeratin, CX19, CX18, and CX8. A sm.,u proportion (<5%) of these epithelial 
cells co-expressed CX5/6, CX 14 and! or vimentin. None of the epithelial cells showed any 
staining for SMA The myoepithelial cells showed strong positive staining for SMA, 
vimentin, CX5/6 and CX 14. 
In IDLUs, 5-50% of luminal epithelial cells showed nuclear staining for ER-ct. The 
expression of ER-ct was significantly lower in IDLUs in pre-menopausal than in 
postmenopausal of both cancer-free cases (6% vs. 35%; p=O.OOOl) and adjacent to cancer 
(23% vs. 45%; p=o.0001), respectively. The expression of ER-a was significantly higher in 
IDLUs adjacent to preinvasive lesions with and without invasive lesions than in IDLUs of 
cancer free cases in both postmenopausal and premenopausal samples (p=O.OOl), (Tables 
3-3 and 3-4). None of the myoepithelial cells in IDLUs showed positive ER-ct. On the 
contrary, E R - ~ 1 1 was expressed in both luminal and myoepithelial cells; =»0% of luminal 
epithelial and myoepithelial cells expressed E R - ~ 1 . . The staining pattern was identical in 
IDLUs of normal control tissue from breast reduction specimens and in IDLUs adjacent 
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to tumour. In addition, no significant difference between the expression of E R - ~ l l in 
premenopausal and postmenopausal cases was detected (Tables 3-3 and 3-4). 
In IDLUs of premenopausal breast reduction specimens, only a few lwninal epithelial cells 
showed a strong Bcl-2 positivity (<10%), whereas strong Bcl-2 staining was fOlUld in 40% 
and >80% of lwninal epithelial cells lining IDLUs of postmenopausal reduction specimens 
and IDLUs SurrolUlding preinvasive/invasive cases, respectively «Tables 3-3 and 3-4). 
cx:::NDl expression was very low (<10%) in the lwninal epithelial cells both pre- and post-
menopausal IDLUs either of reduction breast specimens, preinvasive or of invasive 
carcinoma samples (Tables 3-3 and 3-4). 
The proliferation index (MIBl) was higher in premenopausal than in postmenopausal 
IDLUs of reduction breast specimen (2.5% vs. 0.5%). All IDLUs associated with low 
grade invasive tumours showed low MIB 1 (<10%) however, the expression of MIB-lin 
cases associated with preinvasive invasive lesions was significantly higher compared to 
reduction specimens. 
The epithelial cells lining the IDLUs showed positive expression of H-ITT, A1M, BRCA1, 
and E-Cadherin protein, and negative expression of pS3 regardless of the menopausal and 
malignancy status. 
65 
Oupter 3 I n m ~ ~ (hmuteristia iflawmiatr ?fade brrust 17JJfIasia 
Table 3·3: The average proportion scores* of different biological markers in different breast 
lesions not associated with invasive tumours. 
MaIkelli TDLUs TLDU UEH ax: CC FEA ADHI LN 
{pre Post H DaS 
Menopause Menopause 
ER·OI +2 +4 +3 +6 +6 +6 +6 +6 
E R · ~ t t +6 +6 +5 +5 +4 +4 +4 +4 
MIBt (%) 2.5 0.5 2.5 0.6 5 6.4 7 4 
Bell +1 +3 +3 +6 +6 +7 +7 +7 
CyclinDt +1 +2 +2 +2 +3 +3 +3 +3 
CKI9/19/S +6 +6 +4 +7 +7 +7 +7 +7 
CK5/6 +2 +2 +5 +1 +1 0 0 0 
Vunentin +1 +1 +4 0 0 0 0 
* Average proportion score representing the estimated proportion of positive cells 
(0; none, 1; <1%,2; 1-10% 3; 11 =33%,4; 34-66%, 5; 67-90% 6; 91-99%, 7; 100) 
Table 3·4: The average positive cells of different biological markers in tenninal duct lobular 
unite (IDLUs). 
MaIkelli TDLUs TDLU TDLU TDLU 
{pre· menopause Post· menopause Adjacent to Adiacentto 




% % % % 
ER·", 6 35 42 45 
E R · ~ 1 1 93 91 91 89 
MIB1 (%) 2.5 0.5 1.2 1.1 
Bell 7 40 75 80 
CyclinDI 1 7 6 6 
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3.4.2 Immunohistochemical profile of usual epithelial 
hyperplasia 
UEH showed intact basement membrane and extensive expression (>50% of luminal 
epithelial cells) of both basal cytokeratin (0<.5/6 and 0<.14), vimentin, ATM, FI-IIT and 
BRCA.l (Figure 3-1). However, no UEH epithelial cells showed SMA expression. In 
addition, the epithelial cells lining UEH showed heterogeneous (mosaic like) expression of 
luminal cytokeratin (0<.19, 0<.18 and 0<.8), ER-ct, ER-B, and Bel2. No expression of 
cyelin D 1 or p53 was noticed in any of UEH 
3.4.3 Immunohistochemical profile of CCLs lesions 
All folTI1S of CXl.s showed complete strong positive staining for both L'1!l1inin and collagen 
type VI. The majority of epithelial cells (>95%) lining cx:x::: and CCH showed strong 
positive expression of luminal cytokeratin (CK19, 0<.18 and 0<.8) and lack expression of 
basal O<.s (0<.5/6 and 0<.14), SMA and vimentin. While the neoplastic cells of the FEA 
and CXH with both cytological and architecture atypia showed homogenous expression of 
the luminal O<.S and consistently lacked expression of basaV myoepithelial markers 
(Tables 3-3 and 3-4). The epitheli..u cells of all folTI1S of CXL were strongly positive for 
ER-ct, ER-B, and Bcl2. However, ER-ct expression was reL'ltively lower in the epithelial cell 
lining of cx:x::: in lesions without invasion (75%) than in cx:x::: adjacent to invasive lesions 
(90%). The epithelial cell lining of cx::H, FEA, and CCH with cytological and architecture 
atypia showed strong and diffuse positivity for ER-ct. None of the CXl.s showed either 
HER-2 overexpression or p53 positive expression. All CXl.s were positive for BRCA.l 
andA1M. 
In addition, the epithelial cell population of a:.r., CCH, and FEA, with and without 
either preinvasive or invasive carcinoma were almost exc1usivelycomposed of Bc1-2 
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positive cells and the expression was strong to moderate (I = 3 or 2). Some ax. (39%), 
CXH (61%), and 76% of FEA showed positive expression of cydin 01. All a:r. and 
CCH, and the majority of FEA (92%) showed a low proliferation index (<10%). 
3.4.4 Immunohistochemical profile of LNGBC 
All tumor types belonging to LNGBC (low grade IDe, Te, 1Le, ICC and ILC) showed 
strong positive expression of ER+ and luminal O<s (0<19+, 0<18+ and 0<8+) and 
displayed negative expression of both basal O<s (0<14 and 0<5/6), vimentin and SMA 
compared to HGNBC Although the tubules of 1LC and TC and ICC lack the 
myoepithelial cell layer, they demonstrated discontinuous weak laminin staining at the 
interface with the stroma. While HNGBC and cl.'lSsic ILC and cord like structure of 1LC 
showed no staining at all of either collagen IV or laminin. 
Most LNGBC (93%) showed very low proliferation index (<10%) compared to HNGBC 
(>50% positive cells). Neither HER-2 overexpression nor HER-2 gene amplification was 
detected in any of the prectu'Sor lesions and their associated invasive LGBC/ILC; while 
11 % of HNGBC showed HER-2 overexpression (Table 3-5) 
A1M expression was absent or reduced in all lex:::, 22% of Te, 25% of 1Le, 33% of low 
grade lOG NST and 40% of ILC compared to 53% of HNGBC In cases showing 
coexistent FEA and! or in situ carcinoma with the invasive component, A 1M expression 
was identical in both lesions. No positive nuclear expression of p53 was detected in ICC 
(0%), TC (0%), and 1LC (0%), ILC (2%) and low grade IDC (3%) compared to 44% of 
HGNBC BRCA1 negative expression was very rare in ILC (1%), ICC (0%), and 1LC (0) 
and uncommon in TC(13%). 
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Table 3-5: Summary of immunohistochemical expression of different target antibodies in and 
invasive classic lobular carcinoma 
TC ICC Low grade TLC Cassie ILC X2 
Antibodies IOC 
(n=135) (n=3O) (n={60) (n-20 (n=180) p 
(n) (%) (n) (%) (n) (%) (n) (%) (n) (%) 
CK19 135 100 30 100 60 100 20 100 180 100 NS 
CK7/8 135 100 30 100 60 100 20 100 180 100 NS 
CK18 135 100 30 100 60 100 20 100 180 100 NS 
SMA 1 0.7 0 0 2 3 0 0 1 .06 NS 
Vunentin 1 0.7 0 0 2 3 0 0 1 .06 NS 
CKS/6 1 0.7 0 0 0 0 0 0 2 1.2 NS 
CK14 1 0.7 0 0 0 0 0 0 2 1.2 NS 
ER-OI 132 98 30 100 56 93 20 100 168 93 NS 
E R - ~ ~ 131 97 30 100 58 97 20 100 160 89 0.01* 
p53 3 3 0 0 2 3.3 0 0 6 3.3 NS 
c-erbB-2 0 0 0 0 0 0 0 0 0 0 
E-Cadherin 2 1.5 0 0 2 3.3 1 10 160 89 0.001* 
(Loss) 
There was no significant difference between the expression of luminal CK.s, myoepithelial and basal 
markers, hormonal receptors, HER-2 and p53 in TC, cribriform, low grade IDe, TLC and classic 
ILC 
,. E-Otdherin and E R - ~ ~ showed significant difference between LGBC and ILC 
LGBCs: low grade breast carcinomas; ICC: invasive cribriform carcinoma; CK.: cytokeratin; EGFR: 
epidermal growth factor receptor; ER-a: oestrogen receptor alpha; E R - ~ : : oestrogen receptor beta; 




3.4.5 Lobular differentiation 
AlllDLUs, UEH, ax:" CCH, FEA, ADHilow grade DOS showed normal expression of 
E-cadherin while LN was E-cadherin negative. The majority of Te, cribriform carcinoma, 
low and high grade IDe, and lie, differed from the majority of ILC in being positive for 
E-cadherin (Tables 3-6 and 3-7). In lie, both tubules and cord like cells were positive 
for E-cadherin. In contrary to lie, the separate foci of lobubr carcinoma in mixed 
tubular! classic ILC tumours showed complete loss of E-cadherin 
3.4.6 Evidences of progression of CCLs to invasive 
. 
carcinoma 
All the precursor lesions including CXl..s, DOS and LN showed positive expression of 
luminal CXs (CX19, CX18 and CX 8) and negative expression of CX14, CXS!6, vimentin 
and SMA identical to matching or consequent invasive carcinoma. The ER-a and Bc12 
expressions were significantly higher in all forms of CXl..s (ax:" cx:H, and FEA) than in 
adjacent lDLUs in samples with and without invasive cancers. 
The percentage of E R - ~ ~1 positive cells significantly decreased (P <0.001) in all forms of 
cx:.:L (CX::C: 80%, CXli: 75%, FEA: 60%) compared to matching lDLUs. 
The ratio of ER-IX p o s i t i v e ! E R - ~ l l positive cells progressively increased from normal (OJ) 
to a:r.. (1.13) to cx::H (1.58), to FEN ADHilow grade DOS (1.7) to their co-existing 
invasive low grade nuclear tumours (3.3) and it was statistically significant (p=O.Ol). In 





There was a significant stepwise increase in the percentage of cydin Dl positive cells from 
normal to err, to CXH/FEA to ADHilow grade DOS to invasive carcinoma (p=O.OOl, 
Kruskal-Wallis test), (Figure 3-2). 
There was a positive correlation between the level of ER-IX expression and both Bcl-2 and 
cyclin Dl in the progression from nonnal to invasive ttunours (p=O.OOl). 
Proliferation rate was significantly elevated in CXl-I (5%), FEA (6.4%), ADHIDOS (7%) 
and LN (4%) as compared with IDLUs (1.1%), UEH (2.5%) and err, (1.5%) in both 
cancer-free and cancer samples (Tables 3-4, 3-5 and 3-7). 
The epithelial cells lining the IDLUs and err, showed strong uniform expression of Fl-IIT 
protein regardless of the malignancy status. 80% of low nuclear grade carcinoma showed a 
reduced expression of Fl-IIT in which there was a progressive loss of Fl-IIT in the 
associated putative precursor lesions. In invasive HNGBC showing co-existence in situ 
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Figure 3· 1: Immunohistochemical expression of different target antibodies in different low grade 
breast neoplastic lesions. 
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Figures (1 AI-III) show an example of usual epithelial hyperplasia ( U E I - ~ ~ exhibiting heterogeneous 
expression for CK19 (AI) and extensive expression of CKS/6 and vimentin (AIl, AIII). Figures (1 
BI-IV) show an example of flat epithelial atypia (FEA) with (main fig) and without (inset) complex 
architecture associated with invasive tubular carcinoma (Ie) (main fig). This case showed 
homogenous expression of CK 19 (B I) and lack of expression of CKS/6 (B II) and vimentin (B III). 
Although the expression of CK19, CK8 and CK18 similar in almost all lesions in our series, in this 
example (B IV) the majority of neoplastic in FEA and TC were negative for ex 18. Bcl-2 expression 
is shown in figures (1 C I-III). The epithelial cells (ECs) in the terminal duct lobular units (fDLUs) 
(C I) and FEA (C II) showed strong expression for Bcl.2, whereas TC (C III) showed moderate 
expression of Bcl·2. Figures (1 D I-III) demonstrates levels of expression of oestrogen r e c e p t o r - ~ ~
( E R - ~ I ) ) in a typical case and shows that all ECs in IDLUs (D I) were positive for E R · ~ . . The 
percentage of E R - ~ ~ lpositive cells decreased in columnar cell hyperplasia (D II) and the associated 
TC (D III). Oestrogen alpha (ER-IX) expression is showing in fig (1 E I-VII). Only occasional ECs 
in normal lDLUs (E I) showed positive nuclear stained for ER-IX while the majority of ECs in 
columnar cell changes were positive for ER-IX (E II). A case with FEA ( E III), ADHilow grade 
DOS ( E IV) and lobular neoplasia (LN) (E V) uniformly displayed strong nuclear expression for 
ER·IX Similarly, in the invasive tumours the majority of the neoplastic cells were positive for ER·IX 
with a moderate to weak staining intensity. (E VI TC, E VII invasive lobular carcinoma). FI-IIT 
expression is shown in figures (1 F I-III). ECs lining the IDLUs (F I) showed a strong uniform 
expression of HIlT protein. Progressive loss of FI-llT in the associated IN (F II) and ILC (F III) 
were seen. A1M expression is shown in figure 1 (G) in an example of ILC which showed negative 
expression of A1M while the stromal fibroblasts showed characteristic nuclear positive staining (red 
arrows). Growth fraction assessed using MIB·l staining, figure 1 (H I-II), generally showed low 
levels as illustrated in a case of ILC (H I) with associated IN (H II). 
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Figure 3-2: Comparison between the percentage of positive cells (left) and H-score (right) for 
oestrogen receptor-o: (A), oestrogen r e c e p t o r - ~ ~ (B), Bc12, (q, Cydin Dl (D) in samples belonging to 
the low nuclear grade breast neoplasia family including normal tenninal duct lobular units (TDLUs) , 
columnar cell changes (ceq, columnar cell hyperplasia (CXH), flat epithelial atypia (FEA), 
carcinoma in situ (OS) and invasive low grade breast carcinomas (LGBCs). Only the H-score was 
used to assess HllT (E) . 
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Table 3-6: Q,mparison of immunohistochemical expression of different target antibodies amongst 
low grade breast carcinoma (LGBq, invasive lobular carcinoma ~ L q q and high grade invasive. 
Family Antibodies Expression LGBC High gmde Xl 
(n-415) IOC p 
(n=670) 
n % N % 
Lumina1CKs CK1S/S/19 Positive 415 100 516 77 0.001 * 
High molecular CK5/6 Positive 3 0.7 168 25 0.001* 
weight c}toker.ttin CK14 Positive 3 0.7 154 23 0.001* 
M)OC!pithelial SMA Positive 3 0.7 80 12 0.001 * 
Markers 
Honnone ER-(l Positive 336 95 288 43 0.001* 
Receptors E R - ~ l l Positive 3ll 75 496 74 NS 
Twnour p53 Positive 11 3 295 44 0.001* 
Suppressor BRCAI Loss 21 5 188 28 0.001 * 
ATM Loss 91 22 355 53 0.001 * 
E-cadherin Loss 166 40 14 0.001 * 
EGFRfamily c-erbB-2 Overexpression a a 17 28 0.001 * 
Prolifer.ttion index Ki67 High PI (>10%) 17 4 536 65 0.001* 
Mesenchymal positive 0 a a 141 21 0.001* 
marker 
Table 3·7: Proliferation index (PI) of normal terminal duct-lobular units, breast cancer precursors 
and invasive lesions. 
MIB-! PI TDLUs UEH CCC <Xli FEA ADH/low Gl/G2 
gmde DCIS Invasive 
Range Q.9.9 Q.9.9 Q.9.9 Q.9.9 Q.20 Q.30 Q.36 
Mean ±SD 1.I±2.1 1.6±3.2 1.5±2.3 5±H 6.42±4.9 7.1 ±8.3 9.1±10.8 
Low PI (%) 100 100 100 100 93.5 89 87.3 
Inte nnediate PI a a a a 6.5 11 8.7 
(%) 
High PI(%) 0 a a 0 0 0 4 
ADH: atypical ductal hyperplasia; a:x: columnar cell change; CXH: columnar cell hyperplasia; 
DaS: ductal carcinoma in situ; FEA: flat epithelial atypia; LN: lobular neoplasia; IDLU: terminal 
duct-lobular unit; UEH: usual epithelial hyperplasia. 
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3.5. Discussion 
In this study, we expanded our investigation to explore the immunohistochemical 
phenotype of the putative precursor lesions and related cancers and to test the hypothesis 
of whether low grade IDC TC invasive cribrifonn carcinoma (Ic:q, liC and classic ILC 
carcinomas share a common phenotype supporting their direct evolutionary links to CCLs, 
particularly flat epithelial atypia (PEA). Furthennore, we postulate a model for the 
biological events that are associated with ER-oc in the development of pure invasive low 
nuclear grade carcinoma. 
Low grade IDC TC invasive cribrifonn carcinoma, classic ILC and liC all have a 
relatively favourable prognosis, possibly due to high levels of differentiation which may be 
the consequence of fewer genetic aberrations. In Cbapters 2 and 3, we reported a high 
frequency of co-existence of CXl..s, ADHilow grade DOS and LN, with TC liC and 
ILC respectively suggesting that these lesions fonn a family of low nuclear grade precursor, 
in situ and invasive neoplastic lesions of the breast. In this report, we provide further 
evidence supporting the hypothesis that CXl...s are the precursor of LNGBC using an 
immunophenotyping approach encompassmg expreSSlon of cytokeratin, cell 
proliferation! d i f f e r e n t ~ ' 1 t i o n n markers and a number of putative tumor suppressor genes 
(TSGs). 
Our results call into question the role of UEH as a Be precursor. Firstly, UEH only shows 
a low reL'ltive risk (1.5 times) of subsequent carcinoma development 66. Although some 
studies 89, III, demonstrated similar copy number changes in UEH and DOS, Simpson et al 
(2005) 71 differentiated UEH from some forms of CCLs, and found no or only few and 
apparently random chromosomal changes in agreement with other studies 112, 113. 
Furthennore, UEH does not fit well on the histological continuum to invasive BC 66 and no 
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association between the presence of UEH and LGBC was observed in previous chapter. In 
this study, we found that UEH showed extensive expression for CXS/6, CX14 and 
vimentin and heterogeneous expression for ER. Bcl-2, FI--IIT, cydin Dl and CX19/18/8. 
In contrast, FEA, ADHllow grade DOS, and LN were consistently negative for CXS/6, 
CX14 and vimentin and positive for ER-ex, Bcl-2, cydin Dl, and CX19/1S/S. The latter 
phenotype was shared with their co-located LGBC lesions. The immunophenotype of 
UEH infers that this lesion either is unreL1.ted to or is a side branch of the LNGBC 
evolutionary pathway 52. Based on the morphological, immunohistochemical and molecular 
genetic data, we favour the former interpretation and believe that the vast majority of 
UEHs are not precursor lesions of LNGBC 
Presently, cancer is perceived as a clonal disease that depends on multiple genetic mutations 
in division-competent stem and progenitor cells 62. After transformation, these cells can 
become neoplastic due to deregulation of self-renewal, d i f f e r e n t ~ ' 1 t i o n , , membrane transport 
activity, telomerase activity and anti-apoptotic pathways, resulting in the ability to migrate 
and metastasise 62. Subsequently, the heterogeneity of BCs may derive from inherent 
differences in the underlying originator cell population and! or result from stochastic 
genetic and epigenetic events causing different combinations of oncogene activation and 
loss of tumour suppressor gene (TSG) function in normal breast stem or committed 
progenitor cells 27-30,63-65. 
Several models of stem and progenitor cells of the breast have recently been put forward as 
we mentioned previously in chapter 1. Whilst some suggested that the earliest progenitor 
cells in the epithelial bud are negative for basal cell markers and CXS/18, but positive for 
CX19 and Bcl-2, others suggested the stem cells are positive for CXS/6 and negative for 
CX19. However, some investigators suggested the existence of two distinct epithelial 
progenitor cell types 37-38. According to the latter, one of the precursor cells has a luminal 
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phenotype (CK.8/18+, CK.19+, MUC1+, ESA+, C01C-, CK.14- and CK.5/6-) and a 
second comprises bipotent progenitor cells (MUCl- /C010+ /ESA+) with potential to 
generate mixed colonies of both epithelial cells and myoepithelial cells. In agreement with 
this proposal, some researchers 31, 34 proposed that the CK.19 + and ER + positive cells, 
respectively, were the progenitor cells in their model of hwnan breast progenitors. 
It has been shown that oestrogen can indirectly induce proliferation and inhibit apoptosis, 
resulting in cell proliferation and growth 114. In our study, we fOWld that a high percentage 
of contiguous cells in cx:Ls expressed ER-Q( with a progressive increase in CXl-f, and rising 
even fwther with the appearance of atypia, in agreement with a previous study 115. In 
contrast, normal breast tissue showed ER-Q( positive epithelial cells surroWlded by ER-Q( 
negative cells, indicating proliferation of ER-positive cells in both precancerous and 
cancerous breast lesions 34. Our findings could be interpreted as evidence in support of the 
hypothesis that the ER+ luminal restricted progenitor (ER+, MUC1 +, CK.8/18 + and 
ex 19 +) cells -as we have shown in the introduction- could be the cell of origin that give 
rise to the LNGBC family or families and their precursors. However, there are several lines 
of evidence to suggest that the final phenotype of the tumour should not be regarded as a 
mere reflection of that of its progenitor cell phenotype 116,117. This is also exemplified in the 
mouse model developed by McCarthy and colleagues 118, where the authors inactivated 
Brca1 and tp53 in the epithelial cells of mouse mammary gland and the animals developed 
basal-like cancers. 
In accord with others 103, 108, 119, we have fOWld that E R - Q ( / E R - ~ 1 1 expression ratios 
increased from normal towards the invasive tumours, supporting the hypothesis that ER-Q( 
and E R - ~ - s p e c i f i c c pathways may have an important role in this process 120. It has been 
suggested that the E R - ~ 1 1 gene may have tumour suppressive fWlctions 121. E R - ~ 1 1 may 
80 
regulate ER-IX-mediated transcriptional activation, providing protection against ER-IX 
induced hyper-proliferation 114. 
We found the expression level of the known ER-IX responsive gene cydin D1, increased in 
a stepwise manner from normal to CCLs to invasive lesions 122, 123. In agreement with 
others 124,125, we found positive and negative correlations between C}din Dl with ER-IX and 
E R - ~ 1 1 respectively, suggesting that these receptors may oppose each other for regulating 
cell proliferation via cydin Dl126. Epithelial Bcl-2 expression declined from precursor to 
LNGBC, as previously reported 127,128. Strong Bcl-2 expression was associ.'1ted with ER-a 
positivity, low NITB-1 expression, an absence of p53 mutation and low level of HER-2 
expression. 
We investigated the presence of a number of putative TSGs in our family of precursor and 
LNGBC to assess their involvement at different stages of carcinogenesis. In LGBCs, 
deletion of chromosome 11q23-25, containing ataxia telangiectasia mutated (ATM), is 
common 102. A1M phosphorylates p53 causing its stabilisation which is required for cell 
cycle arrest, DNA repair, or apoptosis. A reduction in A1M protein and mRNA levels has 
been reported in invasive BCs 101,129. In our study, 22% of FEA,.ADHllow grade DaS, 
LN and LNGBC showed low or absent A1M expression compared to normalIDLUs. 
Moreover, concurrent positive expression of Bcl-2 and lack of p53 nuclear expression were 
found in cases with low or absent expression of ATM. In leukaemia, ATM has been 
shown to represent an alternative regulatory mechanism of 11>53 mutation 130 and it is not 
known if it has a similar function in breast cancer. 
The function of BRCA1 is still unknown but it is proposed to be a TSG with transcriptional 
activity; it is involved in cell proliferation processes of mammary epithelial cells in response 
to hormonal stimulation, in apoptosis, control of recombination, and genome integrity after 
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binding to proteins involved in these activities. In accordance with other studies 101. 102 we 
fOWld that BRCAl-associated BCs were associated with HNGBe, high PI, high 
frequencies of high p53 protein expression, loss of A 1M and negativity of ER 
In vivo animal studies support a tumour suppressor role for fragile histidine triad (FHI1) 
131. We fOWld reduced FHIT levels in the majority of CCH, FEA, ADHilow grade DOS, 
LN and the associated invasive lesions, in accordance with others 101. Importantly, we 
noted an inverse correlation between FHIT and Bcl-2, cyclin Dl, and ER-ex expression 
supporting its role in the development of LNGBC 
E-cadherin (CDHl) is a TSG localised on chromosome 16q21 and is frequently lost in ILC 
Our results demonstrate that whilst cx::Ls, ADH'low grade DOS, Te, rex::, low grade 
IDe, and TLC are positive for E-cadherin, LN and ILC lack expression of this tumour 
suppressor gene and adhesion molecule. Our observations support the idea that loss of 
normal CD Hl gene expression may switch on the development of lobular differentiation 52. 
60. 
In summary, our findings demonstrate that FEA, ADH'low grade DOS, LN and invasive 
low grade breast cancers have remarkably similar immWlophenotype and that this 
phenotype is distinct from that seen in high grade breast cancers. Given that the 
morphological and immWlohistochemical features of FEA cells are almost identical to 
those seen in ADHilow grade DOS and LN, and that the molecular genetic changes of 
FEA are similar to those found in matched low grade breast cancers 71, our findings suggest 
that FEA is a conunon non-obligate precursor of LGBC and ILC Taken together, these 
lesions may represent a family of precursor, in situ and invasive neoplastic lesions belonging 
to the luminal 'N subclass of BC Furthermore, our findings demonstrate that the balance 
between ER-ex and E R - ~ ~ expression may be important in driving cydin Dl and Bcl-2 
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expression, that p53 inactivation and HER-2 overexpressionl HER-2 gene amplification 
are uncommon phenomena in this family of lesions. 
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ClJatJter 4: 
... 
The need for a biological grading system and its 
relationship to current Nottingham Histological 
Grading System (NGS) 
4.1 Abstract 
In chapter 3 we found that the low nuclear grade breast neoplasia family including tubular 
carcinoma and invasive classic lobular carcinoma is characterized by low mitotic index and 
positive expression of Bcl2. In this study, we hypothesised that the interaction between 
mitotic index (M) and Bcll accurately discriminates between low and high-grade breast 
cancer {Bq and provides a more objective measure of clinical outcome than histological 
grade especially for patients with intermediate histological grade, small size or oestrogen 
receptor (ER) negative cancers. 
A well characterised senes of 1650 BC with long term follow-up was 
immunohistochemically profiled for Bcll. Mitotic index (M) was assessed according to 
Nottingham Grading System (NGS): M1: <10 mitoses; M2: 10 to 18 mitoses; M3: > 18 
mitoses. Results were validated in an independent series of patients (n=245) unifonnlr-
treated with adjuvant anthracydine-based chemotherapy. Subsequently, BC were classified 
according to the combined WBcll profile and compared to NGS. 
In multivariate Cox regression models including validated prognostic factors, the subgroups 
defined by WBcll profile remained significantly associated with patients' outcome but also 
performed better than lymph node status and tumour size. Incorporation of the WBcll 
profile into the Nottingham Prognostic Index (NPI) accurately reclassified twice as many 
Oupter4 Bida;jml Grade S)5tem 
patients into the excellent prognosis group, improving decision-making for which patients 
should be spared systemic adjuvant therapy. Patients with M2-3/Bcl2- and M3/Bcl2+ (high 
risk) had a 2-3 fold increase in the risk of recurrence when treated with either adjuvant 
honnone therapy or anthracydine-based chemotherapy than those with MlIBcl2± and 
M2/Bcl2 + {low risk) (HR= 3.4 (2.8-5.6); p <!).Q001 and HR=2.3 (11-4.3); p=O.0009). 
In conclusion a grading system defined by mitotic counting and Bcl2 expression accurately 
reclassified patients with NGS-G2, small size cancers or ER negative into two groups: low 
risk (NGS-G 1 like ) versus high risk (NGS-G3 like) of both Be mortality and recurrence, 
improving prognosis and therapeutic planning. 
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4.2 Introduction 
The Elston-Ellis modified Scarff-Bloom-Richardson grading system (aka, Nottingham 
Grading System; NGS) is one of the most widely used methods of breast carcinoma (Bq 
grading 132. NGS provides a consistent prognostic tool which has been validated in multiple 
independent studies 133. One of the main limitations of NGS, however, is that 30%-60% of 
BCs are still classified as grade 2 (G2), which is a category with ambiguous clinical 
significance due to its intennediate risk of recurrence 134. Furthennore, for statistical 
analysis, G2 cancers are often combined together with either G3 or G 1, rendering 
interpretation of the results challenging and leading to a debate of whether grade should 
pbya role in therapeutic planning 1J5. F urtherrnore, it has been argued that NGS has little or 
no prognostic role in either early stage small tumours or in oestrogen receptor (ER-) 
negative subgroup 136. 
In previous chapters, we proposed that some special types of BC including invasive classic 
breast carcinoma (grade 2) and tubular carcinoma (grade 1) constitute a biologically reL1.ted 
neoplastic family named "low nuclear grade breast carcinoma (LNGBq" 104. Our LNGBC 
proposal is based not only on the clinical outcome 10 but also on the remarkable similarity of 
the morphological, immunophenotypic, and reported molecular genetic characteristics 52, 
Among the biological characteristic features of this family were low mitotic index (M) and 
Bc12 positivity (Bc12 +); (Figure 4-1). 
In this study, we explore the hypothesis that a grading system based on balance between 
"M" as a proliferation marker and "Bc12" as a cell cydel apoptosis regulator would be 
capable of accurately discriminating between low and high-grade tumours and providing a 
more objective and clinically valuable measure of tumour grade with prognostic significance 
86 
BidCfiml Grade S)5tem 
for invasive Be in general and particularly in moderately differentiated, small and ER 
negative (ER-) cancers. 
Figure 4-1: Low nuclear grade breast neoplasia family showed strong positive expression of Bel2 
87 
Oupter4 Bid0imJ Grade S)5tem 
4.3 Patients and Methods 
We studied a series of primary operable invasive BCderived from the Nottingham Tenovus 
Primary Breast Carcinoma Series of women age :570 years, Nottingham Oty Hospital 
(1989-1999). 1650 consecutive cases were informative and included in this study as they had 
complete clinical, therapeutic and biological cbta avaibble. The clinicopathological 
characteristics of our cohort are summarised in (Table 4-1). 
Tumour grade and mitotic index data were assessed by experienced pathologists with strict 
adherence to the NGS \32 protocol M was assessed at the periphery- of the tumour and 
scored according to the observed frequency dependent on the field area of the objective 
lens used, for example as follows: M1 = Low, if <10 mitoses, 112 ... medium, if 10 to 18 
mitoses and M3 = high, if > 18 mitoses (per 10 high-power fields with field-diameter; 0.56 
rom). The Nottingham Prognostic Index (NPI) was calculated using the following equation: 
NPI =02 tumour size (em) + grade (1 to 3) + LN score (1 to 3) 137. Six NPI groups are 
recognised according to NPI: an Excellent Prognostic group (EPG); 2.08 to 2.4, Good 
(GPG); 2.42 to 3.4; Moderate I (MPG I) 3.42 to 4.4, Moderate II (MPG II); 4.42 to 5.4, 
Poor (PPG); 5.42 to 6.4 and very- poor (vpG); 65-6.8. 
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Table 4-1: Clinicopathological characteristics of Nottingham whole cohort 
Variable n* Cases (%) 
Menopausal status 1650 
Pre-menopausal 612 37.0) 
Postmenopausal 1038 (63.0) 
TumourGrade (NGS) 1650 
Gl 306 18.5 
G2 531 32.2 
G3 813 49.3 
Lymph node stage 1650 
Negative 1056 64.0) 
Pos itive (1-3 nodes) 486 29.5) 
Pos itive ( >.) nodes) 108 6.5) 
Mitotic activity 1650 
Ml low; mitoses < 10) 617 37.4 
M2 medium; mitoses 10-18) 300 18.2 
M3 high; mitosis >18) 733 44.4 
Survival at 20 years 1650 
Alive and wen 1055 64.0) 
Dead from disease 468 (28.4) 
Dead from other causes 127 7.6) 
Adjuvant systemic thernpy(AT) 1602 
No AT 665 42) 
Hormone therapy (HT) 642 41) 
Otemotherapy 307 20) 
Hormone + chemotherapy 46 3) 
Tumour type 1650 
Ductal no special (NST) 940 57) 
Tubular mixed 295 18) 
Tubular pure 54 (3) 
ILC classic 100(6) 
Othertypes ofILC 122 (7) 
Medullary can:inoma 41 (3) 
Others 98 (6) 
Tumoursize (em) 1650 
Tla +b«1.0) 187 11) 
T1 c (>1.0 -2.0) 868 53) 
T2 >2.CJ.S) 5729 (35) 
T3 >5) 16 (1) 
* Number of cases for which data were available. 
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Adjuvant systemic therapies (A 1) were scheduled on the basis of prognostic and predictive 
factor status including NPI 137, oestrogen receptor-oc (ER-oc) status, and menopausal status. 
Patients with NPI ~ 3 . 4 4 did not receive AT. Hormonal therapy (HI) was prescribed to 
patients with ER-oc + tumours and NPI >3.4. Pre-menopausal patients with NPI >3.4 were 
candidates for CMF (Cyclophosphamide, Methotrexate, and 5-FlourouraciJ) chemotherapy. 
Conversely, postmenopausal patients with (NPI >3.4 and ER-oc +) were offered Hr, while 
ER-oc- patients received CMF if fit. 
Exploratory subgroup analysis of the MlBc12 surrogates was also performed in AT 
untreated lymph node negative patients. 
4.3.1 Clinical outcomes of M/Bc12 profile in specific AT 
settings 
To evaluate whether the different MlBc12 subgroups had different clinical outcomes in 
specific AT settings, we investigated the clinical outcome of 474 and 295 of Nottingham 
high risk patients (NPI >3.4 and ER+) and (NPI >3.4 and pre-menopausal) who had Hr 
and CMF based chemotherapy, respectively. In addition, we compared the survival of high 
risk AT-treated patients to those of AT untreated for each MlIBc12 subgroups. 
4.3.2 Validation Study 
We also used an independent series of 245 invasive Be diagnosed and managed at the 
Royal Mwden Hospital (RMH) between 1994 and 2000 (Breakthrough series). Patients 
were selected on the basis of being eligible for therapeutic surgery and receiving standard 
anthracycline-based AT. All patients were primarily treated with surgery followed by 
anthracycline-based chemotherapy. ill was prescribed for patients with ER+ tumours 
(tamoxifen alone in 96.4% of the patients for the available follow-up period). Complete 
follow-up was available for 244 patients, ranging from 0.5 to 125 months (median = 67 
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months, mean == 67 months). The characteristics of this cohort are described elsewhere 107 
and summarised in (Table 4-2). It should be noted that any differences between 
Nottingham population and RMHIBreakthrough series may be a reflection of the different 
treatment protocols that were used. For instance most of RMI-VBreakthrough cases of 
larger size and higher stage as it is composed solely of patients who received AT. 
4.3.3 Survival data 
SUIVival data including BC sUIVival time (BesS), disease-free sUIVival (DFS) , and 
development of loco-regional and distant metastases (DM) were maintained on a 
prospective basis. BesS was expressed as the number of months from diagnosis to the 
occurrence of BC related-death. DFS was defined as the number of months from diagnosis 
to the occurrence of local recurrence (LR) , local LN relapse or DM relapse. DM-free 
sUIVival (MFS) was defined the number of months from diagnosis to the occurrence of DM 
relapse. 
4.3.4 Immunohistochemistry (IHC) assay 
In both Nottingham and Breakthrough series, tumours were arrayed in tissue microarrays 
(!MAs) constructed with 2 replicate 0.6 mm cores for each marker. The TMAs were 
immunohistochemically profiled for Bc12 and a panel of other antibodies. Details of 
antibodies, antigen retrieval, immunohistochemical methods were summarized ill 
(Table 4-3). A cut-off for Bc12 was selected at 10% as previous described106• 
To validate the use of TMAs for immunophenotyping, full-face sections of 20 cases were 
stained and the protein expression levels of the different antibodies were compared. The 
concordance between TMAs and full-face sections was excellent (kappa=o.8). 
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Positive and negative (omission of the primary antibody and IgG-matched serum) controls 
were included in each run. 
HER-2 expression was assessed according to the new /\SeD/ CAP guidelines 109 (Table 4-
4) using IHC and fluorescence in situ hybridisation (FISH); FISH was perfonned for HER-
2 IHe score 2+ cases using a HER-2 probe and a centromere 17 (CEP17) specific probe 
(Vysis, IL, USA), according to the supplier's instructions. 
For the Breakthrough TMA, immunohistochemistry was perfonned with antibodies raised 
against the following markers: Bcl2, ER, progesterone receptor (PR), HER-2, EGFR, CK 
5/6, ex 14, CK 17, Cyclin D1, KI67, p53, and topoisomerase II IX, as reported elsewhere 
137. TMA sections were also subjected to chromogenic in situ hybridisation (asH) with 
SpotLight probes for CCND1, MYc, HER-2, TOP2A, and chromosome 8 centromere as 
previously reported 138. 
The immunohistochemical scoring for Bcl2 and mitotic count was perfonned by at least 
three observers, who were blinded to the results of the patients' outcome in two different 
settings. There was excellent intra and inter-observer agreements (k > 0.8; Cohen's x and 
multi-rater x tests, respectivel0. 
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Table 4-2: Oinicopathological characteristics of the RMI-VBreakthrough series 
Variable RMH/Breakthrough Series (n=245) 




T w n o u r h i s ~ ! Q g i c a l l grade 2{Q 
G1 23 (10) 
G2 69 (29) 
G3 148(62) 
L}mph node stage 237 
Negative 38 (35) 
Positive 154(65) 
Survival ** 244 
Alive and v.ell 179 
Dead from disease 42 
Dead from other causes NA" .... 
Adjuvant s ~ t e m i ~ ~ the rap): (AI) 245 
No AT 0(0) 
Honnone therapy (I-n) alone 0(0) 
Ckmotherapyalone 53 (22) 
Honnone + chemotherapy 1921781 
Twnoursize (em) 243 





*Number of cases for which data were available. 
** Survival data for NottinghamlTenovus series were available for up to 20 ~ a r s s and for 
RMHIBreakthrough series for up to 10 ~ a r s . .
***: Deaths of causes other than breast cancer were censored at last follow up. 
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Table 4-3: Primary antibodies, clone, source, optimal dilution and scoring system used for each 
immunohistochemical marker 
Antibody aone Source Dilution Cut·!!fu. &i. 
Mouse MAb anti p53 D07 Novocastra I: 50 10% 87, 102 .. 107 
Mouse MAb anti·Bc12 124 Dako-C},{omation 1:100 10% 87, 104, 106, 107 
Mouse MAb anti·BRCAl MSllO Oncogen Research 1:150 25% 87, 102, 104, 
106, 107 
Rabbit MAb anti·ATM Y170 Abeam 1:100 25% 102, 104 
Mouse MAb anti·CKl9 BCK 108 Dako-C},{omation 1:100 10% 87, 104 
Mouse MAb anti·CKIS OCIO Dako-C},{omation 1:100 10% 87, 104 
Mouse MAb anti·CK7/S CAM 5.2 Becton Dickinson 1:10 10% 87, 104 
Mouse MAb anti·CK5/ (; D5/16134 Dako-C},{omation 1:100 10% 87,104 
Mouse MAb anti·CKl4 llO02 Novocastra 1:60 10% 87,104 
Mouse MAb anti· HE(D.l Z ymed Laboratories 1:100 10% 87 
E·cadherin 
Mouse MAb anti·Ki·67 ?vUBI Dako-C},{omation 1:100 10% 104, 107 
Mouse MAb anti·ER·Q! IDS Dako-C}'{omation 1:100 10% 87, 104, 107 
Rabbit antihuman Dako-C}'tomation 1:100 see text 104, 107, 109 
HER·2 
Mouse MAb anti· P21 EAI0 Abeam 5ug/ml 10% 104,106, 107, 
139 
Mouse MAb anti· P27 SX53GS Dako-C},{omation 1:50 10% 104, 106, 107 
All sections were pre-treated with microwave antigen retrieval using 0.1 % citrate except those for c-
erbB2 did not pre-treat. 
ATM: ataxia telangiectasia mutated; BRCA1: Breast cancer 1, early onset; CK.: cytokeratin; ER-cx: 
oestrogen receptor alpha; c-erB2, human epidermal growth factor receptor 2. MAb: Monoclonal 
antibody. 
Table 4-4: HER-2 expression according to ASCD! CAP guidelines 
HER·2 Status Criteria 
Positive 0 IHC staining 3 +: unifonn, intense membrane staining of >30% of 
invasive tumor cells (ory 
0 HER·2:CEPI7 FISH ratio >2.2 
Equivocal 0 IHC staining 2 +: complete membrane staining that is either non-uniform 
or v.eak in 
intensity but with obvious circumferential distribution in at least 10% of 
cells (or) uniform, intense membrane staining of 530% of invasive tumor 
cells (or) 
0 FISH ratio of 1.8-2.2 
Negative 0 IHC staining 0 or 1 +: no or faint incomplete membrane staining) (or) 
0 FISH ratio HER-2:CEPI7 FISH ratio <1.S 
HER-2, human epidermal growth factor receptor 2; IHe, immunohistochemistry; FISH, fluorescent 
in situ hybridisation; CEP17, centromere 17 specific probe 
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4.3.5 Statistical analysis 
Data management and anal,Y3is were performed using both SPSS software (SPSS, version16 
Oilcago, IL) and STATA software (STATA, version 10, StataCDIp LP, Texas, USA). 
Where appropriate, Pearson's Oil-square, Fisher's exact, x2 for trend, Student's t and 
ANOV As one way tests were used. Gunulative swvival probabilities were estimated using 
the Kaplan-Meier method and differences between swvival rates were tested for 
significance using the log-rank test. Multivariate anal,Y3is for swvival was performed using 
the O:>x hazard model. The proportional hazards assumption was tested using standard log-
log plots. When appropn.'1te, variables were assessed in univariate anal,Y3is as a continuous 
and categorical variable and the two models were compared using an appropn.'1te likelihood 
ratio test. Hazard ratios (HR) and 95% confidence intervals (95% a) were estimated for 
each variable. All tests were two-sided with a 95% a and a p value <0.01 was considered 
significant. For multiple comparisons, p values were adjusted according to Holm-
Bonferroni correction method. 
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4.4 Results 
4.4.1 Clinicopathological importance of Bc12 expression 
Positive expression of Bc12 showed a significant inverse association with increasing NGS 
grade, mitotic index and pleomotphism and a significant positive association with glandular 
(tubule) differentiation. In addition, Bc12 expression was significantly associated with other 
favourable clinicopathological features including small tumour size, low NGS grade, low 
LN stage, 0<.18+, 0<.19+, 0<.8+, ER+, PR+, AR+, and absence of both p53 mutation, 
HER-2 overexpression and basal O<.S (0<.5/6 and 0«14), (Table 4-5). 
4.4.2 Survival analyses 
Both histological grade and Bc12 + expression were strongly associated with an adverse 
outcome at 10 years with a significant increase in the hazard of death, recurrence and DM 
in both the whole cohort, AT untreated LN negative subgroups, and in ER+/Hf treated 
patients. However, in ER negative tumours, NGS was not significantly associated with 
patient outcome (Table 4-6). Bc12 and NGS independent association with outcome was 
confinned in multivariate Cox-regression analysis of the whole cohort, AT untreated LN 
negative subgroup, and in ER+/Hf treated patients (Table 4-7). 
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Table 4-5: The association between Bcl2 expression and other clinicopathological variables 
Bel2 Expression 
Yari;ilik BcU+ BcU- XZ 
(N ,.1045) (N =< 605) 
n(%) n(%) P 
Size 3.5E-6· 
:'OZcm 714 (6S) 344 (57) 
>2cm 331 (32) 261 (43) 
Lymph node Stage 
Negative 697 (67) 359 (59) 5.0E-7* 
Positive (1-3 nodes) 305 (29) 181 (30) 
Positive (>3 nodes) 43 (4) 65 (11) 
Grade"" 1.1E-49* 
Gl 279 (27) 27 (4.5) 
G2 389 (37) 142 (23.5) 
G3 377 (36) 436 (72) 
Mitotic Index 1.1E-52* 
Ml Qow; mitoses < 10) 521 (50) 96 (16) 
M2 (mediwn; mitoses 10-1S) 202 (19) 98 (16) 
M3 (high; mitosis >IS) 322 (31) 411 (6S) 
Pleomorphism 5.7E-38* 
1 (small- regular unifonn cells) 38 (4) 9 (2) 
2 (Moderate variation) 534 (51) 122 (20) 
3 (Marked variation) 473 (45) 474 (78) 
Tubule fonnation 2.9E-22* 
1 (>75% of definite tubule) 97 (9) 5 (1) 
2 (10%-75% definite tubule) 395 (38) 159 (26) 
3 ( <10% definite tubule) 553 (53) 441 (73) 
~ ~ 120 (13) 193 (35) 2.9E-14* 
p11(±) 401 (50) 136 (2S) 3.7E-14* 
!illi±). 312 (50) 75(19) 2.3E-23* 
BRCAI (-) 113 (14) 127 (27) 2.8E-9* 
tlER-2( +) 37(4) 85 (16) : 1.9E-14* 
E&t) 868 (87) 253(43.5) 2.2E-14* 
r&..±) 699 (72) 159 (28) 3.2E-14* 
CKllii.±l 101(10) 161(28) 1.6E-14* 
CKI8(-) 52(6) 102 (19) 1.0E-lS* 
B a s a l - l i k ~ ~ phenot}11e ( +) 59 (6) 154(28) S.3E-lS* 
Triole nee:ative p h e n o ~ . L Ltl 76 (7.5) 220 (40) 2.8E-14* 
* Statistically significant; **: grade as defined by NGS; BRCA1: Breast cancer 1,earlyonset; HER-2: 
human epidennal growth factor receptor 2: ER: oestrogen receptor, PR: progesterone receptor; ex: 
cyrokeratin; Basal-like: ER-, HER-2 and positive expression of either CK.S/6, CK.14 or EGFR; Triple 
negative: ER-/PgR-/HER-2-. 
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Table 4-6: Univariate swvival analysis of whole patients' cohort and of both patients who did 
not receive any systemic adjuvant therapy and ER negative subgroups at 10 years 
Variables Whole patients cohort No adjuvant therapy ER negative patients 
(n=1650) (n=673) (n=454) 
HR(a95%) p HR(a95%) p HR(a95%) p 
Grade** 4.8E- 1.2E-15* 0.126 
G1 1 26" 1 1 
G2 2.3 (1.5-3.3) 2.2 (1.4-3.6) 0.99 (0.4-2.6) 
G3 4.7 (3.3-6.8) 5.5 (3.5-8.8) 1.70 (0.7-3.7) 
L l I D ~ h h nod!; 3.08E- 2.7E-7* 7.7E-12" 
~ ~ 46* 
Negative 1 1 1 
1-3 nodes 1.8 (1.4-2.1) 2.3 (1.4-3.8) 1.5 (1.1-2.2) 
>3 nodes) 5.8 (4.4-7.5) 5.1 (2.4-11.0) 4.5 (3.0-6.8) 
Size (>2cm) 2 (1.6-2.4) 1.0E- 1.8 (1.3-2.7) 0.002* 1.6 (1.2-2.2) 0.002* 
13* 
Bel2 (.) 2.8 (2.4-3.4) 5.8E- 3.7 (2.7-5.1) 6.7E·15* 2.0 (1.3-2.9) 0.001" 
29" 
HER·2(±) 2.0 (1.S-2.7) 1.3E-6* 2.1 (1.1-3.8) 0.016* 1.3 (0.9.1.9) 0.187 
P53 (+) 2.0 (1.6-2.4) 1.5E- 1.9 (1.2-0.5) 0.005* 1.2 (0.9-1.6) 0.243 
10" 
ER(+) 0.6 (0.5-0.7) 5.6E-9" 0.4 (0.3-0.5) 2.0E-7* NA NA 
PR(+) 0.6 (0.5-0.7) 2.1E-9* 0.4 (0.3-0.7) 6.3E-6* 1.1 (0.7-1.7) 0.768 
CKS/6 (+\ 1.5 (1.2-1.9) 1.7E-4* 1.8 (1.3-2.7) 0.002* 1.3 (0.9-1.7) 0.111 
* Statistically Significant. HR: Hazard ratio; 0: confident interval; **: grade as defined by NGS; 
HER-2: human epidennal growth factor receptor 2; ER oestrogen receptor; PR: progesterone 
receptor. 
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Table 4-7: Prognostic independence of histological grade and Bc12 expression using multivariate 
Cox regression 
Variable HR(95%O) P 





Lymph node Stage 2.7E-20· 
Negative 1 
Positive (1-3 nodes) 1.7 (1.4-2.2) 
Positive (>nodes) 4.5 (3.3-6.1) 
Size 1.37 (1.2-1.6) UE-5· 
Bcl2 (-) 2.3 (1.6-3.4) 2.5E-S· 
Oestrogen receptor ( +) 1.3 (0.9-1.7) NS 
Progesterone receptor ( +) 0.97 (0.7-1.3) NS 
P53( +) 1.4 (Ll-1.S) 0.006· 
HER-2(+) 1.5 (U-2.0) 0.012· 
ER negative subgroup (n=454) 
Lymph node Stage 
Negative 1 6.6E-12* 
Positive (1-3 nodes) 1.5 (Ll-2.1) 
Positive (>nodes) 4.6 (3.0-7.0) 
Size (>2cm) 1.5 (Ll-2.0) 0.013· 
Bel2 (-) 2.0 (1.4-3.0) 10E-4* 
* Statistically Significant; * > ~ : : grade as defined by NGS; HR: Hazard ratio; 0: confident interval; 
HER-2: human epidennal growth factor receptor 2; ER: oestrogen receptor, PR: progesterone 
receptor. 
4.4.3 Relative prognostic importance of the three 
components of NGS 
The prognostic relevance of the three components of NGS i.e. mitoses, tubule formation 
and pleomorphism was evaluated in univariate and multivariate analysis. The mitotic index 
was found to be the principal prognostic component of NGS in the whole cohort (Table 
4-8) and was further confirmed in both AT untreated-LN negative, ER+/Hf treated and 
ER negative subgroups as well In addition, substitution of histological grade by its three 
components in the multivariate regression analysis including validated prognostic markers 
showed that only mitotic index remained an independent predictor of outcome in the final 
models. Moreover, although NGS did not show any significant association with clinical 
outcome in the ER negative subgroup, mitotic index did retain significance in the 
multivariate analysis (Table 4-9). 
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Table 4-8: Multivariate analysis using Cox model for the three components of Nottingham 
grading system 
Variables D i s e a s ~ ~ S ~ e d f i ~ ~ SulViv.tl Disease Free Survival 
HR(a95%) p HR(a95%) p 
Mitotic a!;livi!;): SE-12* 1.4E-6* 
M1 (low; mitoses < 10) 1 1 
M2 (medium; mitoses 10-1S) 2.32 (1.68-3.22) 1.5S(1.24-2.03) 
M3 (High; mitosis >18) 3.46 (2.50-4.80) 2.00 (1.5S-2.57) 
Tubule Fonnation 0.02800" 0.42800 
1 (>9'5% of definite tubule) 1 1 
2 (10%·75% definite tubule) 2.40 (1.03-5.61) 1.31 (0.82-2.10) 
3 ( <10% definite tubule) 284 (1.23-6.64) 1.36 (0.8S-2.19) 
Nuclear pleomorphism 0.92800 0.87100 
(variation in size and shape) 
1 (small, regular wUfonn) 1 1 
2 (moderate variation) 
3 ( marked variation) . 
0.87 (0.37-2.03) 
0.85 (0$ 2.03) 
1.14 (0.61-2.13) 
1.10 (0.58-2.10) 
* Statistically significant 
100 
Clupter4 Bida;ical Gnufe S)5tem 
Table 4-9: Multivariate Cox Hazard analysis of the components of the Nottingham Grading 
System (NGS), Bcl2 expression and clinicopathological variables. 
Variable HR(95% 0) IP 
Whole patient cohort (n-I650) 
Mitotic activity 7.0E-5" 
MI OOW; mitoses < 10) 1 
M2 (mediwn; mitoses 10-18) 2.0(1.3-2.9) 
M3 (high; mitosis >18) 2.3(1.6-3.4) 
Tubule Fonnation 0.235 
1 (>75% of definite tubule) I 
2 (10%-75% definite tubule) 2.1 (0.8-5. 5) 
3 (<10% definite tubule) 2.3 (0.9-5.9) 
Nuclear pleomorphism (variation in 0.200 
size and shape) 
1 (small, regular unifonn) 1 
2 (moderate variation) 0.4 (0.2-1.1) 
3 (marked variation) 0.4 (0.2-1.1) 
Lymph node stage 2.3E-20· 
Negative 1 
Positive (1-3 nodes) 1. 7 (1.3-2.1) 
Positive (>3 nodes) 4. 5 (3.2-6.1) 
Size 1.3 (1.2·1.5) 6.2E-6* 
Bel2(-) 1. 9 (15-2.5) 1.0E-7* 
ER(+) 1. 2(0.9-1.7) 0.149 
PR(+) 0.97(0.7-1.3) 0.860 
P53 (+) 1.4 (1.1-1.8) 0.009* 
HER-2(t) 1.5 (1.1-2.0) 0.012* 
ER- subgroup (n=355) 
Lymph node Stage 
Negative 1 S.3E-S* 
Positive (1-3 nodes) 1.3 (0.9-2.0) 
positive (>3 nodes) 4.2 (25-6.8) 
Size 1.2 (1.1-1.5) 0.007' 
Bell (-) 2.0 (1.2-3.1) 0.001' 
MI OOW; mitoses <10) I 0.032" 
M2 (mediwn; mitoses 10-18) 




"Statistically Significant. HER-2; human epidermal growth factor receptor2 
4.4.4 Prognostic significance of combined M/Bc12 profiles 
Multivariate Cox regression models were used to assess and compare the prognostic 
performance of WBc12 profiles to that of validated prognostic indicators assessed in the 
total patient cohort and was further confirmed in AT untreated LN negative patients, and 
in those with ER + disease who received Hr. 
We found that the WBc12 profile was significantly associated with DSS, DFS and DM 
along with LN status and twnour size. In the ER negative disease, WBc12 distinguished 
between patients with low risk from those with high risk independently on stage and size 
(Table 4-10) . 
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4.4.5 Prognostic significance of M/Bc12 profiles in small 
early stage (NO, Tt) tumours 
We investigated the clinical outcome of 522 patients with early stage small tumoW'S (lymph 
node negative with primary tumour size ~ ~ 2cm) from the Noningham series who did not 
receive any AT (Figure 4-2). Consistent with the findings in the other groups, patients with 
M1-2/Bd2+ or MlIBc12- phenotypes displayed a bener prognosis than cases with M2-
3/Bc12- or M3/bc12 + (HR; 5.3, a 95%; 3.5-8.0, p=6.7 E-15). In the multivariate analysis, 
WBc12 was the only independent prognostic factor in this subgroup (Table 4-11). 
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Table 4-10: Multivariate analysis using Cox regression in whole patients' cohort, in patients who 
did not receive any systemic adjuvant therapy and ER- subgroups. 
Variables OveraU Survival Disease Free Survival 
HR[095%) Ip HR (0 95%) I p 
Whole Cohort (n=I650) 
MIIBd2 profiles 7.5E-16* 1.0E-ll-
MlIBcI+ 1 1 
M1/Bc12- 2.5 (1.4-4.3) 2.3 (1.5-3.4) 
M21Bc12+ 1.3 (0.8-2.2) 1.2 (0.8-1.7) 
M2/Bc12- 6.0 (3.8-9.3) 3.4(2.4-4.9) 
MJ/Bc12+ 2.9 (2.0-4.3) 1.7 (1.3-2.3) 
MJ/Bc12- 4.2 (2.8-6.3) 2.4 (1.8-3.3) 
Lm1ph nQd, s1;l!;\: 6.2£-20* 1.4£·17* 
Negative 1 1 
Positive (1-3 nodes) 1.7 (1.3-2.1) 1.3 (1.1-1.6) 
Positive (>3 nodes) 4.4 (3.2-6.0) 3.6 (2.7·4.8) 
Siz!: 1.3 (1.2-1.5) 2.4£·6* 1.2 (1.1-1.3) 0.001* 
~ ~ 1.4 (Ll-1.8) O.OOS" 1. 3 (Ll-1.6) 0.02* 
HER-2(t) 1.4 (1.1-1.9) 0.02* 1.4 (1.1-1.9) 0.01* 
EJti±) 1.2 (0.9-1.6) 0.202 1.3 (1.0-1.6) 0.074 
PRLi 0.96(0.7- 1.3) 0.784 1.010.8-1.2) 0.829 
No adjuvant therapy (n =673) 
Mitoses/Bc12 Profiles 1.6E-4· 1.2£-5" 
MlIBcl+ 1 1 
M1/Bc12- 1.3 (0.5-3.0) 2.1 (1.5-4.2) 
M21Bc12+ 2.8(1.3-6.1) 2.5 (0.8-2.4) 
M2/Bc12- 2.4 (1.0-5.5) 4.9 (2.6-9.2) 
MJ/Bc12+ 6.5 (3.0-14.4) 2.1 (1.1-4.0) 
MJ/Bcl2- 3.7 (1.7-8.3) 2.S (1.5-5.3) 
Lm1ph node S1;lge. 0.002* 0.003* 
Negative 1 1 
Positive (1-3 LNs) 3.0 (1.6-5.7) 1.9 (Ll-3J) 
Positive (>3 nodes) 3.1 (0.9-11.27) 4.7 (1.6-13.2) 
Size 1.3 (0.9-1.7) 0.092 1.4 (1.1-1.7) 0.008* 
P53+ 0.7 (0.4-1.3) 0.291 1.2 (0.7-1.9) 0.559 
HER·2 0.9 (0.5-1.8) 0.840 Ll (0.6-2.0) 0.652 
ER O. 6 (OJ-1.1) 0.111 1.2 (0.7-2.0) 0.500 
ProjWsterone receotor O. 98JO.5-I.S) 0.949 0.9 (0.6-1.4) 0.675 
ER- subgroup (n=355) 
Mitoses/Bc12 Profiles 0.002- 5.0E-4 
MlIBcI+ 1 1 
Ml/Bcl2- 1.8 (0.4-8.9) 2.9 (0.7-13.2) 
M2/Bc12+ 1.7 (OJ-S.7) 3.1 (0.7-13.8) 
M2/Bc12- 7.3 (2.0-25.6) S.9 (2.6-30.7) 
MJ/Bc12+ 2.0 (0.6-6.8) 2.5 (O.8-S.4) 
MJ/Bc12- 3.4 (1.1-10.7) 4.4 (1.4-13.S) 
LN Stage. 9.4£-8· 1.8£-S 
Negative 1 1 
Positive (1-3 nodes) 1.3 (0.4-2.0) 1.1 (0.7-1.6) 
Positive (>3 nodes) 4.1 (2.5-6.8) 4.0 (2.5-6.4) 
~ ~ 1.3 (1.1-1.6) 0.005· 1.4 (0.96-1.4) 0.143 
* Statistically significant. HER-2; hwnan epidennal growth factor receptor 2 
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Table 4-11: Prognostic independence of combined mitotic index (MI)/BcL2 profile using 
multivariate analysis using Cox model of patients with small early stage tumour who did not 
receive any adjuvant therapy (n=522 cases) 
Variables Disease Silecific Survival Disease Fn:e Survival 
HR(a95%) p HR(a95%) p 
Mitotie index/Bell- 3.0E-8" 1.5E-9* 
Ml/Bc12+ 1 1 
MlIBe12- 1.7 (0.7-4.0) 2.0 (1.1-3.4) 
M2/Bc12+ 1.2 (0.5-3.0) 1.9 (1.1-3.3) 
M2/Bc12- 9.5 (4.4-20.3) 6.0 (3.2-11.3) 
M3/Bc12+ 6.8 (3.0.15.3) 6.2 (3.3-11.6) 
M2/ Bc12- 4.3 (1.8-11.5) 3.5 (1.&-11.3) 
ER(+) 0.6 (0.3-1.3) 0.212 1.2 (0.7-2.2) 0.560 
P ~ R ( ( +) 0.8 (0.5-1.5) 0.588 0.6 (0.4-0.9) 0.041 
P53i.tl 0.5 (0.3-1.1) 0.096 0.8 (0.4-1.5) 0.502 
, f Statistically significant. ER; oestrogen receptor, PgR; progesterone receptor 
I 
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Figure 4·2: Disease specific survival (DSS) of early stage small tumours stratified by MI/Bcl2 
expression profile 
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4.4.6 Clinical outcome of M/Bc12 in different adjuvant 
therapy settings 
lIT-treated cases of Nottingham series with M2-3/Bc12- and M3/Bc12+ showed 2.5-4.0 
fold increase in the risk of death (HR: 4.3, 95% 0: 2.8-6.6, p=82E-12), recurrence (HR: 
2.7,95% 0: 1.9-3.7, p=3.9E-9) and DM (HR: 3.3,95% 0: 2.2-4.7, p=2.5E-IO) compared 
with those of Ml-2/Bc12 + and MI/Bc12- phenotype. 
Poor outcome of Be with M2-3/Bc12- and M3/Bc12+ phenotypes was further confinned 
in Breakthrough series which comprises patients that were wUformly treated with 
anthracydine based chemotherapy. In this cohort, patients with M2-3/Bc12- and M3/Bc12 + 
showed 2.5 fold increase in the risk of death (HR: 2.5, 95% 0: 1.1-5.6, p=O.03), recurrence 
(HR: 2.3, 95% 0: 11-4.3, p=o.009) and DM (HR: 2.5, 95% 0: 12-5.1, p=o.Ol7) 
compared with those of Ml-2/Bc12 + and MI/Bc12- phenotype. 
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4.4.7 Re-stratification of patients' outcomes according to 
M/Bc12 
Good clinical outcome (Low risk; NGS-GI-like prognosis. n=723; 43%) 
The stuVival ctuVes and clinicopathological features of MlIBc12 + phenotype of either 
NGS-G1 (279/521; 54%) or NGS-G2 (2411521; 46%) were identical (log-rank test, p=NS) 
showing low risk of death, recurrence and DM (Figure 4-3). Similarly, the stuVival and 
clinicopathological characteristics of M2/Bc12+ either of NGS-G2 (147/202; 73%) or of 
NGS-G3 (55/202; 27%) were indistinguishable and showed low risk of death, recurrence 
and DM (Figure 4-3). The 10-year stuVival probability of AT-untreated LN negative 
patients with MI/Bc12 + and M2/Bc12 + was 94% and 92%, respectively which is 
indistinguishable from that of both NGS-G1 (95%) and an age-matched female population 
without Be However; Ml-2/Bc12+ tumours included over twice (723/1650; 43%) as many 
patients as NGS-G1 (306/1650; 19%; Fisher's exact test p<O.OOOl). These results suggest 
that the M1-2/Bc12 + phenotypes more accurately identify patients with low risk than NGS-
Gl and we referred to this as NGS-Gl-like prognosis. 
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Poor prognosis G3 (49%) M3IBcI2+ (19%) 
M2·3JBcI2· (31%) 
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Figure 4-3: Disease specific survival (DSS) of different MlBc12 profiles of whole breast cancer 
cohort compared to Nottingham grading system (NGS). 
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Intennediate clinical outcome (Intennediate risk; NGS-G2-like prognosis. 
n=96; 5.8%) 
MlIBc12- ttunours with either of NGS-Gl (27/96; 28%) or NGS-G2 (69/96; 72%) had 
survival curves and clinicopathological features indistinguishable from NGS G2 (i.e. NGS-
G2-like) AT untreated LN negative patients with MlIBcl2- phenot)pe had 86% 10-year 
survival probability which is equal to that of NGS-G2 (i.e. intermediate risk). Thus MlBc12 
profile reduced the percentage of cases with intermediate prognosis from 32% to only 6% 
and >80% of them was either invasive ductal of no special t)pe or mixed ttunours. 
Poor clinical outcomes (High risk; NGS-G3-like prognosis. n=831; 50%) 
The lO-year survival probability of AT untreated LN negative patients with M2/Bcl2-, 
M3/Bc13- and M3/Bcl2+ phenot)pes was 50%, 54% and 68%; respectively while that of 
NGS-G3 was 62%. M2/Bc12- ttunours displayed poor prognosis similar to those of 
M3/Bc12- which showed a significant worse clinical outcomes and more aggressive 
clinicopathological features than those of M3/Bcl2 + (Table 4-12). 
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Table 4- U: Clinicopathological comparison between MJ/Bcl2- and MJ/Bcl2 + phenotype of 
high Nottingham grade system (NGS 3) 
~ ~
Variable M3/Bcl2+ M3/Bcl2- P 
(N=322) (N=403) 
n(%) n(%) 
Size (>2cm) 151 (47) 193 (48) 0.8160 
Lymph node (+) 138 (43) 165 (41) 0.575 
P53 (+) 97 (30) 181 (45) l.3E-4" 
P21 161(50) 97 (24) 7.8E-11* 
P27 119(37) 52 (13) 4.4E-9* 
BRCA1 (-) 71 (23) 133 (33) 0.004" 
HER-2(+) 32 (10) 72 (18) 0.004* 
ER(+) 235 (73) 113 (28) 1.7E-14* 
PR(+) 170 (53) 68 (17) 1.8E-14* 
CK5/6( +) 60 (18) 133 (33) l.lE-5* 
C1d8(-) 48 (15) 105 (26) <0.001* 
Basal-like ( +) 37 (14) 145 (36) <0.0001* 
Triple negative phenotype ( +) 45 (17) 204 (50) <1J.0001* 
* Statistically significant. BRCA1: Breast cancer 1 early onset; HE-R2; human epidermal growth 
factor receptor 2; ER: oestrogen receptor; PR: progesterone receptor: CK.: c}'tokeratin; Basal like: 
ER-, HER-2 and positive expression of CK.S/6, CK.14 or EGFR; Triple negative: ER-/PR-/HER-2-
4.4.8 M/Bc12 profiles accurately relocated the clinical 
outcomes of NGS 
NGS-G1 clinical outcomes 
Although all NGS-G 1 tumours showed low M (Ml), Bcl2 expression divided NGS G 1 into 
two subgroups with distinct clinical outcomes (Figure 4-4 and Table 4- U). The MlIBcl2-
twnours (27/306; 9%) had a 3-4 fold increased risk of death, rek'1pSe and DM compared to 
MlIBcl2+ (279/306; 91%). 
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Figure 4-4: Disease specLfic survival curve of Nottingham grade 1 (NGS-Gl) stratLfied by 
combined mitotic index (M)/Bcl2 profile 
M/Bcl2 profile identifies prognostically relevant subgroups ofNGS-G3 
NGS G3 twnOlm with a Bc12- phenotype had a 2-fold increase risk of death (fiR: 1.7; 95% 
0: 1.4-2.1; p=4.4E-6), relapse (fiR: 1.6; 95% 0: 1.3-1.9; p=3E-5) and DM (HR: 1.5; 95% 
0: 1.2-1.9; P =2E-4) compared with Bc12 + cases. However, WBc12 profiles reclassified 
tumOlm with NGS-G3 into three clinicopathological subgroups (Table3-12): NGS-G3 with 
M2/Bc12+ phenotype (55/813; 7%) showed good clinical outcome identical to that of 
NGS-G1 while NGS-G3 with either M2/Bc12- (33/813; 4%), M3/Bc12+ (322/813; 40%) 
or M3/Bc12- (403/813; 49%) retained poor outcome and aggressive characteristics of 
NGS-G3 (Figure 4-5), However, NGS-G3 with M2-3/Bc12- showed a worse 
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clinicopathological outcome compared to those of NGS-G3 with M3/Bcl2 +. Similar 
associations between the groups defined by M and Bcl2 and outcome were found in the 
analysis of the AT-untreated LN-negative subgroup. 
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Figure 4-5: Disease specific survival curve of Nottingham grade 3 (NGS-G3) stratified by 
mitotic index (M)/Bcl2 profile 
M/BcJ2 profile identifies NGS-G2 tumours with; good and poor clinical 
outcomes 
Bcl2 expression divided the NGS grade 2 group into two clinical different subgroups: Bcl2-
cases (142/531; 27%) had 3-fold increase risk of death (HR: 3.6; 95% 0: 2.5-5.42; p=3E-
12), disease relapse (HR: 2.5; 95% 0: 1.8-3.3; p=12E-9) and DM (HR: 3.0; 95% Q: 22-
4.2; p=3.9E-ll) compared with Bcl2+ cases (389/531; 73%). We explored the clinical 
significance of MlBcl2 profile of NGS-G2 patients (Figure 4-6) in the whole cohort, in 
AT-untreated LN-negative patients, in those with ER+ tumours who received Hf and in 
patients with ER-negative tumours. We found that only M1/Bcl2- (69/531; 13%) of NGS-
G2 retained the intennediate prognosis o ~ ~ NGS-G2. Moreover, 87% of NGS-G2 was 
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reclassified into either good (74%) or poor (13%) prognosIS. Notably, no significant 
difference was observed between NGS-G2 with either MlIBc12+ (242/531; 46%) or 
M2/Bc12+ (147/531; 28%) and NGS-G1 swvival cwves, or the NGS-G2 with either 
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Figure 4-6: Disease specific survival curve of NGS G2 stratified by combined mitotic index 
(M)/Bc12 profile 
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Table 4-13: Univariate analysis to determine risk of each class of combined mitotic index/Bell 
profile within histologic grade 1 (A), grade 2 (B) and grade (0 
Risk group 
A) Grade 1 
Low risk 
High risk 




















* Statistically significant 
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4.4.9 M/Bc12 profile improves prognosis by NPI 
We investigated whether incorporating the WBcl2 profile, instead of NGS, into NPI could 
improve patient's stratification. A simplified substitution of NGS by WBcl2 profile: score 
1: NGS-Gl-like phenotype, score 2: NGS-G2-like phenotype, and score 3: NGS-G3-like 
phenotype was explored and a modified NPI (mNPI) score was derived The swvival of 
patients stratified into risk groups was then compared between original NPI and mNPI. As 
shown in (Figure 4-7), the swvival cwves of the NPI and rnNPI displayed a moderate 
agreement (k=O.58). Importantly however, the number of patients identified as part of the 
excellent prognostic groups (EPGs; N P I ~ 2 . 4 ) ) was increased 2-fold when AT-untreated 
LN-negative patients were stratified by mNPI as compared to NPI (366 vs. 198 patients, 
respectively. Thus twice as many patients could be accurately cbssified into EPG by mNPI 
suggesting use of the WBcl2 profile could have clinical benefit through more accurate 
classification of patients into prognostic classes and in particular, identifying a greater 
proportion of patients who could potentially be spared AT. Moreover, evaluation of 
tubular fonnation and pleomorphism used in the NGS is subjective, leading to 
inconsistency. Therefore, including WBc12 profile instead of tubular formation and 
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Figure 4-7: Stratification of patients' risk by classic Nottingham Prognostic index (NPI) and 
modified (m) NPI and Kaplan-Meier disease specific survival (DSS) curves. 
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4.5 Discussion 
Histological grade has been shown to be undetpinned by distinct transcriptomic patterns 48-
so. In fact, genetic grade signatures developed to recapitu1.1.te NGS-G 1 and NGS-G3 BO 
have been shown to be able to stratify NGS-G2 tumours into NGS-Gl-like and G3-like 
cancers 48-51. In agreement with these studies, we found by using a simple objective WBc12 
profile that Be with intermediate prognosis is rarer than previously assumed with only 6% 
instead of 32% of Be retaining the intermediate clinical outcome of NGS-G2. The 
prognostic performance of WBc12 profile was found to be independent of LN status, 
tumour size and ER status suggesting that it can substanti.1.l.ly contribute to patient 
prognosis. In addition, by using WBc12 profiles, about twice as many patients could be 
accurately classified into the EPG by mNPI improving identification of patients that could 
be spared of or who require systemic AT thus reducing potential harm due to over- and 
under treatment. 
Meta-analysis of publicly available gene expression data demonstrated that most of the 
genes associated with histological grade are involved in cell cycle regulation, proliferation, 
apoptosis, p53 and ER signalling networks 49-51,133,135,140,141,142,143. In agreement with these 
studies, we found that the mitotic figure recognition as a reflection of growth fraction was 
the most important prognostic factor among the 3 motphologic features of NGS. In 
addition, we confinned that Bc12 expression is strongly associated with tumour 
differentiation and is an independent prognostic factor 14, 141, 144,. There are several lines of 
evidence to suggest that Bc12 plays a central role in breast motphogenesis, Be 
tumourigenesis, and that it may be employed to improve on the prognostic methods for the 
management of Be patients 14, 138 144-148. Furthermore, Bc12 is as a direct downstream 
responsive gene of ER and p53 and plays a crucial role in their molecular network with 
respect to Be development 14,144-147. Bc12 also confers swvival advantage to tumour cells by 
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prolonging cell cycle at GOIG129 (anti-proliferative) and by simultaneously extending cell 
swvival (anti-apoptotic). In this context, the WBcl2 profile is actually a phenotypic profile 
that bears biological significance. For example, tumours with the Ml-2/Bcl2 + profile 
showed low levels of expression of the growth fraction marker MIB 1 and high level of 
expression of the GOIG1 regulatory proteins p21 and p27, implying that the proliferative 
capacity is lowered as these cells exit cell cycle into quiescent (GO), senescent out-of-cycle 
states. Given that engagement of the somatic differentiation progr.unrne is coupled to G 1 
arrest and cell cycle withdrawal into the out-of-cycle state, this phenotype could be 
considered to represent well differentiated fonns of B049. It is noteworthy that acquisition 
of Bcl2 expression could create a restrictive environment for the expansion of these 
neoplastic cells. In addition given that most Ml-2/Bcl2+ cases are ER+/PR+ thus this 
phenotype is likely to be identifying the low proliferation end of the spectnun of 
ER +/PR + cancers. 
On the other hand, most of the neoplastic cells (>50%) of M2-31IBcl2- tumours are 
actively replicative and show the lowest level of both p21 and p27 and highest frequency of 
p53 nuclear expression, and BRCA1 and AlM down-regubtion, as defined by 
immunohistochemistry, compared to other phenotypes, indicating an active cell cycle 
progression with arrested tumour differentiation 148. Moreover this high proliferative 
capacity is coupled with high levels of apoptosis due to absence of Bcl2 reflecting an 
increased cell turnover. Furthennore, this phenotype was associated with ER-/PR-
indicating honnone independence and resulting in resistance to Hf 147. 
Whether grade is a continuum through which Be progresses or merely the end point of 
distinct genetic pathways has been debated. It is not clear whether Be develops along two 
(grades 1 versus 3) or three (grades 1 versus 2 versus 3) distinct pathways. In our study, the 
large majority of Be cases are either low (NGS-Gl-like) or high (NGS-G3-like) grade 
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supporting the genetic pathway.; model of grade origin 52. 134.104. Tumours with intetmediate 
prognosis (NGS-GZ-like) may arise as homogenous tumours that are truly borderline 
between low and high grade, or could rather reflect a heterogeneous composition of both 
low and high grade cell typeS48. 50. Genetic analy.;is of NGS-GZ cancers suggests the 
majority of these tumours constitute the end of the spectrum of NGS G 1 cancers as they 
often harbour deletion of 16q and gains of lq, which are both typical of low grade Be 57. 
Interestingly, we found that LNGBN tumours belonged to the NGS-Gl-like phenotype 
and were either arrested in GO/Gl or out-of-cell cycle state. On the contrary, most basal-
like and HER-Z + tumours were NGS G3-like phenotypes with actively progressive cell 
cycle suggesting that once Be is committed to a specific evolutionary/molecular pathway, 
progression or cross over to other high grade pathways would be an unlikely biological 
phenomenon. However, progression within biological class e.g. luminal "low grade" to 
luminal "high grade" is a possibility140 and could be due to acquisition of additional genetic 
or epigenetic aberrations (e.g., pS3 mutation, gene amplifications), which lead to more 
active cell cycle progression and increased proliferation. 
In conclusion, here we described a grading system based on the balance between mitotic 
frequency and Bcl2 expression which is an independent predictor of outcome in a 
population based cohort. This system accurately reclassified patients with NGS-GZ, small 
early stage Be and ER- into two groups with high versus low risks of death and recurrence, 
and also identified prognostic ally significant subgroups in a cohort of patients treated with 
adjuvant anthracycline-based chemotherapy. The use of this simple and objective grading 
sy.;tem instead of NGS may help improve on the prognostic ability of current algorithms 
for clinical decision making (e.g. NPI). 
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Chapter 5: 
... 
A new genetic map for the evolutionary pathway 
of the low nuclear grade breast neoplasia 
(LNGBN) family 
5.1 Abstract 
In previous chapters, we have shown morphological and immunohistochemical evidence to 
suggest that a number of low nuclear grade invasive breast cancers (LNGBq including 
invasive tubular and lobular carcinoma and their putative precursor lesions: columnar cell 
lesions (CCLs), low grade ductal carcinoma in-situ (DOS) and lobular neoplasia (LN) may 
comprise a family of interrelated lesions. 
In this study, we identified the molecular genetic profiles and potential evolutionary 
pathogenetic pathwa}"3 of matched co-existing lesions belonging to the LNGBN family to 
support their common cell of origin. 
Twentycases of invasive LNGBCs and their matched coexisting CCLs, DOS and LN were 
laser microdissected from formalin fixed paraffin embedded tissues (FFPE1). The isolated 
non-amplified-DNA was subjected to high-resolution array-Comparative Genomic 
Hybridization (aCGH; 32 Kb BAGarray platforms, Breakthrough Breast Cancer Research 
Centre). Results were validated using chromogenic in situ hybridization (asH) and 
immunohistochemistry. Comparative analysis was perfonned on aCGH datasets derived 
from independent BC series of 64 high grade invasive ductal carcinoma of no special type 
(IDG NS1) cases and 171 unselected series of BC in which the results were validated by 
gene expresslon array. 
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We observed that lesions from the same patient displayed remarkably similar patterns of 
genetic aberrations (Pearson's correlations 0.55-0.89; p <0.00001). All CXLs, low grade 
DOS, LN and their matching invasive carcinoma harboured gain/amplification of lq and 
loss of 16q. In addition in situ and matching invasive components displayed additional 
genetic aberrations at one of 16p13.3, llq13.1-q14.1, 17q25.3, 19p13.3. Amplification of 
cyclin Dl was confinned as a target gene by using aSH The MDM4 gene on lq32 was 
confinned as an early genetic change using IHC and gene expression in three independent 
data sets. Moreover, prognostic and predictive implications of MDM4 overexpression were 
proved in a large data set with long tenn follow up. 
In conclusions, our results suggest that 1) Tubular, and lobular carcinomas have a 
remarkable similarities in their genomic plots supporting the proposal that they comprise a 
family of low nuclear grade breast neoplasia (LNGBN), 2) The recurrent genetic changes 
associated with CXLs support that the cx:::Ls are clonal disease., 3) The <Xl.s are non-
obligate precursor components of the LNGBN family, 4) The low nuclear grade breast 
neoplasia family commonly shows gain/amplification at lq21.4 (MUCllocus), 5) The ER+ 
luminal restricted progenitor cell of IDLUs (ER+/MUCI +/CKI8) could be the common 
cell of origin of LNGBN family, 6) Cyclin Dl and MDM4 are oncogenes that could drive 
the progression of the LNGBN family, 7) Such stochastic genetic hits could be responsible 
for the activation of the luminal 'A' pathway in ER + progenitor cells, 8) An alteration of E-
cadherin (CDH1) appears to be a secondaty event resulting in the characteristic 
morphology of both invasive and in situ lobular lesions. 
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5.2 Introduction 
It is known that the progression and clinicopathological outcome of any tumour reflects the 
molecular events acquired during its development 150. Accordingly, the motphological and 
clinical heterogeneity of any tumour including breast carcinoma (BO is likely to derive from 
stochastic genetic and epigenetic events resulting in oncogene activation and loss of tumour 
suppressor gene (TSG) function 29. However, currently the precise cell lineages involved in 
the earliest oncogenic events involving progenitor transfoImation and formation of 
precursor lesions en route to invasive cancer development is not known. Indeed. the 
molecular basis of breast tumourigenesis is poorly understood and this is possibly a 
reflection of a) our inability to study the earliest stages (CCl-s, ADH, DOS and LN) of 
progression, b) the complexity and heterogeneity of breast tissue and c) the microscopic 
size and limited extent of the pre-invasive lesions in pathological specimens. 
Indeed, besides increasing our understanding of breast tumourigenesis, studying the detailed 
molecular profiling of early stages of breast cancer could improve on diagnostic decision-
making and provide advice on the optimal treatment of these lesions, including identifying 
targets for the development of selective customised therapies. G>nsequently, unnecessary 
side-effects associated with over-treatment could be avoided and health economic cost 
efficiencies could be achieved through targeted treatment. 
Recently, comparative genomic hybridization (CGH) technique has been expanding our 
knowledge about tumour pathogenesis as it allows for genome wide detection of deletions 
and gain! amplifications in a single hybridization 151 and for studying the genetic changes of 
some precursor lesions 58, 89, 112, 113, 152 facilitated by using laser capture microdissection 
(LCM), and polymerase chain reaction (PeR.) amplification 152,153. The results have widened 
and even changed our understanding of human cancer development and progression 152. 
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For instance, recent molecular studies imply that the low and high grade forms of both 
invasive breast cancers and ductal carcinoma in situ are distinct entities 154 and that 
progression from low to high grade is rare 26,52,58,61,81. Moreover, Some ffiH 26, 52, 58, 61, 81 
and gene expression clata 155 show that invasive tubular carcinoma and ADHilow grade 
DOS are more closely related to invasive lobular and lobular neoplasia, respectively, than to 
invasive ductal carcinoma and high grade DOS, respectively 154. For instance, high grade 
DOS and high grade BCs are genetically advanced lesions, showing a complex recurrent 
genomic rearrangements including loss of 8p, llq, 13q, 14qj gain of lq, Sp, 8q, 17qj and 
amplifications on 6q22, 8q22, llq13, 17q12, 17q22-24, and 20q13, while most of 
low/intermediate grade DOS and Be showed an increased frequency of losses of 16q and 
lq 26,52,58,61,81. 
As have been shown in (bapters 2 and 3, we found that the columnar cell lesions (CCLs), 
flat epithelial atypia (FEA), lobular neoplasia (LN), atypical ductal hyperpL'lSia/low grade 
ductal carcinoma in situ (ADHIlow grade DOS), invasive tubular carcinoma erG, 
tubulolobular carcinoma (1LG and cL'lSsic invasive lobular carcinoma (ILG not only have 
the same patterns of associated topographic distribution but also have remarkable 
morphological and immunohistochemical similarity. Subsequently, we have proposed that 
they may constitute a family of rebted low nuclear grade precursor, in situ and invasive 
neoplastic lesions collectively called the "LNGBN'. 
In this study, by using high resolution affiH, we aim to identify the molecular genetic 
profiles of this group of lesions and to recognise the potential evolutionary pathogenetic 
pathways of LNGBN that support their common cell of origin. 
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5.3 Material and Methods 
Twenty cases of invasive tubular and lobular carcinoma and their matched coexisting CCLs, 
DOS and LN were laser rrucrodissected from formalin fixed paraffin embedded tissues 
(FFPE1). The isolated non-amplified-DNAs were subjected to high-resolution arraY' 
Comparative Genomic Hybridization (aCGH; 32 Kb BAGarray platforms, Breakthrough 
Breast Cancer Centre, London), (Figure 5-1). 
I Morphological review I 
, 
1 lnununophenotyping of each lesion 1 
.. 
Laser Microdissection of matching co-existent precursors and invasive components 
(using formalin fIXed paraffin embedded tissue) 
, 
1 DNA extraction 1 
• J Quantity I 1..1 Quality I (by u ing PiOOgrttJI dye) I Assessment of DNA ---+ (by using mukiplex PCR quality controQ 
+ + , 
I D N ~ ~ l ' ' • High resolution aCGH ,I Gel electrophoreses J 
(32K BAC-array) I band sized 400bp 
1 
I Data acquisition and analysis 1 
l 
I Validation tests I 
--
~ ~ l ~ ~
aCGH Integrated aCGH Gene expression Otromogenic in Protein 
comparative & meta situ hybridization expression 
ana1y.i. e x p r ~ ~.. ion analysis ana1y1i. (CISH) (IHC) 
Figure 5-1: An overview of the techniques and methods used for array 
comparative genomic hybridization (aCGH). 
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5.3.1 Comparative Genomic Hybridization 
Introduction 
The principle of CGH is that the tumour (test) and nOIlIl.ll (reference) genomic DNAs are 
labelled respectively with red and green fluorescent dye 156. Each labelled DNA is subjected 
to competitive hybridization to either normal metaphase chromosomes (chromosome or M 
CGH) 156, or DNA fragments (DNA microarray CGH) 157. DNA fragments which have 
been spotted onto glass microscope slides using robotic devices may be oligonucleotides 
(ROMA CGH) 158, complementary DNA (c-DNA arra0 t;9 or genomic clone e.g., bacterial 
artificial chromosomes (BAG); matrix array CGH 160 (Figure 5-2 and Table 5-1). 
Hybridization of repetitive sequences is blocked by addition of Cot-l DNA The ratio of 
red and green fluorescent signals in paired samples are measured along the longitudinal axis 
of each chromosome providing a cytogenetic representation of DNA copy number changes 
in the tumour compared to normal sample 161. Ou-omosorn.ll regions involved in deletion 
or amplification in test DNA appear red or green, respectively, but chromosomal regions 
that are equally represented in test and reference DNAs appear yellow i.e., no copy number 
changes 161 (Figure 5-3). Measurement of ratio of the test to reference is performed using 
a digital image analysis system. In array CGH the resolution in detecting segmental copy 
number changes is limited only by the distance between and the size of the genomic DNA 
segments spotted on the array 161, 162. 
Advantages of aCGH 
The rn.'lin advantage of CGH is the whole genome screening which is faster and less 
laborious than low throughput methods such as (peR and FISH) 154-162. Moreover, by using 
array CGH, the segmental amplification of whole chromosome arms, terminal deletions, 
124 
Gerxtic dxucuteristics c{lawnud&r grade bratst rroJiasia 
and discrete, high magnitude copy number gains and losses up to 16Kb are easily 
detected.158- 162 
l CGH J 
Chromosome CGH 
M-CGH DNA-Microarray CGH 
CGH to metaphase chromosome 
[ Arrays based on cloned DNA J [ 










Table 5-1: Comparison between different types of comparative genomic hybridization ( C G I - ~ ~
Olarnctell m-CGH '-DNACGH lAn'ay-CGll 
fargets IMetaphase chromosomes -DNA sequences typically ~ n o m i c c clones: 
only 0.5-2 kb in size 
• YAC(0.2-2Mb) 
• BAC(up to 300 Kb) 
• PI (....;"()'IOO kb) 
• PAC(-130-1S0kb) 
• Cosmid (-30-45 kb) 
Resolution 10Mb for loss and 2 Mb for gain lligh resolution up to 0.5 I 1igh resolution up to 16Kb 
Kb 
IAdvantages .l: Whole genome screening 1- High resolution lAs c-DNA CGH plus 
capability 2- Straightforward and 
k Increasing our undetstanding of automated analysis. Uniformity of hybridization Signal tumour ~ i o l o g y y and fidelity progression. 
fLimitations Low resolution and the need for Low complexity of the target Expensive hard\.\!are and sott \.\!are 
xperience in c}togenetic -DNA sequences leads to 
High false positive and 
negative rates (15%) and 
reduced signal sensitivity 
YAG yeast artificial chromosome; BAG bacterial artificial chromosome: PAG plasmid artificial 
chromosome 
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Figure 5-3: Schematic overview of the microarray-based comparative genomic hybridization 
technique. 
Test and control DNA are labelled with a green and red fluorochrome, respectively. Both DNAs are 
hybridized to cloned DNA fragments that have been spotted in triplicate on a glass slide (the array) . 
Images of the fluorescent signals are captured and analyzed. Red spots indicate loss of test DNA, 
green spots indicate gain of test DNA, and yellow spots indicate the presence of equal amounts of 
test and control DNA (Adapted from Oosclander et a1 2004 162L 
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Limitations of aCGH 
One of the main limitations of the BAC array CX;H is t11.1.t regions not represented on an 
array are not assayed 162-164. Subsequently, smaller or L-u-ger deletions or duplications will 
not be identified because this tool only interrogates gains and losses of chromatin 
approximating the size of a BAC clone (16 to 200 kb). Moreover, epigenetic changes, 
babnced chromosomal rearrangements translocation (reciprocal trans locations , 
Robertsonian trans locations , and inversions), mitochondrial DNA defects, point mutation, 
origin of translocation events or complex chromosomal rearrangements can not be detected 
by using CX;H technique 156-164. Moreover, additional validation tests of the results either 
by using gene expression array, fluorescent in situ hybridization (FISH), chromogenic in 
situ hybridization (asH) or immunohistochemistry (THQ are required to pinpoint the 
genes involved 154-164. Other molecular techniques such as spectral karyot)ping (SKY) or 
muti-colour chromosome painting strategies could be used in conjunction to aCX;H to 
detect reciprocal translocation or subtle rearrangements 162-165. However, even with these 
recognized constraints, array CX;H has the potential to identify twice as many chromosome 
abnormalities as othertechniques 165. 
Challenges facing ouraCGH experiment for analysis ofLNGBN family 
TISSUE MATERIAL 
The successful rate of aCGH using high molecular weight DNA samples i.e., frozen or cell 
line is high in most cases 157-165. However, for the pwpose of our study, we could not use 
DNA derived from either frozen breast cancer tissue or cell lines for many reasons. First, 
there is no cell lines derived from columnar cell lesion or low grade neoplastic lesions such 
as tubuL1.r carcinoma. Second, laser microdissection of frozen section is very difficult 
technically as we should work very quickly against very poor visualization which will lead to 
inevitable errors, inaccuracy and impurity of the highly selected target lesions. Last but not 
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least, most of our lesions are minute in size and no frozen materi.'1ls were available for most 
of them. Subsequently, using DNA derived from fonnalin fixed paraffin embedded tissue 
(FFPE1) was inevitable. In fact, the successful rate of getting informative aCGH results 
from FFPET is very challenging and it is mainly due to a) fragmentation of DNA (quality 
of DNA), b) presence of formaldehyde cross-links of DNA and c) the reL'ltive large amount 
of DNA that is required (SOOng-2ug quantit)1166, 167. 
However, applying aCGH using DNA derived from FFPET has many advantages 
especially for the pwpose of our study 1) DNA is stable for many years, 2) it allows us to 
use the huge clinicopathological and clinical data available, 3) it allows us to compare the 
genetic changes of the different matching lesions with different histological and phenotypic 
characteristics, 4) a successful aCGH requires chopped DNA rather than intact DNA, and 
5) FFPET- sections are compatible and easy to use with laser microdissection with high 
resolution of the histological details of different lesions l 4-15. Moreover, recently a few 
number of studies succeeded to apply CGH on tissue derived from FFPET and their 
results were encouraging 154,166,168-170. 
QUALITY OF DNA 
As aforementioned, one of the major limitations of getting informative aCGH results from 
FFPET is the quality of DNA Because aCGH experiments are very tedious and 
expensive, using unsuitable DNA is a big problem as some tumours may have too degraded 
DNA that is unsuited for aCGH analysis even with repeating the experiment using fresh 
sections 154, 166-170. The integrity of DNA depends on several factors: a) sample type, b) 
sample age, c) storage conditions, d) handling methods, e) fixation conditions (timing of the 
fixation, fixation materials, and the duration of the fixation) and D DNA isolation methods 
154,16(,,170. In fact, some cases may have degraded DNA more than others due to unknown 
causes 166. Subsequently, scanning the FFPET archival blocks to identify which blocks 
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contain high quality DNA that is suitable for aCGH is essential 166. For that reason, we 
adopted the recent published multiplex PeR quality control protocol 166 for scanning more 
than 75 cases of low grade breast carcinoma. In addition the quality and size of the isolated 
DNA samples were evaluated by using 1% gel electrophoreses and NanoDrop 
spectrophometer (NanoDrop Technologies, WUmington, USA) 170. 
QUANTITY OF DNA 
The amount of extracted DNA was measured using a NanoDrop spectrophometer 
however, we and others 167 found that using the NanoDrop spectrophometer to measure 
the very tiny amount of DNA isohted from FFPET is not suitable as the NanoDrop 
spectrophometer reading is up to lO-times higher than using a double stranded DNA 
(dsDNA) binding dye e.g. picogreen. The expLmation for this difference is the NanoDrop 
spectrophometer detects both single-stranded and double stranded DNA and most of our 
DNAs isohted from FFPE samples were denatured and single-stranded. As aCGH require 
dsDNA, we used picogreen dye to quantify our DNA samples 167. 
Because our target lesions are very small and the thickness of FFPET is small too, normally 
5-10 microns thick, the amount of DNA retrieved is minute. For that reason during the 
optimization process for our aCGH experiment, different methods of DNA amplification 
were compared to produce DNA of adequate quantity and quality. 
For instance we have used GenomiPluiM DNA amplification kit (25-6600-01, GE 
Healthcare, USA), Restriction and Greularization-Aided Rolling Grele Amplification 
(Ro\'-Ro\') method 171, GenomePlex complete Whole Genome Amplification kit (Sigma 
WGA2; Sigma-Aldrich, USA) and GenomePlex complete Whole Genome Amplification 
for single cells (Sigma WGA4; Sigma-Aldrich, USA) according to manufacture's 
instructions. We did the experiments on 3 microdissected cases with different DNA 
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template concentrations starting from 5ng, 10, 15, 20, 30, and 50 ng for each method 
According to DNA measurements and multiplex PeR qu.ility control we fOWld that the 
GenomePlex G>mplete Whole Genome Amplification for single cells (Sigma WGA4) with 
starting DNA from 20 ng gave the highest DNA yield with DNA fragment 2:300bp. 
Although we succeeded in performing aCGH experiments using this amplification method, 
we were not able to get infonnative results -even after repeating the experiment- due to the 
presence of high backgrollild noise. In addition, to avoid any possibility of bi.1Ses that 
could arise from the amplification 165-167 of such low concentration especially for lesions that 
we expected to have very few genetic changes; we decided to use non-amplified DNA for 
our aCGH experiments which was bborious. 
5.3.2 Methods 
Immunohistochemical phenotyping 
Four urn thick sections of each case were subjected to irnmWlohistochemistry with a panel 
of antibodies against 0<18, 0<19, 0<8, 0<5/6, 0<14, EGFR, PR, ER-IX, E R - ~ l , , MUCl, 
Cydin 01, p53, MDM2, MDM4, SMA, Vimentin, Bcl2, E-Cadherin, and HER-2 as 
previously described in chapter 3. All markers were scored by two pathologists, blinded to 
the results of the aCGH, expression array and aSH analysis. Utilising the criteria of 
Nielsen et al 26 all of our samples had a luminal phenotype. 
Laser microdissection 
In this study we used a L1Ser microdissection technique to obtain highly pure populations of 
breast lesion cells from invasive and precursor lesions, devoid of normal epithelial or 
SurroWlding stromal cells, which might confoWld the genetic analysis 153. We used two 
systems of laser microdissection. In Histopathology, Queen's Medical Centre, Nottingham, 
we used a PALM Microbeam Laser Capture Microdissector (PALM AG, Bemdried, 
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Germany; www.palmmicrolaser.com). At the Breakthrough Breast Cancer Research Centre, 
Institute of Cancer Research, London, the PixCell II Laser Capture Microdissection sy.;tem 
(Arcturus Biosciences, Genetic Research Instnunentation Ltd, Braintree, UK) was used 172. 
Briefly in both systems, at least 15 consecutive 10 um paraffin embedded tissue full face 
sections from each cases were a) de-paraffinized twice for 5 min in xylene, b) re-hydrated in 
100%,96% and 70% molecular ethanol for 30 second each, c) incubated overnight in 1M 
NaSCN at 37«: to remove DNA cross-links, d) rinsed twice 10 min in 1 x PBS at room 
temperature, e) stained by fresh purified 1% nuclear fast red to identify lesions details and 
finally h) completely air-dried as previous described 166. Under direct microscopic 
visualization, the target neoplastic epithelium cells have been microdissected. For PALM 
Microbeam laser capture microdissection, sections were directly transferred to ultra-violet 
(UV)-cross-linked PEN membrane PALM membrane slides. The neoplastic cells under 
laser pressure were captured (LPG into collection tubes (PALM) 153. Using PixCell II Laser 
Capture Microdissection sy.;tem, sections were mounted directly on the glass slides and the 
pulsed low-power IR laser beam was focused producing one of three manual 
interchangeable predefined laser spot size (7.5, 15 and 30 um) 172. The special cap (CapSure 
1M LCM) which is covered by thin thermoplastic film was positioned directly on the tissue. 
With each pulse of the L1Ser beam, the thermoplastic sheet is melted and the target tissue 
glues onto the film. The target tissue was separated and capture by lifting the cap from the 
slide 172. When completed, the thin film was carefully peeled and transferred into an 
Eppendorf tube under DNase-free and RNase-free conditions. The estimated purity of 
captured target cells was 100% for precursor lesions (columnar cell lesions, DOS and LN) 
and 95% for invasive TC and ILC At least 100,000 neoplastic cells (60,000,000 wn2) were 
microdissected per each lesion (Figures 5-4 and 5-5). 
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Figure 5-5: Columnar cell lesion after laser microdissection dissection by using PixCell II Laser 
Capture Microdissection system. 
DNA extraction 
DNA was extracted using a QlAamp DNA FFPE Tissue Kit (Qiagen, cat. 56404) adapted 
to LMD samples. After microdissection, the DNA was extracted in 180 ul Qiagen A1L 
buffer and incubated overnight with 20 ul proteinase-K (20mg/ ml stock) by shaking at 450 
rpm, at 56CC Another dose (20 ul) of proteinase-K was added ~ e r r 18 hours 166. After 
total proteinase-K incubation of - 22h or until the sample has been completely lysed, the 
samples were incubated at 90CC for no more than 1 hour to inactivate the proteinase-K and 
to reverse the formaldehyde modification of DNA Then 2 f-ll of RNase A (100 mg/ ml) 
was added to obtain RNA-free genomic DNA and the samples were incubated for 2 min at 
room temperature. DNA extraction and purification proceeded according to the 
manufacturer's instructions (Qiagen, cat. 56404). Subsequently, the DNA yield was 
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measured with the PicoGreen® assay according to the IlL:'umfacturer's instructions 
(Invitrogen, Paisley, UK) and DNA fragment size distribution was assessed by 1% agarose 
gel electrophoresis. The DNA purity and quality were assessed by NanoDrop 
spectrophometer (NanoDrop Technologies, WJmington, USA). High quality pure DNA 
samples should have an A260/ A280 urn ratio of 1.8-2.0 and an A260/ A230 urn ratio ~ ~ 2.0 
by NanoDrop spectrophometer 170. 
Assessment of DNA quality 
DNA integrity which is the cornerstone for successful CGH analysis was tested using a 
multiplex pm technique as described by van Beers EH and his colleagues 2006 166• Briefly, 
100 ng of DNA was analysed in a pm reaction that was performed with four primer sets. 
The four primer sets produce 100, 200, 300 and 400 bp non-overbpping fragments of 
GAPDH gene (chromosome 12) in a master mix reaction (10m.M: Tris-HO pH 8.8, 1.5 m.M: 
Mgc12, 75mM, Ka, 0.2m.M: dNTPs, lU Taq DNA polymerase; Invitrogen cat. 18038-26). 
Ten ul of pm products were assessed on a 1.5% agarose geL Samples with DNA 
fragments sized 400 bp were selected for downstream aCGH experiments, catalogued and 
stored at -80'C (Figure 5-6). 
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Figure 5-6: Assessment of formal fixed paraffin embedded tissue DNA integrity by multiplex 
PCRqualitycontrol (Qq technique. 
This gel electrophoresis shows that DNA products of at least 400bp in size (maximum product size 
achievable with the chosen primers) \VaS obtained 
Microanay-Based Comparative Genomic Hybridization (aCGH) 
NUMBER AND TYPES OF LESIONS 
Twenty-one lesions were tested 6 tubular carcinoma, 3 invasive lobular carcinoma, 4 ductal 
carcinoma in situ, 4 lobular neoplasia, 2 flat epithelial atypia, and 2 colwnnar cell lesion 
without atypia, out of 42 rnicrodissected lesions yielded DNA of sufficient quantity and 
quality for aCGH analysis. 
CGH PLATFORM 
The aCGH platform used for this studywas constructed at the Breakthrough Breast Cancer 
Research Centre and comprises 32 000 BAC clones (mORl) tiled across the genome and 
sporred onto Coming GAPSII-coated glass slides (Coming, NY, USA). Previous studies 
have shown that the robustness and resolution of this type of BAC array platform were 
comparable with high density oligonucleotide arrays 140,173. Moreover the small target size 
of oligonucleotides reduces effectiveness of oligonucleotide arrays with degraded FFPET-
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DNA and increases the susceptibility to cross hybridization with multiple genomic loci 
leading to poor signalling 174. 
NORMAL REFERENCE DNA 
Nonna! DNA extracted from blood lymphocytes pooled from 24 females and scanned for 
nonna! variation polymorphism 140. 
DNA LABELLING AND ARRAY HYBRIDIZATION 
As previously described 138, 140 , by default, Cy3 and CyS conjugated dCIP were used to 
label at least 300 ng of tumour (test) and 300 ng nOnna! female (reference) DNA, 
respectively (GE Healthcare Life Sciences, Buckinghamshire, United kingdom, cat number 
P A55321) by using a BioPrime DNA labelling System random primers solution (Invitrogen 
Life Technology; cat number 18094-011) according to the manufacturers p r o t o c o ~ ~
modified to incorporate 1.0mM Cy dye, 0.6 Mm dCfP and 1.2 mM dATP, dGTP, and 
dTIP and subsequently incubated overnight (16-18h) at 37"C After removal of 
unincorporated nucleotides by using MinElute Reaction deanup (Qiagen, Crawley, United 
Kingdom; cat number 28004), Cy3-labeled test and Cy5-labeled reference DNAs were 
mixed together and ethanol precipitated with 100 ug of human Cot-1 DNA (Invitrogen 
Life Technology, cat number 15279011) and 3 M sodium acetate (PH 7). Then the pellets 
were re-suspended in 45 ul hybridization buffer (50% deionised formamide, 10% (w/v) 
dextran sulphate, 2 x SSe 2% SDS, 20 ug Yeast RNA). The labelled DNA was denatured 
at 70°C for 15 min followed by 30 min reannealing at 37"C to allow blocking of repetitive 
sequences by human Cot-1 DNA Subsequently, DNA samples were hybridized to high 
resolution DNA microarray cooperative genomic hybridization slides comprising 32,000 
BAC spots for 18 hours at 37"C as previously described 138,140. 
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WASH 
After hybridization, the cover slips were removed by washing slides in 2x SSCl1% SDS for 
15 min at 45°C followed by washing of the slides in 50% deiorused fonnamide 2 x SSC for 
15 min at 45°C Finally, washing in 2 x SSCI 1 % SDS for 30 min at 45°C and twice in 0.2 x 
SSCfor 15 min at room temperature was followed. The arrays were dried by centrifugation 
at 2000 tpm for 2 min. 
DATA ACQUISITION 
Following hybridization and washes, slides were scanned using a DNA Microarray Axon 
4000B Scanner (Axon Instruments, Burlingame, CA, USA) and the Fluorescent images 
(TIFF images) were processed using GenePix Pro 5.1 lln.1ge analysis software (Axon 
Instruments). Per array, a GenePix results file (Microsoft ExceQ with the extracted Cy3 and 
CyS spot and background raw intensities was been generated. The karyotype for each 
lesion was underwent cluster analysis to identify distinct groups and priro.-uy (bta analysis 
and normalization carried out using Microsoft Excel file. 
DATA ANALYSIS 
C'lSes with >10% of clones missing and clones where data were not available in 10% of 
cases were excluded. The log2 ratios were nonnalized for s p a t ~ l l l and intensity-dependent 
biases using a two-dimensional local regression followed by a BAG dependent bias 
correction as previously described 138, 140. BAC clone replicate spots were averaged across 
dye-swap experiments after exclusion of poorly reproducible replicates (SD > 0.2) and 
excessively fL1gged clones (>?'O% of samples). Results were analysed using plots of log2-
transfonned nonnalized CyS:Cy3 intensity ratios against clone position. Polymotphic 
BAG identified in an analysis of 50 male: fem.lle and female: female hybridizations were 
filtered out. This left a final dataset of 30,606 clones with unambiguous mappmg 
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information according to GENCDDE project; Ensembl release 56-Sept 2009 @ WISr / 
EBI WISr / EBI of the human genome (http://www.ensembl.org).Eachofthe30,606 
BAG defines a genomic region starting from the end position of the previous non-
overlapping clone on the array to the start position of the next contiguous, non-overL'1pping 
array clone. These genomic regions were defined because any deletion or gain! amplification 
seen for a clone may extend beyond the clone, and thus the extent of change was 
determined by the next lUlaffected clone on the array in both directions 59,138, 140,. 
Data were smoothed using the circular binary segmentation (cbs) algorithm 175. A 
categorical analysis was applied to each clone on the array after classification as gain, loss, or 
no-change according to their smoothed log2 ratio values. Smoothed log2 ratio values less 
than - 0,12 were categorized as losses; those greater than 0.12 as gains; and those in between 
as lUlchanged. Amplifications were defined as smoothed log2 ratio values greater than 0.45. 
These threshold values were chosen to correspond to three standard deviations (SD) of the 
notmal ratios obtained from the filtered clones mapping to chromosomes 1-22, assessed in 
comparisons between DNA extracted from a pool of male and female blood donors as 
described before. 
Data processing and analysis were carried out in R 2.0.1 (http://www.r-project.org/) and 
BioConductor 1.5 (http://www.bioconductor.orgl).using modified versions of the 
packages aCGH, marrayand aws. 
Copy number changes were categorized as gains, losses or amplifications according to the 
aforementioned thresholds for each clone before using Fisher's exact test with adjustment 
for multiple testing using the step-down petmutation procedure maxT providing strong 
control of the family-wise type I error rate (FWER) 59, 138, 140, 175 to identify statistically 
significant differences between the genomic profiles of different lesions. A false discovery 
rate-adjusted p <0.05 was considered significant. 
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aCGH comparative analysis 
Comparative analysis was perfonned with publicly available aCGH datasets derived from 64 
high grade breast cancers cases 140 and 171 tulSelected series of Be (Gene expression 
Omnibus (GEO) , series accession munber CE8757) in which the aCGH results were 
validated by gene expression 176 (Table 5-2). 
HIGH GRADE BREAST CANCER CASES 
As previously described 139, sixty-four consecutive grade III invasive ductal Carcin01llc1S were 
retrieved from University Hospital La paz (UHLP), Madrid, Spain. 
Eight-I-I.m thick frozen sections of 64 grade III tumours were microdissected using needle 
to obtain a percentage of tumour cells in the remaining tissue greater than 90% 138,140. DNA 
was extracted as previously described 138,140. RNA was extracted using Trizol according to 
manufacturers' instructions (Invitrogen, UK) and quantified using the Agilent 2100 
Bioanalyzer with RNA Nano LabOUp Kits (Agilent Biosystems). The final dataset 
comprised 48 cases and were subjected to 32K BAC as described before 138,140. 
Gene expression profiling was perfonned using the Illumina human WG6 version 2 
expression array according to the manufacturer's protocol. Briefly 200ng of each RNA 
sample was amplified using the Illumina Totalprep RNA amplification kit following the 
manufacturer'S instructions (Ambion, UK). Labelled cRNA was subsequently hybridised to 
Illumina Sentrix-human 6 version 2 expression bead-chips. Full details on RNA 
amplification and hybridisation can be found at www.illumina.com. Raw gene expression 
values were robust-spline nonnalised using the Bioconductor lumi pack.1ge 
(http://www.bioconductor.org/pack.-tges/2.3/bioc/htmVlumi.html) in R. Genes were 
mapped to their genomic location using the lumiHumanAllv2 annotation database available 
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from Bioconductor. Only Illumina transcript probes with detection p-values <0.01 in 
>25% of samples were included; this resulted in a dataset of 12,699 transcriptionally 
regulated probes with accurate and tmequivocal mapping information. Gene-expression 
data are publicly available at ArrayExpress http://www.ebi.ac.u.kI microarray-as/ ae/ 
(accession number: E-TABM-543). 
UNSELECTED BREAST CANCER CASES 
Primary breast tumour specimens were obtained from the Nottingham Tenovus Primary 
Breast Cancer Series. DNA was extracted using the Promega DNA Wtzard kit (Promega, 
UK) according to manufacturer's instructions. Labelled DNAs were hybridized to a 
customized oligonucleotide microarrays containing 30,000 60-mer oligo probes 176, for 
which 27,801 unique map positions were defined (Human M1l'. 2006 assembly (hg18}). The 
median interval between mapped elements was 39.4 kb, 75% of intervals were less than 
104.2 kb and 95% were less than 402 kb. The raw and mode-normalized data for the 171 
tumoW'S are avaiL'lble from NCBI's GEO 176 under the series accession number GSE8757. 
113 out of the 171 breast tumOW'S were also profiled on Agilent gene expression arrays 176 
in which gene-dosage levels to gene expression were evaluated using WJcox on test to 
evaluate the significance of the association between copy number and aberrant expression. 
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Table 5-2: Sumrneryof material and methods used in this study 
Experiment Group (1) Group (2) Group(J) 
Morphology Breast lesions Low nuclear grade mvaslve High grade invasive ductal Unselectcd series of 
can:inom1. and matching can:inoma no special type invasive can:inoma 
preinvasive including: tubular 
can:moma and mvaslve 
lobular can:inoma. 
AnayCGH No. of invasive 20 64 171 
cases 
Type offixation Formalin Fixed Paraffin Frozen Frozen 
Embedded 
Type of dissection Laser microdissection Needle micro-dissection Full section 
DNA Non-amplified Amplified Non-amplified 
Resolution 32Kb 32Kb <100Kb 
Platform BAC aCGH platform BACaCGH Oligonucleotide 
Gene expression no of case NA 48 cases 113 cases 
Platform NA IUurnina human WG6 version 2 Agilent gene 
Immunohistochemistry No. of cases 145 NA 1081 
(IHC) Type of tissue Full face and 1MA NA 1MA 
omic:!1 follow NA NA Yes 
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Validation tests for MDM4 as a target oncogene in breast cancer 
As we have shown in Cllapter 2, more than 97% of low grade breast cancer had wild type 
p53 suggesting that the p53 pathway is inactivated by alterations other than mutation of 
TP53 itself 102,177-180. Among these, alterations of MDM4 overexpressionlamplification 
were found. MDM4 binds to p53 and thereby inactivates the function of p53 as a 
transcriptional activator of other genes 181. Mice knockout studies suggest that MDM4 has 
been shown to negatively regulate the p53 pathway181. More recently, Danovi et al182 found 
that MDM4 was amplified in 5% of human prirn.-uy breast cancers, all of which retained 
wild-type p53. Moreover, MDM4 was also amplified in MCF-7, an ER+ breast cancer cell 
line harbouring wild-type p53 181. In addition, artificial overexpression of MDM4 led to 
immortalization of prirn.-uy mouse embryonic fibrobbst and neoplastic transfonnation182 
The human MDM4 gene has been rn.'1pped to chromosome lq32 region which is frequently 
amplified in low grade breast cancers. Recent studies have proposed that MDM4 is one of 
the target amplified genes on 1q32 in up to 65% of rn.'1lignant gliomas and urinary bbdder 
carcinoma, detected byaCGH83. Subsequently, we hypothesised that it may be a candidate 
oncogene in Be and we tested this hypothesis at several levels. 
INTEGRATED ARRAY CGH AND EXPRESSION ANALYSIS 
To determine whether MDM4 gene copy numbers correbted with MDM4 rnRNA 
expression levels, cbs-smoothed aCGH cL'1ta were used to assign the median aCGH states 
for MDM4 using the median values for all BACs which overlap with the genomic position 
of MDM4. This resulted in a 1:1 matrix of expression cL'1ta and aCGH values used in 
correbtions. Pearson correlations were performed between rnRNA expression log intensity 
values and median cbs-smoothed ratios derived from aCGH analysis for each gene. P 
values for each test were adjusted with Benjarnini and Hochberg multiple P-value 
adjustment 175. 
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To detennine whether MDM4 is consistently overexpressed when amplified, a Mann 
Whitney U test was performed and adjusted with Benjamini and Hochberg multiple P-value 
adjustment. An adjusted p value of <0.05 was considered significant. 
MDM4 PROTEIN EXPRESSION USING IMMUNOHISTOCHEMISTRY 
Immunohistochemistry for MDM4 (affinity purified rabbit anti-HdrnXlMDM4 clone, 
IHCOOI0S, 1:250, Bethyl Labs)183 was performed on 20 full face section of LNGBC cases 
and 2 sets of TMAs as described before in dlapter 3. The first TMA set include 140 cases 
of low nuclear grade breast can:inoma and their matched co-existing precursor lesions as 
described in OIapter 2. The second data set included a series of primary operable invasive 
BC derived from the Nottingham Tenovus (NottinghamlTenovus) Primary Breast 
Carcinoma Series of women age :90 years, Nottingham City Hospital (1989-1999). Out of 
1,200 tumours consecutively accrued, 1,OS1 cases were included in this study based on the 
following inclusion criteria ~ ~ complete clinical and therapeutic data available and u) 
successful staining for MDM4. The clinicopathological characteristics and swvival data of 
this cohort were previously described in OIapter 3. Median follow up was 111 months 
(range 1 to 233). 
Positive control and negative controls (omission of the primary antibody and IgG-matched 
immune serum) were included in each slide run. MDM4 immunohistochemical intensity 
and percentage of positive cells were scored by two pathologists. Only nuclear staining was 
considered specific183. The analysis was performed blinded to the results of the patients' 
outcome. Statistical analysis was described in chapter 3. 
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Validation tests forCyclin Dl (CCDN1) 
IMMUNOHISTOCHEMISTRY FOR PROTEIN EXPRESSION 
ImmWlohistochemistry for cydin D1 (SP4, 1:50, Neomarkers, UK) was performed as 
previously described in chapter 2. Cyelin D1 immWlohistochemical intensity and 
distribution were semi quantitatively scored by two pathologists as described in chapter 2. 
Only nuclear staining was considered specific. The analysis was performed blinded to the 
results of the aCGH and aSH results. 
CHROMOGENIC IN SITU HYBRIDISATION 
As previously described 138, 140, aSH for CCNDI was performed using the r e a d ~ t o - u s e e
digoxigenin-L'lbelled SpotLight cyclin D1 amplification probe (Zymed, South San Francisco, 
CA.). Heat pre-treatment of deparaffinised sections consisted of incubation for 15 min at 
98°C in aSH pre-treatment buffer (SPOT-light tissue pre-treatment kit, Zymed) and 
digested with pepsin for 7 min at room temperature according to the manufacturer's 
instructions. An appropriate CCNDI gene-amplified breast tumour control was included in 
the slide run. aSH experiments were analysed by two pathologists. Only Wlequivocal 
signals were cOWlted. Signals were evaluated at 400 and 630 magnification and 60 
morphologically Wlequivocal neopl'lstic cells were cOWlted for the presence of the gene 
probe signals. Amplification was defined as >5 signals per nucleus in more than 50% of 
cancer cells, or when large gene copy clusters were seen 138, 140. The scoring was evaluated 
with observers blinded to the results of the aCGH and immWlohistochemical analysis. 
Published copy number and gene expression data bases' 
We have accessed and mined the following database: 
.:. hUp:/ / projects.tcag.cal variation! (for copy number polymorphism) 
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.:. http://www.ensembLorg (for location of genes) 




21 lesions belonging to 10 cases were successfully analyzed for copy munber changes by 
usingaCGH 
5.4.1 Analysis of case 1 (invasive lobular carcinoma) 
Motphology 
Haematoxylin and eosin staining of full face sections showed columnar cell changes, flat 
epithelial atypia (Figure 5-7), low/intermediate grade ductal carcinoma in situ 
[micropapillary (Figures 5-8 and 5-9) and cribrifonn pattern], duct spaces lined by 
columnar cells showing nuclear atypia and apical snout with intraductal islands of paler cells 
of lobular neoplasia morphology, ducts spaces an admixture of Das with islands of lobular 
neoplasia (Figures 5-10 and 5-11); intimately admixed Das and LaS, expanded lobules 
showing features typical of lobular carcinoma in situ (figures 5-12 and 5-13) and tiny focus 
of invasive classic lobubr carcinoma (Figure 5-14). These lesions had the same 
topographic distribution and cytoplasmic and nuclear features. 
Immunohistochemical profile 
The aforementioned lesions showed strong positive staining for CK18+, 0<.19+, CK8+, 
ER + (Figures 5-15 and 5-16), PR +, Bcl2 + (Figures 5-17, 5-18, 5-19 and 5-20) , cydin 
D1+, MUC1+ and negative expression for p53, CK5/6, and CK14 with no HER-2 over-
expression. E-Cadherin inununohistochernistry staining showed strong membrane positive 
reactivity in the cx::Ls, FEA and Das component and negativity in both ILC focus and 
LOS component in the pure and admixed areas. 
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Figure 5-8: Ductal carcinoma in situ from case 1 (H&E) 
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Figure 5-9: Ductal carcinoma in situ showing positive expression of E-cadherin 
Figure 5-10: Duct spaces lined by columnar cells showing nuclear atypia and apical snout with 
intraductal islands of paler cells of lobular neoplasia morphology 
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Figure 5-11: A duct spaces an admixture of Das (E-Cadherin positive) with islands of E-
cadherin negative lobular neoplasia (intimately admixed Das and LaS). 
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Figure 5-12: Expanded lobules showing features typical of lobular carcinoma in situ (H&E) 
Figure 5-13: Lobular carcinoma in situ showing negative expression of E-cadherin 
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Figure 5-14: A H&E section showing classic cord like structure of invasive lobular carcinoma 
OLe). B: ILC showing negative E-cadherin expression 
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Figure 5·15: Columnar cell change lesions showing positive expression of oestrogen receptor 
nuclear staining 
Figure 5· 16: Lobular neoplasia lesions showing positive expression of oestrogen receptor nuclear 
staining 
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Figure 5·18: Columnar cell lesions showing strong positive cytoplasmic expression of Bc12 
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Figure 5-19: 
expression 
Invasive lobular earcmoma showing positive Bel2 
Figure 5-20: Columnar eeiliesions showing positive Bel2. 
-------------------------------------------
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Genome profiles 
Four components were separately laser microdissected including FEA, DOS, LN and ILC; 
however, the microdissected ILC did not yield DNA of sufficient quantity for aCGH 
According to the genomic patterns described by Hicks et al 55, all lesions were of simplex 
pattern, characterized by broad segments of duplications and deletions comprising part or 
entire chromosome arms (lq+, llq22- and 16q-) with occasional amplifications. A 
comparison between distinct morphological components of case 1 (pEA, DOS and LN) in 
a pairwise fashion revealed that they shared strikingly similar genomic profiles (Figures 5-
21,5-22 and 5-23 and Table 5-3). Pearson's correlation performed with normalized Log2 
ratios showed the following corrections: FEA vs. DOS: r=O.647; FEA vs. LN, :r=0.434 
and DOS vs. LN: r=O.802. The common genetic changes among FEA, DOS and LN 
were gains of Ip36.31, lq21.1-44 (lq+), 3p21.31-p21.1, 5q35.2-35.3, llq13.3-11q13.4, 
lSqll1, 18q21.1 and 19p13.2 and losses of Ip34.3, llq22.3 and 16pl1.2-q24.3 (16q-). 
Amplifications of llq13.3-11q13,4 (CCND1) and 19p13.2 (ADAMS10) were common 
between DOS and LN. LN showed additional amplification at llplS.1 and llq13.1-
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Figure 5-21: Genome plot of flat epithelial atypia which has been dissected from case 1 showing 
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Figure 5-22: Genome plot of ductal carcinoma In situ from case 1 showing gain! amplification of 
lq, llq and 19p and loss of llq, llq and 19q. 
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Figure 5-23: Genome plot of lobular neoplasia that laser micro-dissected from case 1 showing 
gain! amplification of lq, Up, llq, 16p and 19p and loss of 6q, llq and 16q. 
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Table 5-3: Genetic changes of different components of case number 1: columnar cell lesion 
(CeL-1), ductal carcinoma in situ (DaS- 1) and lobular neoplasia (LN-i) . 
c hrom m a p Cytogenetic Band CCL-1 DCIS-1 LN-1 
1 1:2277295 . . 2485326 Ip36.33-p36.32 GAIN GAIN 
1 1:2697923 .. 3757389 Ip36.32 LOSS GAIN 
1 1:4114075 .. 5665582 Ip36.2 LOSS 
1 1:5873942 .. . 6950771 Ip36 .31 GAIN GAIN GAIN 
1 1:34515166 .. 35375482 'p34.3 LOSS LOSS LOSS 
1 1: 144452745 .. 246624589 0 21.1-044 GAIN GAIN GAIN 
2 2:10092490 .. 10269500 2 p25.1 GAIN 
2 2 : 10224532 .. 10608610 2p25.1 GAIN 
3 3:46851921..53308680 p21.3 1-p21. 1 GAIN GAIN GAIN 
3 3 :125828183 .. 129284640 p 21.31-021.1 GAIN 
3 3 :183258533 .. 195960808 0 26 .33-029 GAIN 
4 4:9371304 .... 23169797 1016.2-0 15.2 LOSS 
5 5 :43351415 . .43702315 5p12 GAIN 
5 5 :176368478 .. 180676573 1035 .2-035 .3 GAIN GAIN GAIN 
6 6 :42373615 . .44434337 IP21.1 GAIN 
6 6:57335587 ... 58075261 Ip_11.2 LOSS LOSS 
6 6 :80657246 .. 92946437 1014 .1-q16.1 LOSS LOSS 
7 7 :61091237 .. 62439460 Iql1.1-q11.21 GAIN GAIN 
7 7 :72815547 . . 75193290 1011.22-011.23 GAIN 
8 8 :6755220 .. 8042158 Ip23.1 LOSS 
8 8 :21864085 .. 23175482 p 2 1 . 3 ~ R 2 1 . 2 2 GAIN 
8 8: 143743728 .. 144743580 q24 .3 GAIN GAIN 
9 9:39131199 ... 71033904 p13.1-q12 LOSS 
9 9:130513305 .. 138069659 q 3 3 .1-034.3 GAIN GAIN 
10 10 : 38598310 .. .43015352 p l1.21-011.21 LOSS 
10 10 :43498972 . .44019673 0 11.21 GAIN GAIN 
11 11 : 4 ~ ~ l t i ~ 4 4 .. . t i b t l 4 ~ b ~ ~ Ip15.5-pI5.4 _055 
11 11 :17520419 .. 19540446 Ip15.1 AMP 
11 11 :49003873 . .49980055 1 1 1 1 . 2 ~ q I I . 1 1 LOSS 
11 11:60166833 .. 61767307 1202 GAIN 
11 11 :64845754 .. 68578000 11013.1-11013 .3 GAIN AMP 
11 11: 68523084 .. 71362638 110 13.3-11013.4 GAIN AMP AMP 
11 11:80636716 .. 108525726 11014.1- 22 .3 LOSS LOSS 
11 11 : 108450613 .. 108525726 11022.3 LOSS LOSS LOSS 
12 12: 5972109 .. 7247166 013 .31 GAIN 
12 12 :48027380 .. 55251462 013 .11-013.2 GAIN 
12 12: 121193338 .. 125667418 0 24.23-024.31 GAIN 
14 14:50264879 . . 51754207 022. 1 GAIN 
15 15 : 20829066 .. 22596193 011.2 GAIN GAIN GAIN 
16 16:11139 .. 31764125 p13.3-p l1.2-p11.2-011.2 GAIN GAIN 
16 16: 48900991. .84593836 p11.2-0 24.3 LOSS LOSS LOSS 
17 17: 2256623 .. 5083694 p13 .3- p13 .2 GAIN 
17 17 :6879623 .. 8614953 1013 .2-013. 1 LOSS GAIN 
17 17: 16917282 .. 18377155 1011.2 GAIN GAIN 
17 17:36690553 . .49204340 Iql2-_q21.33 GAIN 
18 18 :44404930 . .44713872 1021.1 GAIN AMP GAIN 
18 18 : 74032492 .. 74812028 Iq23 GAIN 
19 19:8649225 .. 8687198 1013 .2 (ADAM SlO) GAIN AMP AMP 
19 19 : :9074066 . . 19919144 1013.2-13.11 GAIN GAIN 
19 19 : 28680998 .. 32819119 1012-013 .11 LOSS LOSS 
21 21: 43466719 .. .45929047 !022 .3 GAIN 
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Validation of CCNDI as a tamet candidate gene 
Immunohistochemistry and OSH analysis of full face sections revealed amplification and 
overexpression of CCNDI in all co-existing lesions including columnar cell changes, flat 
epithelial atypia, low/intermediate grade ductal carcinoma in situ (micropapillary and 
cribriform pattern), duct spaces lined by columnar cells with intraductal ishnds of lobular 
neoplasia morphology, intimately admixed DOS and LOS, expanded lobules showing 
features typical of lobular neoplasia and invasive classic lobular carcinoma (Figures 5-24, 
5-25, 5-26, 5-27, 5-28, 5-29, 5-30 and 5-31). TIlls finding was compatible with what we 




Figure 5-24: Columnar cell change lesion showing positive nuclear Cydin D 1 IHC staining 
Figure 5-25: Atypical ductal hyperplasia s showing positive nuclear Cydin Dl IHC staining 
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Figure 5·26: A duct spaces lobular neoplasia showing positive nuclear Cyclin Dl IHC staining 
Figure 5·27: lobular neoplasia showing positive nuclear Cyclin DlIHC staining 
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Figure 5-28: Invasive lobular carcinoma showing positive nuclear Cydin Dl IHC staining 
Figure 5-29: Flat epithelial atypia showing amplification of Cydin Dl (CCDJ); chromogenic m 
situ hybridization 
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Figure 5·30: Lobular neoplasia showing amplification of Cydin D1 (CCD1); chromogenic in situ 
hybridization (low power). 
Figure 5·31: Lobular neoplasia showing amplification of Cydin Dl (CCDl); chromogenic in situ 
hybridization (high power). 
164 
Oxzpter 5 Gemic cbtracteristia cf law nud£tlr grade brrust rrotiasia 
5.4.2 Analysis of case 2 (mixed tubular carcinoma) 
MoWhology 
This is an example of mixed tubular carcinoma in which about 80% of the tumour showing 
tubules formation at the centre and 20% of solid sheets with less occasional tubules at the 
periphery of the tumour. A range of preinvasive lesions including columnar cell lesions, 
usual epithelial hyperplasia (UEH) and ductal carcinoma in situ (mainly cribrifonn pattern) 
was noticed. These lesions had same topographic distribution and cytoplasmic and nuclear 
features. 
Immunohistochemical profile 
The aforementioned lesions showed strong positive staining for 0<.18+, CK19+, CK8+, 
ER +, PR +, Bc12 +, MUG 1 + and negative expression for pS3, 0<.5/6, and CK 14 with no 
HER-2 over-expression. E-Cadherin immunocytochemistry staining showed strong 
membrane positive reactivity in all of them. 
Genome profiles 
Four components were laser microdissected separately including ax: with atypia, DOS, 
and invasive tubular carcinoma (one sample from the centre of the tumour and the other 
from the periphe1J1. 
The genomic patterns of all lesions (Figures 5-32, 5-33, 5-34 and 5-35 and Table 5-4) 
were of simplex pattern, characterized by broad segments of duplications and deletions 
comprising part (16p13-qll + and 20p13.3-q13,33), entire chromosome arms (whole 1q+ 
arm, whole 13q + ann and whole 16q- arm) and whole chromosome (loss of whole 
chromosome 22) with occasional amplifications. A comparison between the distinct 
morphological components of case 2 (eeL, DOS, invasive from centre and invasive from 
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periphery) in a pairwise fashion revealed that they shared strikingly similar genomic profiles; 
Pearson's correlation perfonned with norm.1lized Log2 ratios revealed r values of CCLs vs. 
DOS: r=O.661; CCLs vs. invasive from centre: r=O.695; CCLs vs. invasive from periphery: 
r=O.681; DOS vs. invasive from centre: r=O.933; DOS vs. invasive from periphery: 
r=O.931 and invasive from centre vs. invasive from periphery: r ... 0.954. The common 
genetic changes among CCLs, DOS and invasive components were gains of Ip36.31, 
lq21.1-44 (gain of whole long arm; lq+), 3p21.31-p2.1, 5q35.2-35.3, 13q34, 16p13.3-ql1.2, 
20p13-q13.33 and losses of Ip36.32, Ip35.3-35.2, Ip34.3, 4p16.2-14.2, 6pll.2, 8p23.1, 
15ql1.l-15ql, 16p1l2-q24.3, 19p12-q13.11, and whole chromosome 22. Amplifications of 
Sq13.2, 13q14.3 (DLEUl, RNASEH2B am GUCYIB2) and 17q12-21.33 were noticed in 
the invasive component from the periphery of the tumour. In addition, all samples showed 
high gain in lq12 and lq+ especially at lq32.1-322. 
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Figure 5-32: Genome plot of columnar cell lesion which has been dissected from case 2 showing 
gain of lq and 20q and loss of Ip, lSp, 16q, 19p and 22q 
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Figure 5-33: Genome plot of ductal carcinoma in situ which has been dissected from case 2 
showing high gain of lq, 13q, 16p and 20 and loss of Ip, lSp, 16q, 19p and 22q 
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Figure 5-34: Genome plot of invasive tubular carcinoma from the centre which has been 
dissected from case 2 showing high gain of lq, 13q, 16p and 20 and loss of Ip, 15p, 16q, 19p and 
22q 
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Figure 5·35: Genome plot of invasive tubular carcinoma from the periphery which has been 
dissected from case 2 showing high gain of lq, 13q, 16p and 20 and loss of Ip, 15p, 16q, 19p and 
22q 
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Table 5-4: Genetic changes of different components of case 2: colwnnar cell lesions (ca..). 
ductal carcinoma in situ ( ~ O S ) . . and tubular carcinoma (Tq 
chrom map CvtoQenetic Band CCL-2 OCIS-2 TC-2 cenreal TC-2 Oerioherv 
1 1:2697923 .. 3757389 p)6.32 LOSS LOSS LOSS LOSS 
1 1 :4114075 .. 5665582 36.2 LOSS LOSS LOSS LOSS 
1 1:5873942 ... 6950771 36.31 GAIN GAIN GAIN GAIN 
1 1:29549713 .. 31394713 35.3-035.2 LOSS LOSS LOSS LOSS 
1 1:34515166 .. 35375482 34.3 LOSS LOSS LOSS LOSS 
1 1: 104025830 .. 104426934 l.Q21.1 LOSS 
1 1: 120436410 .. 120650514 1012 GAIN HiQh oain High gain Hioh oain 
1 1: 144452745 .. 246624589 1021.1-44 GAIN Hioh ga in Hi h gain Hlghgain 
3 3:46851921..53308680 I p 2 1 . 3 3 ~ p 2 1 . 1 1 GAIN GAIN GAIN GAIN 
44:9371304 .. 23169797 16.2- 15.2 LOSS LOSS LOSS LOSS 
5 5:65203593 .. 68826309 12.3 GAIN 
5 5:69035579 .. 703B8712 13.1-013.2 GAIN GAIN AMP 
55: 170368478 .. 180676573 'Q35.2-Q35.3 (jAIN GAIN GAIN GAIN 
66:57335587 ... 58075261 11.2 LOSS LOSS LOSS LOSS 
77:61091237 .. 62439460 11.1-011.21 GAIN GAIN 
77:98820572 .. 102185532 21.3-022 .1 LOSS LOSS LOSS 
88:6755220 .. 8042158 023 .1 LOSs LOSS LOSS LOSS 
9 9:39131199 .. . 71033904 13.1-012 LOSS 
99 :91735900 .. 92122168 21.33-022.32 GAIN GAIN 
9 9 : 130513305 .. 138069659 33 .1-Q34.3 GAIN 
9 9: 136583961..138069659 1034.11-034.3 LOSS LOSS LOSS 
10 10: 38598310 .. .43015352 1011.21 -011.21 LOSs 
10 10: 46812978 . .49450532 1011.21-011 .22 LOSS LOSS LOSS LOSS 
10 10:87865548 .. 88179055 Ig23.1 -Q23 .2 LOSS LOSS LOSS 
10 10 : 131479757 .. 133626641 IQ26.2-q26 .3 LOSS LOSS LOSS 
11 11: 17520419 .. 19540446 1015 .1 LOSS LOSS LOSS 
13 13: 20904235 .. 113346314 1011-034 GAIN GAIN GAIN 
13 13: 50698010 ... 51585238 Iq14.3 IGAIN (jAIN AMP 
13 13 : 110995727 .. 111374279 34 GAIN GAIN GAIN GAIN 
14 14 :50264879 .. 51754207 22 .1 GAIN 
15 15 ; 20094045 .. 32954812 q11.1 -q15.1 LOSS LOSS LOSS LOSS 
16 16:11139 .. 31764125 013.3-011.2 GAIN GAIN GAIN GAIN 
16 16:48900991. .84593836 11.2-024 .3 LOSS LOSS LOSS LOSS 
17 17 :9455707 .15687248 P12 LOSS 
17 17 : 16917282 .. 18755715 11.2 LOSS LOSS 
17 17: 36690553 . .49204340 12-021.33 GAIN GAIN AMP 
17 17 : 729302663 .. 78900648 25 .1-q25 .3 LOSS LClli.S 
19 19:960519 .. 2970392 13.3 GAIN 
19 19:28680998 .. 32819119 p12-o13 .11 LOSS LOSS LOSS LOSS 
19 19 : 54392659 .. 54877591 Iq13 .41-g13.42 LOSS LOSS LOSS 
19 19 :8629145 .. 9060080 1013 .2 LOSS LOSS LOSS LOSS 
20 20:90210 .. 59535518 Ip13-q13.33 GAIN GAIN GAIN 
20 20: 29421720 .. 29996640 1011.21 GAIN GAIN 
2? 22:17724207 .. 49794172 220 laSS laSS lOSS lOSS 
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5.4.3 Analysis of case 3 (pure tubular carcinoma) 
Motphology 
This is an example of pure tubular carcinoma in which > 95% of the tumour showed 
tubules, low mitosis and mild pleomotphism (Ml, Tl, and PI). Extensive colwnnar cell 
changes (cx:x:) without atypia, columnar cell hypetpbsia without atypia and ductal 
carcinoma in situ (mainly cribriform pattern) were intimately coexistence with invasive TG 
All these lesions had same the cytopbsmic and nuclear features. 
Immunohistochemical profile 
The aforementioned lesions showed strong positive staining for 0<.18+, 0<.19+, 0<.8+, 
ER+, PR+, Bc12, MUG 1 + and negative expression for p53, 0<.5/6, and CX14 with no 
HER-2 over-expression. E-Cadherin immunocytochemistry staining showed strong 
membrane positive reactivity in all of them. 
Genome profiles 
Three components were separately laser microdissected including rrx:J CXH without 
atypia, DOS, and invasive tubular carcinoma 
This case showed fewer genetic changes compared to the previous two cases. The genomic 
patterns (Figures 5-36,5-37 and 5-38 and Table 5-5) were of simplex, characterized by 
broad segments of duplication at lq+ and deletion at 16q with occasional amplification at 
7p12.3-12.2, 7pl1.2 and 18q21.1 in the invasive component. Pearson's correlation 
performed with normalized Log2 ratios revealed remarkable similarity in the genomic 
profiles CXl.. vs. DOS: r=O.717; CXl.. vs. invasive; r=O.670; DOS vs. invasive: r=O.832. 
The common genetic changes among CXl.., DOS and invasive component were gains of 
lq21.1-44 (gain of whole long arm; lq+), 7q1121 and 18q21.1 and losses of Ip36.32, 
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Ip36.2, Ip36.11, 2p2S.1, 4p16.2-14.2, Sq13.1-13.2, 7p13, 9p34.11-34.3 and 16pl1.2-q24.3. 
Invasive lesion showed amplification at 7pl1.2 (VWC2, ZPBP, IKZFl, DDC, FfNGNLl 
arriRBlO), 7p12.3 (EGFR, LANa2, VOPPl, SEPT14, ZNF713, MRPS17, GBAS, PSPH, 
CCT6A, SUMF2, PHKGl, CHCHD2) and 18q21.1 (PAS2, KA TNAL2, HDLD2, 
IERJP!). In the llilSelected Be series there was significant correlation between copy 
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Figure 5-36: Genome plot of columnar cell lesion which has been dissected from case 3 showing 
gain lq, 7q and 18q and loss of Ip, 16q and 19q 
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Figure 5-37: Genome plot of ductal carcinoma in situ which has been dissected from case 3 
showing gain/amplification 1q, 7p, 7q and 18q and loss of 1p, 16q and 17. 
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Figure 5-38: Genome plot of invasive tubular carcinoma which has been dissected from case 3 
showing gain/amplification 1q, 7p, 7q and 18q and loss of Ip, 16q and 17. 
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Table 5-5: Genetic Changes of case 3: columnar cell lesion (Ca), ductal carcinoma in situ 
(DO S) and tubular carcinoma (Tq 
r"hrom map Cytogenetic Band CCL-3 DCIS-3 TC-3 
1 1 :2697923 .. 3757389 p36.32 LOSS LOSS LOSS 
1 1:4114075 .. 5665582 p36.2 LOSS LOSS LOSS 
1 1 :25312395 .. 25779600 p36.11 LOSS LOSS LOSS 
1 1: 104025830 .. 104426934 p21.1 LOSS 
1 1: 120436410 .. 246624589 p12-q44 Gain GAIN GAIN 
2 2 : 10224532 . . 10608610 2p25.1 LOSS LOSS LOSS 
4 4:9371304 .... 23169797 p16.2-p15.2 LOSS LOSS LOSS 
5 5:69035579 . . 70388712 q 13.1-q 13 .2 LOSS LOSS LOSS 
7 7 :44083631..45018187 p13 LOSS LOSS LOSS 
7 7 :48747468 .. 50823472 p12.3-p12.2 GAIN AMP 
7 7: 54988969 .. 56402107 p11.2 GAIN AMP 
7 7:64877310 .. 65190324 q11.21 GAIN GAIN GAIN 
7 7 : 98820572 .. 102185532 q21.3-q22.1 LOSS LOSS 
8 8 :6755220 .. 8042158 p23.1 LOSS LOSS 
9 9: 136583961 .. 138069659 q34.11-q34.3 LOSS LOSS LOSS 
10 10 :46812978 . .49450532 q11.21-q11.22 LOSS 
10 10 :87865548 .. 88179055 q23.1-q23.2 LOSS 
10 10: 131479757 .. 133626641 q26.2-q26.3 LOSS LOSS 
11 11 :80636716 .. 133454282 q14.1-q25 LOSS LOSS 
16 16 :48900991..84593836 p11.2-q24.3 LOSS LOSS LOSS 
17 17: 729302663 .. 78900648 q25.1=-q25.3 LOSS LOSS LOSS 
18 18:44404930 . .44713872 q21.1 GAIN AMP AMP 
19 19:8629145 . . 9060080 p13 .2 LOSS 
19 19 : 54392659 .. 54877591 q13.41-q13.42 LOSS 
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5.4.4 Analysis of case 4 (pure tubular) 
Morphology 
TIlls is another example of pw-e tubular carcinoma in which > 90% of the tumour showed 
tubules, low mitosis and mild pleomorphism (M1, T1, and P1). There were extensive areas 
of colWlUlar cell changes with and without atypia and minimal low grade ductal carcinomas 
with cribriform and micropapillary patterns. 
Immunohistochemical profile 
The aforementioned lesions showed strong positive staining for CX18+, 0(19+, 0(8+, 
ER+, PR+, Bcl2, MUC1+ and negative expression for p53, 0(5/6, and 0(14 with no 
HER-2 over-expression. E-Cadherin immunocytochemistry staining showed strong 
membrane positive reactivity in all lesions. 
Genome profiles 
CCL without atypia and invasive carcinoma were subjected to aCGH Similar to previous 
cases, the genomic patterns (Figures 5-39 and 5-40 and Table 5-6) were of a simplex 
pattern. Pearson's correlation performed with normalized Log2 ratios revealed remarkable 
simibrity in the genomic profiles of CCL and TC (r =O.679). The common genetic changes 
were gains of 1p36.31, 1p12-42 (gain of whole long arm; 1q+), 3p21J1-p21.1, 9q33.1-34.3, 
13q34, 16p13.3-qll.2 and losses of p34.3, 4p16.2-14.2, 6pll.2, 8p23.1, 9q13.1-q12, 
15q11.1-q15.1 and 16pll1-q24.3. TC showed amplification at p12 (start at 1:120436410 
and end at 20650514. Three genes located on this locus: ADAM30, NaJa-!2 ani 
PHGDH which their gene expressions related to low grade tumours (www.oncomine.com). 
However, only PHGDH showed a significant correlation between copy number changes 
and mRNAexpression, p=o.005 (gene expression array of unselected cases). 
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Table 5-6: Genetic changes of case 4: Columnar cell lesion (Co...) and tubular carcinoma (TC) 
chrom map Cytogenetic Band CCL-4 TC-4 
1 1:2277295 .. 2485326 p36.33-p36.32 GAIN 
1 1:4114075 .. 5665582 p)6.2{AJAP1) LOSS 
1 1:5873942 .. . 6950771 p36.31 GAIN GAIN 
1 1:7038707 .. 12129387 p36.23-p36 .22 GAIN 
1 1:23800462 .. 24461606 p36.12-p36 .11 GAIN 
1 1:29549713 .. 31394713 p35 .3-p35.2 LOSS 
1 1:34515166 .. 35375482 p34.3 LOSS LOSS 
1 1:120436410 .. 24662788 p12-q42 GAIN AMP 
2 2:87128774 .. 98327997 2q11.2 LOSS 
33:46851921..53308680 p21.31-p21.1 GAIN GAIN 
33:183258533 .. 195960808 q26.33-q29 GAIN 
4 4:9371304 .... 23169797 p16.2-p15.2 LOSS LOSS 
5 5 :65203593 .. 68826309 q12.3 GAIN 
5 5:176368478 .. 180676573 q35 .2-q35 .3 GAIN 
66:57335587 ... 58075261 p11.2 LOSS LOSS 
77:44083631..45018187 p13 GAIN 
7 7 :61091237 .. 62439460 Iq1 1.1-q11.21 GAIN 
88:6755220 .. 8042158 Ip23.1 LOSS LOSS 
8 8: 143743728 .. 144743580 Iq 24.3 GAIN 
99:39131199 .. . 71033904 Ip13.1-q12 LOSS LOSS 
9 9 : 130513305 .. 138069659 Iq 33.1 -q34.3 GAIN GAIN 
11 11 :46261972 .. 48165018 Ip11,2 GAIN 
11 11 :49003873 .. 49980055 Ip11,2-q12.1 LOSS 
11 11:60817912 .. 64500237 Iq 12.2-q14.1 GAIN 
11 11:80636716 .. 133454282 Iq 14.1-q25 LOSS 
11 11: 129590768 . . 130258566 Iq24.3 GAIN 
12 12: 5972109 .. 7247166 Ip 13 .31 GAIN 
12 12: 121193338 .. 125667418 Iq24.23 -q24 .31 GAIN 
13 13: 110995727 .. 111374279 Iq34 GAIN GAIN 
14 14:50264879 .. 51754207 Iq22 . 1 GAIN 
14 14:99683934 .. 100817227 Iq32.2-q32.33 GAIN 
15 15 :20094045 .. 32954812 iq11.1-q15.1 LOSS LOSS 
16 16: 11139 .. 31764125 I p13.3-p11.2-p11. 2-q 11. 2 GAIN GAIN 
16 16 :48900991. .84593836 p11.2-q24.3 LOSS LOSS 
17 17:2256623 .. 5083694 pI3.3-pI3.2 GAIN 
17 17: 16917282 .. 18377155 pl1.2 GAIN 
17 17:729302663 .. 78900648 q25.1-q25.3 GAIN 
18 18: 14304059 .. 14984939 pl1.21 LOSS 
19 19 :960519 .. 2970392 p13.3 GAIN GAIN 
19 19 :2795315 .. 8663945 p13 .2-q12 GAIN 
19 19 :45182685 .. 51060676 q13 .31 -q13.42 GAIN 
20 20: 29421720 . . 29996640 Iq1 1,21 LOSS 
21 21 : 10907345 .. 15399525 Ip11.2-q11.2 LOSS 
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Figure 5-39: Genome plot of coluITUlar cell lesion which has been dissected from case 4 showing 
gain lq and loss of Ip, and 16q . 
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Figure 5-40: Genome plot of invasive tubular carcinoma which has been dissected from case 4 
showing gain/amplification lq, 16p, and 19p loss of Ip, and 16q. 
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5.4.5 Analysis of case 5 (pure tubular carcinoma associated 
with lobular neoplasia) 
Morphology 
TIlls is an example of pure tubular carcinoma (MI, Tt, and P2) which showed extensive 
areas of lobular neoplasia and low/intennediate grade DOS with cribrifonn, 
micropapillazy, and solid patterns. 
Immunohistochemical profile 
The aforementioned lesions showed strong positive staining for 0(18+,0(19+,0(8+, 
ER+, PR+, Bc12, MUCI+ and negative expression for p53, 0(5/6, and 0(14 with no 
HER-2 over-expression. E-Dclherin immtmocytochemistry staining showed strong 
membrane positive reactivity in TC and all patterns of DOS. Lobular neoplasia was 
negative for E-Cadherin. 
Genome profiles 
TC LN and DOS were laser microdissected and subjected to aCGH The genomic 
patterns (Figures 5-41, 5-42 and 5-43 and Table 5-7) of these lesions were of 
"sawtooth", characterized by many narrow segments of gains and losses, often alternating, 
more or less affecting all the chromosomes without copy number amplification. Pearson's 
correlation revealed remarkable similarity in the genomic profiles of TC vs. DOS (r 
=0.820), TC vs. LN (r=O.714) and DOS vs. LN (r=802). The common genetic changes 
were involving most of the chromosomes. LN showed amplification at 8p21.3-21.2. Both 
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Figure 5-41: Genome plot of ductal carcinoma in situ which has been dissected from case 5 
showing genetic changes of most of the chromosomes 
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Figure 5-42: Genome plot of tubular carcinoma which has been dissected from case 5 showing 
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Figure 5·43: Genome plot of lobular neoplasia which has been dissected from case 5 showing 
genetic changes of most of the chromosomes 
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Table 5-7: Genetic changes of case 5: ductal carcinoma in situ ( ~ O S ) , , lobular neoplasia (LN) and 
tubular carcinoma (TO 
chromosom e Ma p Cytoge netic Ba nd DCIS-S TC-S LN-S 
1 1 : 2277295 .. 24461606 36.33-p36.32 GAIN GAIN GAIN 
1 1:25312395 . . 25779600 36.11 GAIN 
1 1 : 29549713 . . 31394713 35.3-p35 .2 ~ ~
1 1 : 34515166 .. 35375482 IP34.3 L ~ ~ L O S ~ ~ LO"" 
1 1 : 150269698 . . 156948996 la21.3- 22-a23 .1 GAIN GAIN uAIN 
1 1 : 159793016 .. 182853014 23.3- 25-Q31.3 GAIN 
1 1: 206559883 . . 225499515 la32 .1-a32. 2- 41 GAIN 
1 1 : 225593333 . . . 236748304 [q42 GAIN GAIN GAIN 
1 1 : 236749347 .. 246624589 43- 44 GAIN 
2 2 : 10092490 .. 10608610 2p25.1 GAIN 
2 2 :79440056 .. 80833098 2 12 LOSS LOSS 
2 2:87128774 . . 98327997 ~ 1 1 . 2 2 LOSS 
22: 132279581 .. 132994118 2 2 1.1- 21.2 LOSS LOSS LOSS 
33:9467084.10540466 25.3 GAIN GAIN AIN 
3 3: 46851921..53308680 21.31- 21.1 GAIN GAIN GAIN 
33:56708117 . . 58368941 14.3-QI4.2 GAIN 
3 3: 125828183 . . 129284640 21.31- 21.1 GAIN 
33 : 183258533 .. 195960808 26.33- 29 GAIN GAIN GAIN 
4 4 :38594738 .. 41243420 14:Q13 GAIN GAIN GAIN 
5 5 :34060230 .. 34334851 13.3 LOSS LOSS LOSS 
5 5:43351415 . .43702315 ~ 1 2 2 GAIN GAIN 
5 5 :65203593 .. 68826309 12.3 GAIN GAIN 
5 5 :69035579 . . 70388712 la13 .1-aI3 .2 LOSS LOSS LOSS 
5 5 : 176368478 .. 180676573 [q35 .2-g35.3 GAIN GAIN ~ A I N N
66: 17526937 . . 18404236 23- 22.3 GAIN [GAIN GAIN 
6 : 42373615 .. 44434337 ~ 2 1 . 1 1 GAIN GAIN 
6 6 : 57335587 ... 58075261 11 .2 LOSS LOSS LOSS 
66:61959143 .. 62918629 12 LOSS LOSS 
6 6 : 160773903 . . 161249786 25.3-Q26 LOSS LOSS 
77 : 5155898 . . . 6721092 7p22.1 GAIN GAIN 
7 7 :44083631..45018187 13 GAIN GAIN ~ A I N N
7 7 :72815547 . . 751932 90 11.22- 11.23 GAIN GAIN 
7 7 :98820572 . . 102185532 21.3,q22 .1 GAIN GAIN 
8 8 :6755 2 20 . . 8042158 23 .1 LOSS 
88: 21864085 .. 23175482 21.3-p21.2 <.iAIN AIN AMP 
B 8 : 143743728 .. 144743580 24 .3 GAIN GAIN GAIN 
99 :3913 1199 . .. 71033 904 13.1 -QI2 LOSS LOSS L(lliS 
9 9:91735900 .. 92 122 168 la21.33-a22.32 GAIN 
9 9 : 130513305 .. 138069659 [q33 .1 -q34 .3 GAIN GAIN GAIN 
1 0 10: 38598310 .. .430153 52 11.21 -a11. 2 1 L O S ~ ~ LQ?S LOSS 
10 10 : 43498972 .. 440 19673 11.21 GAIN GAIN GAIN 
10 10 : 4681 2 978 .. 49450532 11.21-ql1.22 LOSS L SS L SS 
11 11 :4551894 . . . 8684969 15.5 - pI5.4 LOSS 
11 11 :462 61972 .. 48165018 ~ 1 1 . 2 2 GAIN 
11 11 :49003873 . . 49980055 11.2- 12 . 1 LOSS LOSS LOSS 
11 11 : 60817912 .. 64500237 12.2:g14 . 1 GAIN GAIN 
11 11 :80636716 . . 133454282 14.1- 25 LOSS 
1 1 11 : 129590768 .. 130258566 24.3 GAIN GAIN 
1 2 12: 5972109 . . 7247166 13.31 GAIN GAIN 
1 2 12 : 48027380 .. 55251462 13.11 - 13 .2 GAIN 
1 2 12 : 12 1193338 .. 125667418 Iq24.23 - 24.31 uAIN GAIN GAIN 
14 14 : :.0264879 .. 51754207 22 .1 GAIN 
14 14 : 63767854 .. 782874:.0 23 .2 - 24.1 AIN GAIN 
14 14:99683934 .. 100817227 [ g ? ? . 2 ~ 3 3 . 3 3 3 GAIN GAIN 
1 5 15: 20094045 .. 32954812 [gJ1 .1,q15.1 LOSS LOSS 
11> 16 : 11139 . . 31764125 13.3-pl1.2- 1 1 . 2 ~ 1 1 . 2 2 AIN ~ A I N N GAIN 
16 16 : 48900991..84593836 !pl1.2-q24.3 LOSS LOSS LOSS 
17 17 : 2256623 .. 5083694 13.3 - pI3 .2 GAIN ~ A I N N
17 17: 6879623 .. 8614953 13.2- p13.1 GAIN GAIN 
17 17 :9455707 .15687248 P12 LOSS 
17 17 : 16917282 .. 18377155 11 .2 GAIN GAIN 
17 17 : 18276146 .. 18755715 11.0! LOSS 
17 17: 36690553 . .49204340 12- 21.33 GAIN GAIN 
17 17 : 729302663 . . 78900648 25.1 -q25.3 GAIN AIN 
18 18 : 14304059 .. 14984939 11.21 lOSS 
18 18 : 44404930 .. 44713872 21.1 GAIN 
18 18 : 74032492 .. 74812028 23 ~ A I N N ~ A I N N
19 19 :960519 . . 2970392 13.3 AMP ~ A I N N AMP 
19 19 : 2795315 .. 806394 13.2 -qI2 GAIN GAIN ~ A A N 
19 19 :43266180 .. 43833261 13.13- 13 .2 LOSS LOSS LOSS 
1 9 19: 45182685 .. 51060676 [ g 1 1 . 3 1 ~ 1 3 . 4 2 2 GAIN GAIN GAIN 
19 19 : 54392659 . . 54877591 13.41- 13.42 GAIN GAIN AIN 
19 19 : 8629145 . . 9060080 lPJ3.2 LOSS LOSS 
20 0 : 29421720 .. 29990040 11 .21 LOSS LOSS LOSS 
21 2 1: 10907345 .. 15399525 IPl1.2-al1.2 LOSS LOSS LOSS 
2 1 21 :43466719 ... 45929047 [q22 .3 GAIN GAIN GAIN 
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5.4.6 Analysis of case 6 and 7 (classic ILC and LN) 
Theses two cases showed classic invasive lobular carcinoma (Ml, P2, and T3) with 
extensive areas of lobular neoplasia. Both ILC and LN components were laser 
microdissected and subjected to aCGH (Figures 5-44,5-45,5-46 and 5-47 and Tables 5-
8 and 5-9). 
There was marked similarity of the genomic profiles, of ILO of case 6 and (r=O.850) which 
is higher than that recorded for ILC and LN from the same patients (r=O.627). Both 
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Figure 5-44: Genome plot of lobular neoplasia which has been dissected from case 6 showing 
genetic changes of most of the chromosomes including gain of 1q, l1p, 16p, and 19p and loss of 
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Figure 5-45: Genome plot of lobular carcinoma which has been dissected from case 6 showing 
genetic changes of most of the chromosomes including gain of lq, IIp, 16p, and 19p and loss of 
8p, 9p, lOp, llq, 16q, and 17q 
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Table 5-8: Genetic changes of case 6; lobular neoplasia and invasive lobular carcinoma (ILq 
ch rom m a p Cytogenetic Band LN - 6 ILC- 6 
1 1 : 2277295 . . 3757389 p 36 .33- p 36.32 GAIN G AIN 
1 1:5873942 .. 1212938 7 p 36.3 1 G AIN GAIN 
1 1 : 23800462 .. 25779600 p36.12- p 36 . 1 1 G AIN G AIN 
1 1 : 34515166 .. 35375482 p34 . 3 LOSS 
1 1 : 145190320 .. 246624589 21. 1 - q4 4 G A I N G AI N 
2 2 : 10092490 .. 10608610 2p25 . 1 G A IN G AI N 
2 2 : 79440056 . . 80833098 2p 1 2 LOSS LOSS 
2 2 : 87128774 . . 9832 7 997 2Q l 1.2 LOSS 
2 2 : 132279581 .. 132994 11 8 2 Q2 1.1 - Q2 1. 2 LOSS 
3 3 : 9467084 . 10540466 Ip 2 5 . 3 GAIN GAIN 
3 3 : 46851921 .. 53308680 Ip 21.3 1 - p 2 1.1 GAIN G AIN 
3 3 : 56708117 .. 58368941 Ip 1 4 . 3- p 1 4 .2 G AI N 
3 3 : 125828183 .. 129284640 .p21.3 1 - p2 1. 1 G AIN GAIN 
3 3 : 183258533 .. 195960808 q26.33- q 29 GAIN G AIN 
4 4 : 9371304 . . . . 23169797 P I 6.2 - pI5 . 2 I ~ O S S S
4 4:38594738 .. 41243420 p14- Q13 GAIN 
5 5: 34060230 ... 3433485 1 p 1 3.3 LOSS LOSS 
5 5 : 43351415 .. 437023 1 5 5p12 G AIN G AIN 
51 5 : 65203593 .. 68826309 q 12.3 G AIN 
5 5 : 69035579 .. 70388712 QI3 . 1-QI3.2 LOSS LOSS 
5 5 : 1763 6 8478 .. 180676573 q35 . 2- q 35.3 GAIN GAIN 
6 6 : 17526937 .. 18404236 p23 - p 22 .3 GAIN G AI N 
6 6 : 4 2 37 3 615 .. 44434337 p 21. 1 GAIN GA I N 
6 6 : 57335587 . . . 5807526 1 p 11 .2 LOSS LOSS 
6 6 : 160773903 . . 161249786 25 .3 - q 26 LOSS LOSS 
7 7 : 5155898 ... 6721092 7 22. 1 GAIN GAIN 
7 7 : 44083631 .. 45018187 Ip13 GAIN GAIN 
7 7:72815547 .. 75193290 Iqll . 22-ql l . 23 GAIN GAIN 
7 7 : 98820572 .. 102185532 IQ21.3-Q22. 1 GAIN GAIN 
8 8 : 6755220 .. 8042158 Ip 2 3.1 LOSS LOSS 
8 8 : 21864085 . . 23175482 10 21.3- 2 1 .2 G AIN 
8 8 : 399 3 7888 .. 58230 03 7 IPI2- Ql 1. 2 1 AMP 
8 8 : 143743728 .. 14474358 0 IQ 24 . 3 GAIN GAIN 
9 9:39131199 ... 71033904 IpI3.1-qI2 LOSS LOSS 
9 9 : 91735900 .. 92122168 Q21 . 33-Q22 .32 G A I N GAIN 
9 9 : 13051 3 305 .. 138069659 q33.1-q34 . 3 GA I N GAIN 
10 10 : 38598310 .. . 430 15352 p l1.2 1 -Ql 1. 21 LOSS LOSS 
10 10 : 43498972 .. 440 19673 q l1.21 GAIN G AIN 
10 10 : 46812978 .. 49450532 Ql 1.2 1 - Ql1. 22 LOSS LOSS 
11 11 : 4!>!> It!94 ... 8684969 15 . 5- pI 5.4 LOSS LOSS 
11 11 : 46261972 .. 48165018 p i!. 2 GA I N 
11 11 : 49003873 .. 49980055 1 1. 2- q I 2 . 1 LOSS LOSS 
11 11 : 60817912 . . 64500237 qI 2.2 - q14 . 1 GAIN GAIN 
11 11 : 80636716 .. 133454282 14 . 1- 25 LOSS LOSS 
12 12 : 48027380 .. 55251462 191 3 . 11 - QI3.2 GAIN GAIN 
1 2 12 : 121193338 .. 125667418 IQ24.23-q24.31 GAIN GAIN 
14 14 : 50264879 .. 51754207 IQ 22 . 1 GAIN GAIN 
14 14 : 63 67t!54 .. 78287450 IQ23 . 2-Q2 4 . 1 GAIN GA I N 
14 14 : 99683934 .. 100817227 IQ32.2-Q32 . 33 GAIN GAIN 
15 15 : 20094045 .. 32954812 Iq 11 . I -g 15 . 1 LOSS LOSS 
16 16 : 111 3 9 .. 31764125 10 1 3 . 3 - P 11 . 2 - 0 1 1 . 2 - q 11 . 2 GAIN GAIN 
16 16 : 48900991 .. 84593836 'p l 1.2 - Q24 .3 LOSS LOSS 
17 17 : 6879623 .. 8614953 pI 3.2 - pI 3. 1 GAIN GAIN 
17 17 : 9455707.15687248 P 1 2 LOSS LOSS 
17 17 : 18276 146 .. 1 87557 1 5 011. 2 LOSS LOSS 
18 18 : 14304059 .. 14984939 pl1.2 1 LOSS LOSS 
18 18 : 74032492 .. 74812028 q23 GAIN 
19 19 : 960519 .. 2970392 P 13 . 3 GAIN AMP 
19 19 : 2795315 .. 8663945 Q Q 3 . 2 2 g g 2 2 GAIN GAIN 
19 19 : 8629145 . . 9060080 P 13.2 LOSS LOSS 
19 19 : 43266180 .. 4383326 1 q I3 . 13- qI 3.2 LOSS 
19 19 :45182685 .. 5 1 060676 QI 3.3 1 - 13.4 2 GAIN GAIN 
20 20 : 29421720 .. 29996640 Ql1. 2 1 LOSS LOSS 
2 1 21 : 10907345 .. 15399525 0 11.2-Ql1. 2 LOSS LOSS 




" + - ~ - - - + - - - - r - - - r - ~ - - - + - - ~ ~ - - ~ - + - - + - - r ~ - - + - + - 4 - 4 - + - + 4 ~ + + - - 4 + ~ ~
10 11 12 13 1. 15 , . 17 , . , . 20 21 X Y 
Figure 5·46: Genome plot of lobular neoplasia which has been dissected from case 7 showing 
genetic changes of most of the chromosomes including gain of lq and loss of 16q 
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Figure 5·47: Genome plot of invasive lobular carcinoma which has been dissected from case 7 
showing genetic changes of most of the chromosomes including gain of lq and loss of 16q. 
184 
Oxtpter 5 
Table 5-9: Genetic changes of case 7: invasive lobular (ILC) lobular neoplasia (LN) 
chrom map Cytogenetic Band LN-7 ILC-7 
1 1 : 2277295 .. 3757389 ~ 3 3 . 3 3 - p 3 3 . 3 2 2 GAIN GAIN 
1 1 :58739 4 2 . . . 69 5 0 7 7 1 IP3 6 .3 1 GAIN GAIN 
1 1 : 7038707 .. 12129387 Ip36 .2 3 - p 3 6 .22 GAIN GAIN 
1 1 : 23800462 .. 25779600 10 36. 1 2 - p 36 . 11 GAIN GAIN 
1 1 : 34515 166 .. 35375482 34 .3 lOSS lOSS 
1 1: 145190320 .. 148644689 q21 . 1 -q2 1 . 2 GAIN 
1 1 : 150269698 .. 246624:>89 21 . 3 - 044 GAIN GAIN 
2 2 : 10092490 . . 106 08 6 1 0 2p2 5 . 1 GAIN GAIN 
2 2 : 79440056 .. 8 08 3 3 0 98 2p12 lu!)!) l I!)!) 
2 2 : 871 28774 .. 98327997 201 1.2 lOSS 
2 2: 132279581..132994 11 8 2q21 . 1 - q21.2 lOSS lOSS 
3 3 : 9467084 . 10540 4 66 102 5 . 3 GAIN GAIN 
3 3 : 4685192 1 .. 53308680 Ip21.31 - p21. 1 GAIN GAIN 
3 3 : 56708117 .. 5836894 1 Ip 14 .3 -p 14 . 2 GAIN 
3 3 : 12:>828183 .. 129284640 Ip 2 1 .3 1 - p 2 1.1 GAIN GAIN 
3 3 : 18 3 258533 .. 195960808 102 6 . 33- 0 2 9 GAIN GAIN 
4 4 : 9371304 ... . 2JlbY7Y7 IpI 6 . 2 - pI5 .2 lOSS 
4 4:38594738 .. 4 1 243420 Ip14 - p1 3 GAIN GAIN 
5 5 : 34060230 ... 3433 4 851 Ip 13 .3 lOSS lOSS 
5 5 : 433 5 1415 .. 43702315 5p1 2 GAIN GAIN 
5 5 : 65 2 0 3 593 . . 688 26309 0 12 .3 GAIN 
5 5 : 69035 579 .. 70388112 qI3 . 1 - q I3. 2 lOSS lOSS 
5 5 : 1 76368478 .. 180676573 '135 . 2- 0 35 .3 GAIN GAIN 
6 6 : 17526937 .. 18404236 2 3 - p 2 2. 3 GAIN GAIN 
6 6 : 4 23 7 3615 .. 4443433 7 p 21.1 GAIN GAIN 
6 6 : 57335587 . . . 58075261 pll . 2 lOSS lOSS 
6 6 : 160773903 .. 161249786 25.3 - q 26 lOSS 
7 7 : 51 5 5898 . .. 672 1 092 P 2 2 . 1 GAIN GAIN 
7 7 : 44083631 . . 450 18 187 013 GAIN GAIN 
7 7 : 728 1 5547 .. 75193290 11 . 22- q 1 1 .23 GAIN GAIN 
7 7 : 9882057 2 . . 102 185532 102 1.3-q 22 . 1 GAIN GAIN 
B 8 : 6755 2 20 .. 8042158 Ip 23 . 1 lOSS lOSS 
8 8 :2 18 6 4085 .. 23175482 Ip 2 1 .3 -Jl.2 1 .2 AMP GAIN 
8 8 : 14 3 743728 .. 144743580 1024. 3 GAIN GAIN 
9 9 : 3913 1 199 ... 7 1033Y 4 IpI 3 . 1 - qI 2 lOSS LuS!) 
9 9 : 13 0 5 13305 .. 138069659 103 3 . 1 - 0 34 .3 GAIN GAIN 
10 10 : 38 5 9831 0 ... 43 0 1!> 3 !>2 'pl1.21 - ql 1. 2 1 lOSS lOSS 
10 10 : 4 3 498972 . . 44019673 11. 2 1 GAIN IGAIN 
10 10 : 4 6 812978 . . 4945 0 532 11.21 - 0 11. 22 lOSS lOSS 
11 1 1 : 4 ~ 1 8 8 4 4 ... 8684969 p I 5 . 5- pI5 .4 LOSS lOSS 
11 11 :40l019 I l .. 48165 18 011 . 2 GAIN GAIN 
11 11 :49003873 .. 499 800 55 pl1. 2 - qI 2 . 1 LOSS lOSS 
11 11 : 0081791l .. 645002J7 1 2 . 2- 14 . 1 GAIN llAIN 
11 11 :80636716 .. 13345 4 2 8 2 014 . 1- 0 2 5 lOSS lOSS 
12 1 2 :5 972109 .. 7247 1 66 013 .3 1 GAIN llAIN 
12 1 2 :480 llJllO . . S ~ 2 2 5 140 2 1 3 . 1 1 - 1 3.2 GArN GAIN 
12 12 : 12 1 193338 .. 1 2566 7 4 18 q24 . 23 - q24 .3 1 GAIN GAIN 
14 14 :5 0264879 .. 51754207 102 2 . 1 GAIN 
14 1 4 : 6 3 76 7854 .. 7828 7 450 Iq 23 . 2 - q 24. 1 GAIN GAIN 
14 1 4 : 99t>S3934 .. 1008 1 722 7 Iq 32 . 2 - q 32 .33 GAIN GAIN 
15 15 : 20094045 . . 32954 81 2 Iql 1. 1- qI5 . 1 LOSS LOSS 
16 1 6 : 1 1139 .. 31764 1 25 IPI 3 . 3 - 011 . 2 - 0 11 . 2 - q l 1.2 GAIN GAIN 
16 16:48900991 .. 84 593 8 36 Ip 11. 2 - 024 .3 lOSS lOSS 
17 17 : 087YbL3 .. 86 1 49!l3 l.L l - pl J . l GAIN AIN 
17 17 : 16Y 17282 . . 18377 1 55 P 11. 2 GAIN GAIN 
17 17 : 18276 146 .. 18 7 55 71 5 P 1 1. 2 lOSS lOSS 
17 17: 36690%3 .. 492 04 3 40 '012 -021 .3 3 GAIN GAIN 
18 18 : 14304059 .. 1498 4 939 pl1. 2 1 lOSS 
18 IJl.: 4440493U . . 447 1 38 7 2 21. 1 GAIN GAIN 
19 19 :9605 1 9 .. 297039 2 P 13. 3 AMP GAIN 
19 19 :2 7953 1 5 .. 80639 4 5 0 1 3 . 2 - 012 GAIN GAIN 
19 19 :8629 1 4!> .. Y06 00 S 0 P 13 . 2 LOSS lOSS 
19 19 : 43266 180 .. 438 3 3 2 6 1 qI3.1 3 - qI3 .2 lOSS LO!)S 
19 19 : 4 5182685 .. :> 1 0606 76 q13 . 3 1 - qI 3 .42 GAIN GAIN 
19 19 : 5439 26:>9 .. 54877 591 013 .4 1 - 13 .4 2 GAIN GAIN 
20 20 : 2 9421720 .. 299966 4 0 ql1. 2 1 lOSS lOSS 
21 2 1 : 1 090734!l .. 15399525 p l 1. 2- ql1.2 LOSS LOSS 
21 2 1 :43466719 .. . 4 5929 047 22 .3 GAIN GAIN 
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5.4.7 Analysis of case 8 and 9 (Classic ILC and tubular 
carcinoma) 
Theses two cases showed classic invasive lobular carcinoma (case 8) and pure tubular 
carcinoma (case 9). The genetic changes and genome plots (Figures 5-48 and 5-49 and 
Table 5-10) were summarized in table (4-10) and figure (4-13). ILC showed amplification 
at lq3l.1, lq32.2, 1q41, 8p12-11.21 and 13q11.34. 
- 0 
·1 +-+--+--f---+-+--+----1r-+--+--+-+----1'--f--t---1f--f-+-t-t++t+---+t--i 
I 10 11 12 Il 14 15 II t7 la II 20 2t X Y 
-
Figure 5·48: Genome plot of invasive lobular carcinoma which has been dissected from case 8 
showing gain/amplification of lq, 8p and 13q and loss of 15p, 16q, 17p 19q and 20q 
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Figure 5-49: Genome plot of invasive tubular carcinoma which has been dissected from case 8 
showing genetic changes of most of the chromosomes including gain of lq and 16p and loss of 
16q 
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Table 5-10: Genetic changes of case 8 ~ L q q and 9 erq 
ch rom map Cytogenetic Band ILC-S TC-9 
1 1 : 2277295 .. 3757389 p36 . 33 - ~ 3 6 . 3 3 2 GAIN GAIN 
1 1 : 7038707 .. 12129387 p36.23-p36.22 GA IN 
1 1 : 23800462 .. 24461606 p36.12-p36.11 GAIN GAIN 
1 1 : 25312395 .. 25779600 p36.11 GAIN 
1 1 : 34515166 .. 35375482 p 34.3 LOSS LOSS 
1 1:150269698 . . 246624589 q21.3-q44 AMP GAIN 
2 2 : 87128774 .. 98327997 2ql1.2 LOSS 
2 2 : 132279581 .. 132994 1 18 2Q21.1-Q21.2 LOSS 
3 3 : 9467084.10540466 Ip 2 5.3 GAIN 
J 3 : 46851921 .. 53308680 Ip 21.31-p21.1 GAIN 
3 3 : 183258533 .. 195960808 q26.33 - q29 GAIN GAIN 
4 4 : 9371304 .... 23169797 pI6 . 2-p I5 . 2 LOSS 
4 4 : 38594738 .. 41243420 p14-p13 GAIN 
5 5 : 43351415 .. 43702315 5p12 GAIN 
5 5 : 65203593 .. 68826309 q 12 . 3 GAIN 
5 5 : 176368478 .. 180676573 q35. 2- q35 .3 GAIN 
6 6 : 42373615 .. 44434337 p 21.1 GAIN 
6 6 : 57335587 ... 58075261 p 11.2 LOSS LOSS 
6 6 : 61959143 .. 62918629 Iq 12 LOSS 
6 6 : 160773903 . . 161249786 Iq 25.3-Q26 LOSS 
7 7 : 44083631 .. 45018187 Ip 13 GAIN 
8 8 : 21864085 .. 23175482 ip 21 .3 - p 2 1 .2 GAIN 
8 8:39937888 .. 58230037 Ip I2-Qll.21 AMP 
8 8 : 143743728 .. 144 743580 IQ 24.3 GAIN GAIN 
9 9 : 39131199 ... 71033904 IpI 3.1- qI 2 LOSS 
9 9 : 130513305 .. 138069659 Q33 . 1-q34.3 GAIN GAIN 
10 10 : 38598310 ... 43015 3 52 pl1 .2 1-g11.21 LOSS LOSS 
10 10 : 43498972 .. 44019673 ql1.21 GAIN 
11 11 : 46261972 .. 48165018 pI!. 2 GAIN 
11 11 : 4900387 3 .. 49980055 pl1.2 - qI2.1 LOSS 
11 11 : 6081791 2 .. 64500237 QI2 .2- qI4 . 1 GAIN 
11 11 : 80636716 .. 133454282 IQI 4.1-Q25 LOSS 
12 12 : 5972109 .. 7 2 47166 Ip 13.31 GAIN 
12 1 2 : 480 2 7380 .. 5 5251462 IqI 3.11-qI3.2 GAIN 
12 12 : 121193338 .. 125667418 Iq 24.23-q24.31 GAIN 
13 13 : 20904235 . . 113346314 Iql1-q34 AMP 
13 13 : 110995727 .. 111374279 Iq 34 GAIN 
14 14:99683934 . . 100817227 Iq 32.2-q32.33 GA IN 
15 15 : 20094045 . . 32954812 'Q l1.1-QI5.1 LOSS 
16 16 : 11139 .. 31764125 pI3.3 - pl1.2 - pll .2- Ql GAIN GAIN 
16 16 : 48900991 .. 84593836 p11.2 - q24 . 3 LOSS LOSS 
17 17 : 2256623 . . 5083694 pI3.3-pI3 .2 GAIN 
17 17 : 6879623 .. 8614953 013.2 - 013 .1 GAIN 
17 17 : 9455707 . 15687248 P12 LOSS 
17 17 : 16917282 .. 18377155 Ip 11. 2 GAIN 
17 17 : 36690553 .. 49204340 IqI 2- q21.33 GAIN 
17 17 : 729302663 . . 78900648 Iq 25.1-q25.3 GAIN 
18 18 : 14304059 .. 14984939 Ipl 1.21 LOSS 
18 18 : 44404930 . . 44713872 Iq 2 1.1 GAIN 
18 18 : 74032492 .. 74812028 Iq 2 3 GAIN 
19 19 : 960519 .. 2970392 p13.3 GAIN GAIN 
19 19 : 2795315 .. 8663945 p13 .2- q12 GAIN 
19 19 : 8629145 .. 9060080 p 13 . 2 LOSS 
19 19 : 43266180 .. 43833261 QI3 .13- qI3.2 LOSS LOSS 
19 19 : 45182685 .. 51060676 013.31 -013.42 GAIN 
19 19 : 54392659 .. 54877591 QI3.41-qI3 . 42 GAIN 
20 20: 2 94217 2 0 .. 29996640 ql1.21 LOSS LOSS 
21 21 : 10907345 .. 15399525 Ip 11.2- ql1.2 LOSS 
21 21 : 43466719 . . . 45929047 Iq 22.3 GAIN 
188 
5.4.8 Chromosomal regions frequently affected in LNGBN 
family 
LNGBN family showed recurrent gains at 1p12-q44 (100%), 16p13J-11.2, 1p36.21-35J, 
13ql1-34, 20q13-33 (::::60%) and losses at 16qll.2-24.3 (100%), 1p35.1-34.3, 4q13-22.3 and 
9p13.l-q12 (>80%), (Figures 5-50, 5-51 and 5-52) . 





'-- 1\ I I ~ ~ 11'1111 ,I, I I ~ ~ nJ [I . II ~ i i I II , Irl Ir 
~ ~ 01 
c: 






I I I 
-0.8 
3 5 6 7 8 9 10 11 12 13 14 15 17 19 21 X Y 
Figure 5-50: The proportion of low nuclear grade neoplastic lesions in which each clone is gained 
(green bars) or lost (red bars) is ploned (Yaxis) for each BAC clone according to genomic location 
X axis . 
189 
~ ~______ ~ O ~ ~ . 1 q a a p s s
L o w ~ , . b r e a I t t I . r--U-nseIedId---breast--cal-I'a'I-·.-.. ---1 
~ ~ ;0. ... . 
senes 


















ChrolDOSOme 16 changes 
r------------------------, 
Low 1IICH!Jade breast 




COIIHIticII will IIIIIA 


















Figure 5-52: Common genetic changes on chromosome 16 in both low nuclear grade and 
unselected breast cancer series . 
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5.4.9 Common genetic changes of columnar cell les ions 
All columnar cell lesions showed simplex pattern genome plot including gain of lq whole 
ann and loss of 16q whole ann. None of co... showed amplification. Common genetic 
changes of columnar cell les ions were summarized in (Table 5-11). 
Table 5-11: Common genetic changes of columnar cell lesions 
chromosome map Cytogenetic Band Genebc changes % 
1 1:2697923 . .3757389 p36.32 LOSS 100 
1 1:4114075 .. 5665582 p36.2 LOSS 100 
1 1:5873942 ... 6950771 p36.31 GAIN 50 
1 1:34515166 .. 35375482 p34.3 LOSS 50 
1 I: 120436410 .. 246624589 pl2 GAIN 100 
1 1:236749347 .. q43·q44 GAIN 100 
3 3:46851921..53308680 p21.31-p21.l GAIN 75 
4 4:9371304 ... .23169797 pI6.2-pI5.2 LOSS 100 
5 5: 176368478 .. 180676573 q35.2-q35.3 GAIN 75 
6 6:57335587 .. .58075261 pll.2 LOSS 75 
7 7:61091237 .. 62439460 qll.1-qll.21 GAIN 75 
8 8:6755220 .. 8042158 p23.1 LOSS 75 
9 9: 130513305 .. 138069659 q33.1-q34.3 GAIN 75 
16 16:48900991..84593836 p 11.2-q24.3 LOSS 100 
18 18:44404930 .. 44713872 q21.l GAIN 50 
19 19:28680998 . .32819 119 pI2-q l3. 1l LOSS 75 
19 19:8629145 .. 9060080 p13.2 LOSS 75 
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5.4.10 Frequently amplified regions in LGBN family 
The most conunon amplified regions in LGBN family were 1q42.13 (4 cases out of 9), 
19p13.3 (3 cases out of 9), 1p12, lq32.1, and 1q21.1 (2 cases out of 9). None of the 
columnar cell lesions showed recurrent amplification. Conunon amplified genes are listed 
in (Tables 5- U, 5-13, 5-14, 5-15, 5-16, 5-17 and 5-18). 
Table 5-12: list of genes that were relevant to low grade breast cancer 
Gene Location Function <.M:rexpression References 
and breast cancer 
ARFI lq42-13 Involved in protein trafficking and signal transduction. ER+ breast cancer 184,185 
OBSCN lq42-13 Involved in m}UfibriIlogenesis. Low grade/ER+ 176, 186, 
breast cancer. 187 
Overexpression was 
associated with low 
risk of 5 ~ m m distant 
metastases 
PNPEP Iq32.1 Involved in intracellular transpon. ER+ 176, 186-
191 
PPPIRUB Iq32.1 It regulates m}USin phosphatase activity and augments Low grade 176, 186-
Calcium sensitivity of the contractile apparatus. 191 
CYB5RI Iq32.1 Involved in desaturation and elongation of fatty acids, ER+ 176, 186, 
cholesterol biosynthesis, drug metabolism, and, in 191 
el)throcyte, methemoglobin reduction. 
BTG2 lq32.1 It is p53 inducible antiproIUerative gene that modul.u:es ER+/low grade, wild 176, 186-
transcription regulation modulated by ESRI. type p53 and good 194 
prognosis 
FMOD Iq32.1 It may panicipate in the assembly of the extracellular ER+/low grade, wild 176, 186-
matrix as it interactS with type I and type II coll1gen type p5? and good 195 
fibrils and inhibits fibrillogenesis in vitro. It may also prognosIS 
regulate TGF-beta activities by sequestering TGF-beta 
into the extrace llular matrix 
MDM4 Iq32.1 Inhibits p53- and p73-mediated cell C}de arrest and ER+ and amplified 176-183, 
apoptosis and inhibits degradation of MDM2. MDM4 in 5% of breast 186-191 
can reverse MDM2-targeted degradation of p53 while cancers 
maintaining suppression of 
p53 transactivation and apoptotic functions 
MUCI Iq22 Its protein selVes a protective function by binding to ER+ and marker of 196-198 
pathogens and also functions in a cell signaling luminal restrictive 
capacity. Overexpression, aberrant intracellular progenitor ce Us 
localization. and changes in gl}\:osylation of this 
protein have been associated with can:momas. 
Multiple alternatively spliced trarlSCript variants that 
encode different isoforms of this gene have been 
reponed. 
MAPKAPKl lq32.1 In conjunction with p38 MAP kinase, this kinase is ER+ 176. 186-
known to be involved in many cellular processes 191, 199-
including stress and inf1ammatol)' responses, nuclear 201 
expon, gene expression regulation and cell 
proIUeration. Heat shock protein HiP27 was shown to 
be one of the substrates of this kinase in vivo. T \\Q 
transcript variants encoding two different isoforms 
have been found for this gene 
NOTD-U Ip12 It functions as a receptor for membrane-bound ligands Overexpressed in Be 176, 186-
Jagged 1, Jagged2 and Deltal to regulate cell-fate 191, 202-
detennination. Upon ligand activation through the 205 
released notch intracellulardomain(NICDl it forms a 
193 
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transcriptional activator complex with RBP-J kappa 
and activates genes of the enhancer of split locus. It 
affects the implementation of differentiation, 
proliferation and apoptotic programs 
TRAF3IP3 lq32.2 The gene encodes a protein that mediates cell gro\\1h ER +/low grade, wild 176, 186-
by modulating the c-Jun N-terrninal kinase signal type p53 and good 191,206 
transduction pathway. The encoded protein may also prognosis 
interact with a large muhiprotein assembly containing 
the phosphatase 2A c a t a l ~ i c c subunit 
IRF2BP2 lq42.3 This gene encodes an interferon regulatory factor-2 ER +7fow grade 176, 186-
~ R F 2 ) ) binding protein that interacts with the C 191,207 
terminal transcriptional repression domain of IRF2. 
Alternative splicing results in 
variants encoding distinct isoforrns 
multiple transcript 
CCNDI llq13.3 It is essential for the control of the cell C)de at the ILC, ER+ and low 100 
G 115 (start) transition grade 
FADD llq13.3 It is an apoptotic adaptor molecule that recruits Ductal carcinoma 202, 208, 
caspase-8 or caspase-l0 to the activated Fas (CD95) or 209 
lNFR-l receptors. The resuhing aggregate called the 
death-inducing signaling complex (DISq performs 
caspase-8 proteol}tic activation. 
MKNK2 19q13.3 MAP kinase- interacting kinase-2 (Mnk2) is one of the ER +/low grade, wild 176, 186-
downstream kinases activated by MAP kinases. It type p53 and good 191, 202, 
phosphory\ates the eukai)otic initiation factor 4E 
(e1F4E), although the role of eIF4E phosphorylation 
prognosis 210,211 
and the role of Mnk2 in the process of protein 
translation are not ~ U U understood 
NME3 16p13.3 Probably has a role in normal hematopoiesis by Luminal cancers 212,213 
inhibition of granuloc}te differentiation and induction 
of apoptosis 
Otndidate amplified genes on chromosome 1 
The most frequently amplified region among LNGBC was lq42.13 starting at (228270361) 
and ending at (228683467). This region contains 15 genes (Table 5- U) and only 6 of them 
showed significant correL1tion between copy number changes and mRNA expressions 
(ARFI, CIarjJ5, GUKI, OBSCN, TRIMll amHIST3H2A) 176. However, according to the 
meta-analysis of publicly available gene expression data, ARFI and OBSCN were the only 
relevant genes as overexpression of ARF and OBSCN-mRNAs was more common in low 
grade/ER positive breast cancer 176-186. Moreover, overexposing of OBSCN was associated 
with low risk of 5-year distant metastases 176,187. 
The second most common amplified region on chromosome 1 was lq32.1 which was 
commonly amplified in lwninal cancer 38, Genes showed correbtion between copy number 
change and their gene expression are presented in (Table 5- U). Meta-analysis of gene 
expression data bases has demonstrated that RNPEp, PPPIR12B, CYB5RI, BTG2, FMOD, 
194 
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MDM4, LGTNI ardMA PKA PK2 ·are associated with ER+ and low grade phenotype 17&. 
202. Interestingly, MDM4 is one of the major regulator genes of the most important tumour 
suppressor genes in human cancer, p53. For that reason we decided to explore this further 
by exploring the role of MDM4 in Be and details are shown at the end of this chapter. 
Overexpression of NOTCH2, TRA F3IP3 ani IRF2BP2 genes that located on Ip12, p32.2 
and p42.3, showed significant association with ER positive expression 17&.202. 
Table 5- U: List of genes on lq42.13 that were frequently amplified in low nuclear grade breast 
neoplasia and the correlation between their copy number changes and both mRNA expression and 
traditional clinicopathological features in breast cancer. 
ch start end Band Gene Com:lation Com:lation No No ot 
with gene of lesions 
expression cases 
1 228270361 228286912 q42.13 ARFl YES ER+ 4 5 
_(P- 2E-6) 
I 228288429 228293112 q42.13 Clort35 YES High grade 4 5 
_(P- 2E-6) 
1 228294380 228297013 q42.13 MRPL55 NA NA 4 5 
1 228327663 228336685 q42. 13 GUK I YES High grade 4 5 
(P -2E-6) 
1 228337415 228347523 q42. 13 GJCl NA NA 4 5 
1 228351787 2283532 13 q42.13 Clorf148 NA NA 4 5 
1 228353429 228369957 q42. 13 Clort69 NA NA 4 5 
1 22839 1204 228401365 q42.13 Clortl45 NA NA 4 5 
1 228395861 228566575 q42.13 OBSCN YES -ER+ 4 5 





1 22858 1381 2285945 17 q42.13 TRIMll YES NA 4 5 
(p - 2E·6) 
I 228595636 228604583 q42. 13 TRIMI7 NA NA 4 5 
1 228612546 2286 13026 q42. 13 HISDH3 YES NA 4 5 
(p- 2E-6) 
I 228645065 228645560 q42. 13 HISDH2A NA NA 4 5 
1 228645808 228646259 q42. 13 HISDH2BB NA NA 4 5 
I 228675094 228683467 q42. 13 RNFI87 NA NA 4 6 
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Table 5-14: List of genes on lq32.1 that were frequently amplified in low nuclear grade breast 
neoplasia and the correlation between their copy number changes and both mRNA expression and 
traditional clinicopathological features in breast cancer 
at start end Band Gene Com:lation Com:lations No No 01 
with gene of lesions 
expression C:lSes 
1 200708686 200829829 q32.1 CAMSAPIL1 NA NA 2 4 
1 200842083 200843306 q32.1 GPR25 NA NA 2 4 
1 200860639 200884863 q32.1 Clorfl06 NA NA 2 4 
1 200938520 200992828 q32.1 KIF21B NA NA 2 4 
1 201008640 201081694 q32.1 CACNAIS YES NA 2 4 
(p-o.005) 
1 201103901 201140702 q32.1 TMEM9 NA NA 2 4 
1 20/159953 201198080 q32.1 IGFNI NA NA 2 4 
1 201252580 201302115 q32.1 PKPI NA NA 2 4 
1 201328136 201346808 q32.1 1NNf2 NA NA 2 4 
1 201349970 201368669 q32.1 lAD 1 NA NA 2 4 
1 201372896 201398994 q32.1 1NNII NA NA 2 4 
1 201434622 201438365 q32.1 PHLDAJ NA NA 2 4 
t 201452658 201478584 q32.1 CSRPI NA NA 2 4 
t 201592601 201796097 q32.1 NAY 1 NA NA 2 4 
1 201798288 201853422 q32.1 IP09 NA NA 2 4 
1 201857817 201861426 q32.1 SHISM NA NA 2 4 
1 201865584 201915716 q32.1 LMODI NA NA 2 4 
1 201924619 201939787 q32.1 TIMM17A NA NA 2 4 
t 201951766 201975262 q32. 1 RNPEP YES ER + 2 4 
(p -o.ool) 
1 201977073 201986304 q32.1 ELF3 YES NA 2 4 
(p-o.ool) 
1 202092029 202098634 q32.1 GPR37L1 NA NA 2 4 
1 202101977 202113866 q32.1 ARL8A YES NA 2 4 
(p-o.ooI) 
1 202 116141 202130709 q32.1 P1PNl NA NA 2 4 
1 202163118 202288889 q32.1 LGR6 NA NA 2 4 
1 202300786 202311094 q32.1 UBE2T NA NA 2 4 
1 2023 17836 202557697 q32. 1 PPPIR12B YES Low grade 2 4 
(p -o.OO3) 
1 202559724 202679551 q32.1 SIT2 NA NA 2 4 
1 202696533 202778563 q32.1 KDMSB NA NA 2 4 
1 202848088 202858263 q32.1 RABIF NA NA 2 4 
1 202860230 202897764 q32.1 KLHLI2 NA NA 2 4 
1 202909963 202927700 q32.1 ADIPORI YES NA 2 4 
(p-o.OO3) 
1 20293 1004 202936404 q32.1 CYB5Rl YES ER+ 2 4 
(p -o.OO3) 
1 202976534 202993197 q32.1 TMEMI83A NA NA 2 4 
1 202995626 203047864 q32.1 PPFlA4 YES NA 2 4 
(p-o.OOO7) 
1 203052257 203055377 q32.1 MYOG NA NA 2 4 




Ot stut end Band Gene CorrelatlOn Correlations No No or 
with gene of les ions 
express ion C:lSes 
1 203136939 203144942 q32.1 MYBPH NA NA 2 4 
1 203148059 203 155922 q32.1 QiI3L1 NA NA 2 4 
1 203185207 203198860 q32.1 QiITI NA NA 2 4 
1 203274664 203278725 q32.1 BTG2 YES ·ER+ 2 4 
(P - SE-6) - Lowgrade 
- Good 
prognosis 
-Wtld rwe o53 
1 203309753 203320289 q32.1 FMOD YES -ER+ 2 4 




1 203444883 203460475 q32.l PRELP NA NA 2 4 
1 203463271 203478077 q32.1 OPTC NA NA 2 4 
1 203595928 203713207 q32.1 A1P2B4 NA NA 2 4 
1 204001575 204010393 q32.1 Clorf157 NA NA 2 4 
1 204042246 204096867 q32.1 SOX 13 YES NA 2 4 
(p-5E-6) 
1 204100190 204121307 q32.1 E1NK2 NA NA 2 4 
1 204123944 204135465 q32.1 REN YES NA 2 4 
(p-SE-6) 
1 204159469 204165628 q32.l KISS 1 NA NA 2 4 
1 204167288 204183220 q32.l GOLTIA YES NA 2 4 
(p-5E-6) 
1 204187982 204329044 q32.1 PLEKHA6 NA NA 2 4 
1 204372494 204380944 q32.1 PPPIR15B NA NA 2 4 
1 204391770 204463852 q32.1 PIK3C2B YES NA 2 4 
(p-SE-6) 
1 204485511 204598840 q32.1 MDM4 YES ER+ 2 4 
(P- 5E-6) 
1 204586298 204654597 q32.1 LRRN2 NA NA 2 4 
1 204797804 204991950 q32.1 NFASC NA NA 2 4 
1 205012340 205047136 q32.1 CNTN2 NA NA 2 4 
1 205052258 205053588 q32.l TMEMSI NA NA 2 4 
1 205055270 205091143 q32.l RBBP5 NA NA 2 4 
1 205111632 205180727 q32.1 DSlYK NA NA 2 4 
1 205197038 205242465 q32.1 TMCC2 NA NA 2 4 
1 205271187 205290888 q32.1 NUAK2 NA NA 2 4 
1 205305220 205326166 q32.1 KlHDC8A NA NA 2 4 
I 205350506 205419059 q32.1 LEMDI NA NA 2 4 
1 205473723 205501921 q32.1 POlO NA NA 2 4 
1 205538112 205572045 q32.1 MFSD4 NA NA 2 4 
1 205585237 205602000 q32.1 ELK4 NA NA 2 4 
1 205626981 205649630 q32.1 SLC45A3 NA NA 2 4 
1 205681947 20571936 1 q32.1 NlXXSI YES NA 2 4 
(0 -o.(XXlJ) 
1 205737115 2057446 10 q32.1 RAB7L1 YES NA 2 4 
(p-o.0003) 
1 205758224 205782198 q32.1 SLC41Al NA NA 2 4 
1 205797154 2058 19260 q32.1 PM20DI NA NA 2 4 
1 205882176 205912588 q32.1 SLC26A9 NA NA 2 4 
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Ch start end Band Gene Correlation Correlations No No of 
with gene of les ions 
expression cases 
1 206137335 206155066 q32.l FAM72A NA NA 2 4 
1 206224347 206231639 q32.1 AVPRlB NA NA 2 4 
1 206238872 206306131 q32.1 Clorfl86 NA NA 2 4 
1 206317459 206332104 q32.1 CfSE NA NA 2 4 
1 206515187 206637783 q32.1 SRGAP2 NA NA 2 4 
1 206643796 206670222 q32.1 IKBKE NA NA 2 4 
1 206664449 206671061 q32.1 Clorf147 NA NA 2 4 
1 206680879 206762615 q32.1 RASSF5 NA NA 2 4 
1 206764977 206785904 q32. 1 LG1N YES Low grade 2 4 
(p-o.OOO3) 
1 206800108 206857758 q32.1 DYRK3 NA NA 2 4 
1 206858289 206907626 q32.1 MAPKAPK2 YES ER+ 2 4 
(p-o.OOO3) 
1 206940947 206945839 q32.1 ILtO NA NA 2 4 
1 206972215 207016325 q32.1 ILt9 NA NA 2 4 




Table 5- 15: List of genes on p12, q32.2 and q42.3 that were frequently amplified in low nuclear 
grade breast neoplasia and the correlation between their copy number changes and both mRNA 
expression and traditional clinicopathological fearures in breast cancer 
01 stlrt end Band Gene Correbtion Correbtions No of No of 
with gene cases lesions 
expression 
1 120454178 120612276 p12 NOTO-J2 Oven:xpn:ssion 2 4 
in BC 
1 207191866 207206101 q321 Oorf1l6 YES NA 2 4 
(p-o.0003) 
1 207217194 207226325 q321 YODI NA NA 2 4 
1 207226620 207254368 q321 PFKFB2 NA NA 2 4 
I 209757045 209787283 q321 CAMKIG NA NA 2 4 
I 209788220 209825820 q322 lAMB3 NA NA 2 4 
I 209848670 209849732 q322 GOS2 NA NA 2 4 
I 209859510 209908295 q322 HSDIIBI NA NA 2 4 
1 209929399 209955665 q322 TRAF3IP3 YES - ER+ 2 4 
(p -o.0003) - Low grade 
- Good 
prognosis 
- Wild type p53 
I 209955661 209957904 qJ21 Oorf74 NA NA 2 4 
I 209961262 209979479 q32.2 [RF6 YES NA 2 4 
(p-o.0003) 
I 2[0001333 210030908 q32.2 Clorfl07 YES NA 2 4 
(p-o.0003) 
1 234527059 234614849 q42.2 TARBPI YES(p- l.lE- NA 2 4 
9) 
1 234740017 234745271 q42.3 IRF2BPZ YES - ER+ 2 4 
(p-5E·7) 
- Lowgrade-
t 235272662 235292256 q42.3 TOMM20 YES NA 2 4 
(p - 5E·7) 
t 235294950 235324573 q42.3 RBM34 NA NA 2 4 
199 
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Candidate genes of chromosome 19 
aCGH of 2 cases of ILC and DOS of another case showed amplification of 19p13.3 
region. CNN2, ABC4 7, HMHA I, Clm/23, aRBp, am CI9arf24 fPH showed significant 
correlation between their copy number changes and gene expression 176. Interestingly, 
meta-anal)-Sis showed that overexpression of mRNA of these genes was related to either 
ILC and! or DOS. MKNK2 174-180 is another gene showing correlation between its copy 
number and mRNA expression. MKNK2 overexpression commonly occurred in ER+, 
low grade tumours that lack p53 mutation 191. 
Candidate genes of chromosome 11 
Two cases of ILC carcinoma showed amplification at q13J which is the home of C}din Dl 
gene (CCNDI), PPFlA I, DHCR7 amFADD genes that showed up regulation in relation to 
amplification 202. CCNDI is commonly overexpressed in ILC and we confinned its role in 
the development of LNGBN earlier in this chapter and in Olapter 3. 
Candidate genes of chromosome 16 
16p13+, lq+ and 16q- is the common genetic changes triad of low grade/ER+. Among 
genes on 16p13 regions that have shown significant correlation between copy number 
changes and mRNA was NME3 genes 176-202 which is one of ER responsive genes and is 
commonly overexpressed in the luminal Be subclass 213. 
200 
T able 5- 16: List of frequently amplified genes on chromosome 19 of low nuclear grade breast 
neoplasia, correlation of copy number changes of each genes and mRNA expression in unselected 
breast cancer and associations of each gene expression and clinicopathological parameters. 
Ot start end Band Gene Gmc:iation Comlations No 01 No of 
with gene cases les ions 
expression 
19 496454 505340 p13,3 MADCAMI NA NA 3 3 
19 507497 519653 p13.3 C190rf20 NA NA 3 3 
19 531733 542084 p13.3 CD04 NA NA 3 3 
19 544027 549919 p13.3 GZMM NA NA 3 3 
19 571325 583492 p13.3 SSG NA NA 3 3 
19 589893 617157 p13.3 HCN2 NA NA 3 3 
19 617223 633568 p 13.3 POLRMf NA NA 3 3 
19 639895 643703 pl3.3 FGF22 NA NA 3 3 
19 647530 663227 p13,3 RNFI26 NA NA 3 3 
19 676389 683392 p13,3 FSlU NA NA 3 3 
19 685548 695483 p13,3 PRSSLl NA NA 3 3 
19 708953 748328 p13,3 PAlM NA NA 3 3 
19 751133 764318 pI3,3 C190rf21 NA NA 3 3 
19 797392 812327 p13,3 PTBPI NA NA 3 3 
19 825097 832017 p13,3 AZUl NA NA 3 3 
19 840985 848 175 p13,3 PRlN3 NA NA 3 3 
19 852291 856242 p13.3 ELANE NA NA 3 3 
19 859665 863606 p13.3 CFD NA NA 3 3 
19 867964 893218 p13,3 MEDI6 NA NA 3 3 
19 896503 913225 p13.3 CI90rf22 NA NA 3 3 
19 917342 921014 p13.3 K1SS IR NA NA 3 3 
19 926037 97278 1 p13,3 ARlD3A NA NA 3 3 
19 984328 994569 p13,3 WORIS NA NA 3 3 
19 1000437 IE +06 p13.3 GRl N3B NA NA 3 3 
19 1009650 IE+06 p13,3 CI90rf6 NA NA 3 3 
Overexpressed in 
19 1026298 IE +06 p13.3 CNN2 NA ILC 3 3 
Overexpressed in 
19 1040102 IE+06 p13.3 ABeAl NA ILCandDOS 3 3 
Overexpressed in 
19 1066025 IE +06 p13.3 HMHAI NA ILC 3 3 
19 1086578 IE+06 p13.3 POLR2E NA NA 3 3 
19 1104043 IE +06 p1 3,3 GPX4 NA NA 3 3 
19 1107634 IE +06 p13,3 SBN02 NA NA 3 3 
19 1205798 IE+06 p13.3 STK I I NA NA 3 3 
19 1229 178 IE+06 p13,3 CI90rf26 NA NA 3 3 
19 1241749 IE+06 pD,3 ATP5D NA NA 3 3 
19 1248552 IE+06 pD.3 MIDN NA NA 3 3 
Overexpressed in 
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Ot start end Band Gene Correlation Correlations No of No of 
with gene cases lesions 
expression 
Overexpressed in 
19 1269267 IE +06 p13.3 aRBP NA !LCandIXlS 3 3 
19 1275520 IE +06 p13.3 C19orf24 
Overexpressed in 
NA ILC 3 3 
19 1285892 IE +06 ]> 13.3 MUM 1 NA NA 3 3 
19 1286168 IE +06 p13.} EFNA2 NA NA 3 } 
19 1383883 IE +06 p13.3 NDUFS7 NA NA 3 3 
19 1397089 IE +06 p13.3 GAMf NA NA 3 3 
19 1407584 IE +06 pU.3 DAZAPI NA NA 3 3 
19 1438363 IE +06 pl3.3 RPS1 5 NA NA 3 3 
19 1450148 IE +06 p13.3 APC2 NA NA 3 3 
19 1473203 IE +06 pl3.3 C19orf25 NA NA 3 3 
19 148 1427 IE +06 pl3.3 PCSK4 NA NA 3 3 
19 1491067 IE +06 pl3.3 REEP6 NA NA 3 3 
19 1505023 2E+06 pl3.3 ADAMTSLS NA NA 3 3 
19 1524073 2E+06 p13.3 PLK5P NA NA 3 3 
19 1554669 2£+06 p13.3 MEX3D NA NA } 3 
19 1576678 2£+06 p13.3 MBD3 NA NA 3 3 
19 1597180 2£+06 pl3.3 UQCR NA NA 3 3 
19 1609293 2£+06 p13.3 TCF3 NA NA 3 3 
19 1753662 2E+06 ~ ~ 3 . 3 3 ONEaJr3 NA NA 3 3 
19 1782076 2E+06 p l3.3 ATP8B3 NA NA 3 3 
19 1815245 2E+06 p13.3 REXOI NA NA 3 3 
19 1852398 2£+06 p13.3 KLF16 NA NA 3 3 
19 1876976 2E+06 p13.3 FAMI08Al NA NA 3 3 
202 
Gemic chzracteristia cflownudeu grade broot rmpIasia 
Table 5-17: List of frequently amplified genes on chromosome 11 of low nuclear grade breast 
neoplasia, correlation of copy number changes of each genes and mRNA expression in unselected 
breast cancer and associations of each gene expression and clirUcopathological parameters. 
en start end Band Gene Com:1ation Com:1ations No of No 0 
with gene cases les ions 
expression 
11 68522090 68609399 q13.3 Q>T1A NA NA 2 2 
11 68658747 68671303 q13.J MRP121 NA NA 2 2 
11 68671319 68708069 q13.3 IGHMBP2 NA NA 2 2 
11 68747490 68748455 q13.J MRGPRD NA NA 2 2 
11 68771863 68780850 q13.J MRGPRF NA NA 2 2 
11 68816350 68858072 q13.J lPCN2 NA NA 2 2 
11 69061622 69064753 ql3.J MYEOV NA NA 2 2 
11 69455873 69469241 q13.3 CXNDI contirmed Confumed 2 2 
11 69468073 69490165 qlJ.3 ORAOVI NA NA 2 2 
11 69513007 69519106 qIJ.3 FGF19 NA NA 2 2 
11 69587797 69590171 q1J.3 FGF4 NA NA 2 2 
11 69624736 69634192 ql3.J FGF3 NA NA 2 2 
11 69924664 70035633 q1J.3 AN01 NA NA 2 2 
11 70049269 70053508 q13.J FADD YES (p-2.7E-7) Ductal carcinoma 2 2 
11 70116823 70230500 q13.3 PPFIAl YES(p-2.7E-7) Ductal carcinoma 2 2 
11 70244612 70282689 qIJ.J CITN NA NA 2 2 
11 70313961 70963623 q13.4 SHANK2 NA INA 2 2 
11 71145457 71159477 ql3A DHClV YES (p-Q.Q3) Ductal carcinoma 2 2 
11 71164217 71212579 qIJA NADSYNI NA NA 2 2 
11 71238302 71280091 ql3A KRTAPS- IO NA NA 2 2 
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Table 5-18: List of frequently amplified genes on chromosome 16 of low nuclear grade breast 
neoplasia, correlation of copy number changes of each genes and mRNA expression in unselected 
breast cancer and associations of each gene expression and clinicopathological parameters. 
Pt tart Fnd Band ~ n e e p>rrelabon p>rrelations ~ o o o ~ o o 0 
~ t h h gene ases esions 
expression 
IE 475619 572478 p13.3 iRAB llFIP3 NA NA < 
11 577856 604634 p13.3 pOLH iNA iNA < 2 
IE 61042 619494 p13.3 -...160rfll ~ ~ iNA 2 
16 617011 634108 p13.3 IPIGQ NA NA i. < 
IE 640176 679271 p13.3 !RAB4OC INA NA '-
H 680932 684116 p13.3 [WFIKKNI INA iNA , 2 
If 684429 686347 p13.3 1'-'16orf13 INA INA I. 
If 6 9 1 8 4 ~ ~ 698474 pl3.3 1'-'16orf14 ~ ~ iNA 2 L 
IE 699363 717829 p l3.3 rwoR9O ~ A A r<A L 
IE 718133 724170 p13.3 ~ 0 T 2 2 INA NA L 
IE 72570E 728261 p13.3 jRHBDLt INA INA < , 
IE 73011: 732761 p13.3 plUBl !YES 
KP_- 1.15E·6) 
iNA 2 , 
IE 734648 740444 p13.3 IWlJR24 INA r<A , L 
IE 74250C 755829 p13.3 BXL16 iNA ~ ~ L 
II 765173 767478 p13.3 jMElRN INA iNA 2 
11 77115S 772589 p13.3 IFAM173A INA INA , 2 
II 772582 776846 p l3.3 ~ 8 8 INA iNA 2 
IE 776958 797295 p13.3 IHAGHL iNA iNA I. , 
IE 779771 79099 p13.3 INARFL INA INA 
IE 812631 818865 p13.3 jMSLN INA INA , , 
1/ 819428 833370 pl3.3 jMSLNL ~ A A INA 2 , 
H 834975 838383 p13.3 IRPU>Dl IYES INA , 2 
I(p-o.QO§l 
H 838046 848074 p13.3 ~ I F F 8 8 INA INA , i. 
16 848044 850733 pl3.3 GNG13 ~ A A NA < , 
11 903638 1020984 p13.3 I.1W'1 ~ ~ NA '- 2 
II 1031808 1036979 p13J :>0X8 NA NA '-
II 112275E 1131437 p13J ~ S T R 5 5 NA iNA L 2 
IE 113822E 1146244 p13.3 dQ1NF8 NA ~ ~ 2 L 
IE 1203241 1271771 1'13.3 pCNA1H NA ~ A A L 
IE 1271658 1275256 p13J [TPSGI NA ~ A A L 
IE 1278336 1280214 p13.3 [TPSB2 [YES LC 2 L 
KP-l.15E·6) 
16 1290678 1292555 p13.3 1PSABI [YES LC , 
I (p-l.15E-6) 
IE 130606C 1308609 p13.3 [IPSDl ~ A A NA < , 
11 1307043 1326838 pl3.3 RSS29P ~ A A NA L , 
11 1359180 1375390 p13.3 UBEZI [YES 
~ - 1 . 1 5 E - § l l
DC < , 
IE 1383654 1399440 p13.3 BAlAP3 [YES INA 
I (p - 1.l5E-6) 
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PI tart ~ n d d lBand pene p>rrelation R:Orre lations 1'-10 oljNo 0 lwith gene ase s esions 
expression 
1/ 1399243 140187 5p13.3 r---160rt42 INA JNA • • 
1/ 140 1932 141335 Ip13.3 ~ N P T G G IYES INA 2 2 
~ ~ - 1 . 1 5 5 - - ) )
1/ 14132et 146470 5p13.3 fUNKL iNA ~ ~ , 
IE 1469754 147934 5p13.3 ~ 1 6 0 r t 9 1 1 INA INA 2 
1/ 1484386 149455 7p13.3 ~ 1 5 4 4 INA INA 2 2 
1/ 149493 152508 5p13.3 G-CNl INA INA :I. :I. 
11 153594( 1538910 p13.3 r---160rf38 INA INA :I. :I. 
11 1543364 1560453 p13.3 [fEL02 iNA INA 2 2 
H 1560421 1662109 p13.3 iIFTl40 INA INA , 2 
1/ 1583651 1605577 p13.3 [IMEM204 NA INA , , 
IE 1662338 1736716 p13.3 pw.1PIL INA iNA 2 2 
IE 1728278 1752072 p13.3 HNIL INA NA 2 2 
IE 1756221 1820317 p13.3 MAPK8IP3 INA NA 2 2 
16 1820322 1821710 p13.3 jNME3 IYES lLurninaI 2 
Kp - 1.l5E-6) brcinoma 
1/ 1821891 1823151 p13.3 1MRPS34 [YES DC < 
Kp-1.l5E-6) 
1/ 1823229 1830628 p13.3 IEME2 YES ~ ~ 2 2 (p- 1.l5E-6) 
IE 1826714 183258 1 p13.3 ~ P S B 3 3 YES iNA 2 2 
(p- 1.15E-6) 
IE 1832933 1839191 p13.3 INUBP2 NA NA :I. 2 
16 1840416 1843734 p13.3 GFALS INA NA z 2 
16 1859 108 1877195 p13.3 HAGH IYES iNA 2 2 
I (p- 1.15E-6) 
16 1877225 1890201 p13.3 AHDI IYES INA 2 '-
I (p - l.15E-6) 
16 1883989 1922102 p13.3 ~ ~ 6 0 r f 7 3 3 INA NA 2 :I. 
H 196 1464 1968441 p13.3 1HS3ST6 iNA NA :I. '-
1/ 19882 11 1993327 p13.3 ~ E P X l l NA NA 2 2 
IE 199397E 2004671 p13.3 ~ L 3 L L NA NA 2 2 
IE 2009511 2011976 p13.3 NDUFBIO YES NA 2 
kp - 1.I5E-6) 
It 2012062 201 4821 p13.3 1RPS2 INA INA 2 2 
It 2017274 2018976 p13.3 iRNF151 IYES (p- 1.l5E-6) INA 2 
It 2022064 2028751 p13.3 rrnL3 INA INA 2 
11 20289 19 203 1550 p13.3 INOXOI INA INA 2 
IE 2034 1SC 2037746 p13.3 ~ F E R R IYES INA 2 < I (p - 1.15E-6) 
11 2 0 3 9 9 6 ~ ~ 2044275 p13.3 ~ Y N G R 3 3 NA INA < 2 
II 2 0 4 7 7 6 ~ ~ 2059763 p13.3 !£-NF598 IYES INA < 
I (p- 1.I5E-6) 
1 ~ ~ 206952 1 2070755 p13.3 jNPW INA JNA 2 
1/ 20898lE 2097861 p13.3 !NTHL1 iNA rNA 2 2 
1/ 2097981 213872 1 p13.3 rrsa IYES I (p - l.15E-6) INA 
IE 213871 1 2185899 p13.3 KDI INA iNA 2 2 
1/ 2198645 2204140 p13.3 iRAB26 INA INA , 
IE 2205799 2228129 p13.3 1rRAF7 [N'A INA • 
, 
IE 2227184 2246465 p13.3 CASKlNI INA INA 2 , 
IE 2259254 226 1011 p13.3 d60rf79 INA INA 2 :I. 
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lwith gene :lses es ions 
expression 
1E 2261603 2264822 p13.3 PGP ~ A A NA 2 2 
IE 227356/ 2285743 Pl3.3 lE4Fl ~ A A NA l 2 
IE 2286468 2288709 P13.3 DNASE 112 NA NA l l 
t ~ ~ 228990C 2301603 p13.3 DO NA iNA 1. 
t ~ ~ 2303124 23 18114 p13.3 RNPS I NA iNA 1. < 
t ~ ~ 2325879 2390747 p13.3 ABCA3 INA ~ A A 2 2 
Table 5·19: List of frequently amplified genes on chromosome 1 of low nuclear grade breast 
neoplasia, correlation of copy number changes of each genes and mRNA expression in unselected 
breast cancer and associations of each gene expression and clinicopathological parameters. 
Ot start end Band Gene Correlation Correbtions No No of 
with gene of lesions 
expression cases 
18 44392060 44497466 q21.1 PlAS2 NA Invasive Ductal 2 3 
carcmoma 
18 44526787 44627658 q2 1.1 KAlNAl2 NA NA 2 3 
18 44542731 44544607 q21.1 TCEB3Cl2 NA NA 2 3 
18 44548658 44550534 q21.1 TCEB3G. NA NA 2 3 
18 44554573 44556449 q21.1 TCEB3C NA DOS 2 3 
18 44558943 44561992 q21.1 TCEB3B NA DOS 2 3 
18 44633782 44676871 q2 1.1 HDHD2 NA NA 2 3 
18 44681415 44702745 q2 1.1 IER3IPI NA NA 2 3 
19 1905371 1926011 p13.3 SCAMP4 NA Overexpressed 2 2 
BC 
19 1905417 1913444 p13.3 ADAD NA NA 2 2 
19 1941161 1981309 p13.3 CSNK IG2 NA NA 2 2 
19 1952526 1954548 p13.3 C19orf34 NA NA 2 2 
19 1985447 2015702 p13.3 B1'8D2 NA NA 2 2 








5.4.11 Genetic alteration of tubular carcinoma and invasive 
lobular carcinoma 
Several prevalent alterations (>1'0%) were common to both TC and ILQ gains of lq+ 
whole ann, 16p13.3-q112+, Ip36.33-32+, 3p21, 8q24.3+, 9q33.1-34.3+, 19q13.3+, 
19p131 11+, 11q14.1-25, 20qll11 and 21q22.3 and losses of 16q whole are, Ip34.3, 
6p111, 19p132, 4p161-p152, 9p13.l-q12, llq14.1-q25 and 20q112l (fable 4-20). 
Orromosomal changes differentially associated with tubular carcinoma compared to ILC 
were summarized in Table and included gains of Ip36.11, 3p21.31-p21.1, 12q13.11-q132 
and losses of Ilp15.5-p15.4. Compared with tubular carcinoma, ILC harboured gains of 
Ip3623-p3622, Ip12 (NOTQ-I2), lq21.1, 5q12.3, 75p13, 12q2423-q24.3l, 13q34, 
17p13.3-p132, 17q25.1-q25.3, 19q13.31-q13.42 and losses of 2q112, p112l, q1121-
ql1.22, p112-q12.1 and p112-q112. 
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Table 5·20: Comparison between genetic characteristics of both tubular carcinoma and invasive 
lobular carcinoma 
ch map Cytogenetic Band Genetic changes Number of Number of 
TCcount ILC 
1 1: 150269698 . .246624589 q21.3-q44 GAIN 5 4 
16 16:11139 . .31764125 p13.3- ql1.2 GAIN 4 4 
3 3:46851921..53308680 p21.31-p21.1 GAIN 4 3 
1 1:2277295 .. 2485326 p36.33-p36.32 GAIN 3 4 
1 1:2697923 . .3757389 p36.32 GAIN 3 4 
8 8: 143743728 .. 144743580 q24J GAIN 3 4 
9 9: 130513305 .. 138069659 q33.1-q34.3 GAIN 3 4 
19 19:960519 .. 2970392 p13.3 GAIN 3 4 
1 1:5873942 ... 6950771 p36.31 GAIN 3 3 
1 1:23800462 .. 24461606 p36.12-p36.11 GAIN 3 3 
1 1:145190320 .. 148644689 q21.l-q21.2 GAIN 3 3 
3 3:183258533 .. 195960808 q26.33-q29 GAIN 3 3 
12 12:5972109..7247166 p13.31 GAIN 3 3 
19 19:27953 15 .. 8663945 p132-qI2 GAIN 3 3 
21 21:43466719 ... 45929047 q22.3 GAIN 3 3 
16 16:48900991..84593836 pl1.2-q24.3 LOSS 5 3 
1 1:34515166 .. 35375482 p34.3 LOSS 4 3 
6 6:57335587 .. .58075261 pi 1.2 LOSS 4 3 
19 19:8629145 .. 9060080 p13.2 LOSS 3 3 
4 4:9371304 .... 23169797 pI62-pI5.2 LOSS 3 3 
9 9:39131199 . ..71033904 pl3.1-qI2 LOSS 3 3 
11 11:80636716 .. 133454282 qI4.1-q25 LOSS 3 3 
20 20:29421720 .. 29996640 ql1.21 LOSS 3 3 
1 1:25312395 .. 25779600 p36.11 GAIN 0 3 
3 3: 125828183..129284640 p21.31-p21.1 GAIN 0 3 
12 12:48027380 .. 55251462 q13.11-q13.2 GAIN 0 4 
11 11:4551894 ... 8684969 p 15.5-p 15.4 LOSS 0 3 
1 1:7038707 .. 12129387 p36.23-p36.22 GAIN 3 0 
1 I: 120436410 .. 120650514 pl2 (Nararz) GAIN 3 0 
1 I: 144452745 .. 145210875 q21.1 GAIN 3 0 
5 5:65203593..68826309 q12.3 GAIN 3 0 
7 7:44083631..45018187 p13 GAIN 3 0 
12 12: 121193338 . .125667418 q24.23-q24.31 GAIN 3 0 
13 13:110995727 . .111374279 q34 GAIN 3 0 
17 17:2256623..5083694 p13.3-p13.2 GAIN 3 0 
17 17:729302663 .. 78900648 q25.1-q25.3 GAIN 3 0 
19 19:45182685 . .51060676 ql3.31-q13.42 GAIN 3 0 
2 2:87128774 .. 98327997 2ql1.2 LOSS 3 0 
18 18: 14304059 . .14984939 pl1.21 LOSS 3 0 
10 10:46812978 .. 49450532 ql1.21-ql1.22 LOSS 3 0 
11 11:49003873 . .49980055 p 11.2-q 12.1 LOSS 3 0 
21 21: 10907345 .. 15399525 pl1.2-ql1.2 LOSS 3 0 
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S.4.U MDM4 is subject to early genetic changes in Be 
development 
As has been demonstrated in section 5.4 most low nuclear grade breast carcinoma cases 
(:>85%) showed gain in 1q+ especially at 1q31-32 locus and 15% of our LNGBC had 
amplification at 1q32 region. Moreover .MDM4 which is one of the main regulatory genes 
of p53 maps to this region and is frequently amplified! overexpressed in 65% of 
retinoblastoma 181-183. Subsequently, we hypothesised that it may be a candicbte oncogene 
in BC and we tested this hypothesis on several levels: 
1- Copy ntunber changes in two independent data sets in which the results were 
validated by gene expression array. 
2- Immunohistochemistry for protein expression 
3- dinical outcome of a large BC coholt with long follow up 
Copy number changes in high grade BC series and unselected series: 
We found the .MDM4 locus showed gain in 40% and 57% of high grade Be series and 
unselected BC series, respectively. Moreover, the .MDM4 locus was amplified in 8% and 
10% of high grade BCI38 and unselected BCseries 176. 
Integrated aCGH and expression analysis 
In both high grade and unselected BC series 176, .MDM4 mRNA expression levels displayed 
a statistically significant correL'1tion with copy number (Spearman's r= 0.58172, adjusted p 
value - 0.00012). In addition, 4 out of 48 cases of the high grade series (3 luminal and 1 
basal-like breast cancers) displayed MDM4 gene amplification and these cases harboured 
significantly higher levels of MDM4 mRNA expression {Mann-Whitney U test, adjusted p 
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value = 0.00934). In addition, mRNA expression showed a statistically significant 
correlation with ER protein expression (p <0.0001). 
MDM4 protein expression 
There was no expression of .MDM4 protein in nol111.-U breast tissue while 17% Be of the 
Nottingham series showed overexpression of .MDM4. .MDM4 overexpression was 
statistically significant (<0.0001) associated with small size, low grade, ER + (Figures 5-53 
and 5-54) and normal expressions of p53, AIM and BRCAt. In low grade breast cancer 
we fOlUld .MDM4 overexpressed in 30% of cases and in cases showing coexistent 
precursors (columnar cell lesion, DOS, and LN) with invasive component, .MDM4 
expression was identical in both lesions (Figure 5-55). 
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Figu re 5-53: Tubular carcinoma showing positive nuclear staining of MDM4 
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Figure 5-55: Genome plots and MDM4 immunohistochemistry staining of different components 
of case 2. 
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Clinical outcome of MDM4 overexpression 
Absence of MDM4 over-expression was strongly associated with an adverse outcome at 10 
years with a significant increase in the hazard of death, recurrence and DM in the whole 
Nottingham Be cohort (Figures 5-56 and 5-57). Furthermore, the clinical outcomes of 
MDM4 overexpression of 301 patients with early stage small tumours (LN-negative with 
tumour size ~ ~ 2cm) who did not receive any AT were investigated. Consistently, patients 
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Figure 5-58: Breast carcinoma specific survival curve of small size early stage adjuvant therapy-
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Figure 5-59: Disease free survival curves of small size early stage adjuvant therapy non treated 
patients 
Prognostic significance ofMDM4 
Multivariate Cox regression models were also used to assess and compare the prognostic 
performance of MDM4 overexpression to that of validated prognostic indicators including: 
stage, size, grade, ER, PR, p53, Bc12, CKS/6 and HER-2 overexpression. We found that 
the MDM4 overexpression was an independent prognostic rnarker{Table 5-20). 
Table 5-21: Multivariate Cox regression analysis of MDM4 overexpression including validated 
prognostic factors: size, stage, grade, Bc12, p53, ER, PR, and HER-2 overexpression 
MDM4overexpression HR 95%Q P 
Risk of death 0.29 0.17-0.49 6.4£-6 
Risk of relapse 0.40 0.27-0.58 2.9E-6 
RiskofDM 0.37 0.24-0.59 2.2£-5 
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MDM4 overexpression and clinical outcome of honnone ther.tpy 
To evaluate whether the expression of MDM4 had different clinical outcomes in specific 
AT settings, we investigated the clinical outcomes and survivals of Nottingham high risk 
patients (n=309; N P I ~ 3 . 4 ) ) and ER+ who had received Hr. We found that patients with 
Absence of MDM4 had the worst outcome (Figure 5-60). Moreover, when we compared 
the survival of high risk Hr-treated patients to those of Hr untreated for MDM4 negative 
subgroup, we found patients with negative :MDM4 expression who received Hr had a 
better outcome than those who did not (Figure 5-61). 
In summary, MDM4 is an independent prognostic and predictor of Be and its 
overexpression could represent a novel molecular mechanism by which low nuclear grade 
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Figure 5-60: Disease free survival of high risk Nottingham patients with positive oestrogen 
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Figure 5-61; Disease free survival of high risk Nottingham patients with positive oestrogen 
receptors and NPI >3.4 who were negative fo r MDM4 
217 
-------------------------------------------
cmpter5 Gen:ticdunuteristi<.s rflawnllilazr gnu Ie bratst rropI&ia 
5.5 Discussion 
In this chapter we used aCGH to define the genetic profiles of some lesions of low nuclear 
grade breast neoplasia including invasive tubular and invasive lobular carcinoma and their 
matched co-existing precursor lesions: columnar cell lesions low/intermediate grade DOS 
and lobular neoplasia. We found that the genomic profiles of these lesions showed 
remarkable similarity supporting their monoclonality from a common cell of origin. 
Moreover, our results provide substantial evidence that Ols are the early non obligate 
precursor lesions for some tubuL1r and 10buL1r carcinomas in the low-grade molecuL1r 
pathway of Be in agreement with other studies 52.69.71.75.85. 
Previously, recurrent loss of heterozygosity (LOW) at llq21-23.2, 16q23.1-242, and 3p142 
was observed in CXl.. and in adjacent DOS 52, 69. 71. 75. 85. Moreover, in agreement with 
Simpson et al (2005) 71 , we found that the morphologic classification of CXl.. closely 
mirrored the level of genetic instability seen with comparative genomic hybridization 
(CGH), such that a stepwise increase in the mean number of genomic changes coincided 
with a rise in severity of the morphologic classification. According to Simpson et al2005 71, 
lesions categorized as ax:: with or without atypia (category 1 and 6) showed a lower level 
of copy number changes relative to ca-r (category 2). The genetic complexity further 
increased with the presence of either cytologic or architectural atypia (categories 3 and 4), 
and then further still in category 5 with the combination of cytologic and architectural 
atypia showing equivalence at the molecular level to that observed in DOS. In agreement 
with others 52,69,71,75,85, our study has shown CXX'Jca-r without atypia and FEA forms a 
biologic continuum that merges into low-grade DOS and lobular neoplasia. Interestingly, 
in view of their consistence to harbour recurrent chromosomal abnormalities, CXl..s could 
be considered clonal and neoplastic lesions rather than hyperplastic proliferative lesions. 
Moreover, in addition to the common genetic changes they shared, arJ ca-r without 
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atypia, FEA, DOS, LN, TC and classic ILC is associated with distinct and progressively 
greater molecular alterations as previous reported 58, 81, 89, lOS, 106, lSI, 152. Moreover, we fOW1d 
that the genetic profiles of a:rJ CXJ-I without atypia are more advanced th,Ul we have 
thought. However, further studies including a larger number of cases and lesions not 
associated with invasive carcinoma is 'WalTanted. 
Although the number of samples is small for each category, the simihrity in genomic 
profiles among representative lesions is dramatic and could provide insight into some of the 
earliest events leading to invasive breast cancer. 
For instance, most of the lesions (>15%) included in this study showed a characteristic 
rearrangement in chromosome 16 Ooss of 16q ann) and concomitant gain of 16p which is 
coupled with converse rearrangement of chromosome 1 (gain of the lq whole ann and loss 
of Ip) and chromosome 8 (8p loss and 8q gain, in agreement with previous studies 55,52,71, 
81. In the literature, gain of lq is one of the most common acquired genetic abnolTIlalities 
in hum.'Ul cancer 214. There are several putative mechanisms underlying gain of lq in breast 
cancer including duplication, isochromomsome fOlTIlation or unbal.'Ulced translocations214-
223. The current data indicate that near centromeric regions of both lq and 16q is 
breakprone 215-216, The reasons behind this phenomenon are presently unknown although it 
has been hypothesized that demethylation of the pericentric heterochromatin is associated 
with decondensation and subsequent instability of satellite sequences219-22J. Satellite 
sequence instability could be responsible for lq and 16q rearrangements (W1bal.'Ulce 
translocation) that are commonly reported in low grade (near-diploid) breast cancer219. In 
fact, these chromosomal imbalances seem to play a pivotal role in breast cancer 




In addition, we found in agreement with others, that one of the common genetic changes in 
LNGBC involved llq with 2 narrow (<2 Mb) amplicons at llq13 and one at llq15 100,202· 
213 suggesting the important role of llq13 in the progression of LNGBC CCNDI maps to 
one of these loci and we validated its amplification by using aSH technique. Furthennore, 
we found that there was a significant correhtion between copy number changes and protein 
expression by IHC in agreement with what we have previously demonstrated in Olapter 3. 
Genetic alterations at chromosome 1 is a hallmark of low nuclear grade breast neoplasia as 
all LNGBN lesions showed one or more events including gain of lq+ and Ip36. Actually 
chromosome lq harbours more than one gene in both ER and p53 network. Among these 
genes are MDM4, TP73, MUC1, RNPEp, PPPIR12B, CYB5R1, BTGG2, FMOD, LGTNI 
and MAPKAPJQ2. For instance, we found in this study that .MDM4 was overexpressed 
and amplified in a subset of ER +/LNGBC in agreement with recent published reports 181, 
182. In fact, .MDM4 overexpression could be an alterative mechanism by which LNGBC 
could escape the suppressor neoplastic effect of p53. Moreover, we found that .MDM4 is 
an independent prognostic factor and predictive marker which could have therapeutic 
implications similar to its brother.MDM2 182. 
By using comparative analysis with high grade and unselected BC series in which CXJH cL'1ta ' 
were valicL,1.ted at mRNA expression by gene expression array, we have suggested a list of 
target genes on the loci that showed recurrent amplification/high gain in our LNGBC 
Furthennore using meta-analysis gene expression d.'1ta in wwww.oniscomine.org d.'1ta bases 
we found a number of genes that their mRNA over-expression are related to ER +, low 
grade tumour and absence of p53. 
Previously in the introduction, we described ER + luminal restrictive progenitor cells that 
perceived to reside in the lumina layer of the IDLUs. One of the characteristic of this cell 
is its positive expression for MUCI +. MUCI maps to lq22: the region that showed high 
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gain in all of our samples. Given that the inunlmohistochemical profiles of all LNGBN are 
identical to that of the ER + lwninal restricted progenitor cell (ESR +, MUC1 +, ER +, 
0<.19 +, 0<.18 + and 0<.5/6-) of nonnalIDLUs, we could cbim that the common cell of 
origin of LNGBN could be that cell Subsequently, ER + lwninal restricted progenitor cells 
could acquire stochastic genetic and epigenetic hits such as CCNDl and MDM4 
amplifications that lead to the activation of the 'luminal N pathway and that these events 
determine the phenotype of the pre-invasive and invasive lesions. Fwthennore, these hits 
may be an early event in the progression of 'lwninal N tumoillS and once committed to this 
specific 'molecuLtr pathway', progression to a 'high grade' (basal-like or HER-2 +) 
phenotype would be an unlikely biological phenomenon. 
LNGBN family showed morphological diversity between some family members, for 
example low grade DOS versus LOS and invasive tubuLtr carcinoma versus cL1Ssical 
invasive lobular carcinoma. E-cadherin (CDH1) is a TSG localised on chromosome 16q21 
and is frequently lost in ILC It is recognised that CCLs, ADHilow grade DOS, Te, IG:; 
low grade IDe, and lLC are positive for E-cadherin, and in contrast LN and ILC bck 
expression of this tumour suppressor gene and adhesion molecule. Given that, most of the 
LNGBN family were associated with loss of the whole 16q arm, we speculate that loss of 
nonnal CDHI gene expression, which is associ.'lted with the development of lobular 
differentiation 2-10,34, is a secondary epigenetic rather than a genetic event which confers 
particular morphological and behavioural characteristics to these members of the LNGBN 
family. 
In conclusion, given that the morphological and immunohistochemical features of CCL 
cells are almost identical to those seen in ADHI low grade DOS and LN, and that the 
molecuLtr genetic changes of CCL are similar to those fOlUld in matched low grade breast 
cancers our findings suggest that CCL is a common non-obligate preCillSor of LGBC and 
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ILC Taken together, these lesions may represent a family of precursor, in situ and invasive 
neoplastic lesions belonging to the lwninal 'A' subcbss of breast cancer. Cyclin D 1 and 
MDM4 are among early genetic changes that activate luminal "A" pathway and drive 
progression of LNGBN family. 
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CiJatJter6: 
.. 
The Biological, clinical and prognostic 
implications of p53 transcriptional pathways in 
breast cancers 
6.1 Abstract 
In Cllapter 5 we have shown that MDM4 was amplified in -10% and overexpressed in up 
to 17% of Be respectively. In addition, we found that MDM4 was an independent 
prognostic and predictive marker in Be MDM4 is one of the m.-un regulatory gene of the 
tumour suppressor gene TP53. Subsequently, in this study, we hypothesised that the 
functional status of p53 transcriptional pathways, rather than p53 protein expression alone, 
could accurately discriminate between low and high risk breast carcinoma {Bq and inform 
about individuals tumour biological behaviour. A well characterised series of 990 Be with 
long term follow-up was immunohistochemically profiled for p53, its main regulators and 
downstream genes. Results were valicL'lted in an independent series of patients (n ... 245) 
uniformly treated with adjuvant anthracydine-based chemotherapy. Eleven p53 
transcriptional phenotypes were identified with just 2 m.-un clinical outcomes: (a) Low 
risk/good prognosis group (active/partially inactive p53 pathways) defined as 
p53 ±/MDM4 +/MDM2 ±/Bc12 ±/ p21 ±, p53-IMDM4-/MDM2 +/Bc12 +1 p21 ± and 
p53 ±/MDM4-/MMD2-/Bd2 +1 p21 ±. These tumours had favourable clinicopathological 
characteristics including ER + and long survival after systemic adjuvant-therapy (A 1). (b) 
High risk/poor prognosis group (completely inactive p53 pathways) defined as 
p53 ±/MDM4-MDM2-/Bc12-/ p21-, p53-/MDM4-MDM2 +/Bc12-/ p21-, p53 ±/MDM4-
/MDM2-/Bc12-/ p21 +. These tumours were characterised by aggressive clinicopathological 
p53 trar601ptiornl fUIlJ7.iR)5 in Imilst CUrm" 
characteristics and showed a shorted survival when treated with AT. Completely inactive 
p53 pathwa}"3 but intact p21 axis p53 ±/MDM4-/MDM2-/Bc12-1 I p21 + had the worst 
prognosis particularly patients who received AT. Multivariate Cox regression models 
including validated prognostic factors for both test and validation series revealed that the 
functional status of p53 transcriptional pathwa}"3 was an independent prognosticator for Be 
specific survival (HR: 2.64 and 4.5, p <0.001, respectively) and disease-free survival (HR: 
1.93 and 2.5, p<O.OOl, respectively). In conclusion, p53 functional status determined by 
assessment of p53 regulatory and downstream targets provides independent prognostic 
value and may help determine more adequate therapeutic regimens for specific subgroups 
of breast cancer patients. 
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6.2 Introduction 
The TP53 gene encodes a nuclear transcription factor, p53, which is regarded as a guardian 
of the genome. p53 trans activates numerous target genes 177 (Figure 6-1), and play.; pivotal 
roles in the regulation of cell cycle arrest, apoptosis, DNA repair, angiogenesis and 
differentiation 177-180. 
Although 25% of breast cancer (BQ harbours TP53 mutation ISO. 225. 226, the biological role 
and clinical importance of p53 alterations in Be may have been underestimated 180. 224. 225 
due to several reasons: 1) conflicting published data about its prognostic implications ISO, 2) 
extensive p53 network 179 and 3) technical problems associated with surrogate markers to 
identify TP53 gene defects, as most of detecting tests k1Ck sensitivity and specificity 178. For 
instance, p53 immunostaining has been used as a surrogate marker for the existence of 
TP53 gene mutations which subsequently, translated into a non-functional p53 178. Both 
concepts have several pitfalls. First, about 30% of Be carrying TP53 point missense 
mutations do not express p53 immunohistochemicaUy, especially those associated with 
therapy resistance 22&-227. Second, null p53 mutation (nonsense, frame shift, deletions, 
insertions, and splicing junction mutations) may not produce p53 protein at all 228. Third, 
some mutations of TP53 could generate abnormal p53 protein that keeps most of its 
biological function 177-228. Lastly, the biological functions of wild-type TP53 might be 
disrupted by alterations in other proteins e.g., oestrogen receptor (ER) 229-232, .MOM2 233-236, 
MDM4 181- 183 andATM 102.237 (Table 6-1). 
In the vast majority of studies addressing p53 dy.;function in Be, nuclear 
immunohistochemical expression of p53 was used as a surrogate marker of TP53 mutation 
177-ISO.224-228. Despite lacking sensitivity and specificity, numerous studies have demonstrated 
that p53 immunohistochemistry is a prognostic factor in Be and that it may determine the 
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sensitivity to specific therapeutic agents 177-180,224-229. In fact, there is accumulating evidence 
suggesting that p53 dysfunction could be responsible for the development of antiestrogen 
therapy resistance of ER + tumour.; 230 , whereas in ER- tumour.; p53 mutation is 
considered as a key predictor for chemotherapy failure 178, 180,224,229. 
Given that >10% of Be and more than 97% of low nuclear grade breast neoplastic family 
have wild-type p53 as shown in Cbapter 2, we could claim that p53 dysfunction as a tumour 
suppressor gene in the majority of Be especially low nuclear grade may be due to other 
mechanisms rather than mutation. 
In Cbapter 5, using array comparative genomic hybridization (copy number changes), gene 
expression array (mRNA expression), immunohistochemistry (protein expression) and 
clinical outcome, we have identified that MDM4 as one of the amplified target genes that 
has independent prognostic and predictive implication on breast cancer. MDM4 is one of 
the main regulatory genes of p53. 
In fact, analysis of the transcript profiles of primary breast tumour.; of known p53 status 
have shown that the transcriptional profile of p53 is a more definitive indicator of p53 
function than its mutational status 181. Moreover, an immunohistochemical panel combining 
p53, with two of its down-stream targets, namely p21 and MDM2, has proven to be more 
sensitive and specific to detect p53 pathway dysfunction than immunohistochemical 
assessment of p53 itself 228. 
In this study, we hypothesised that the functional status of p53 transcriptional pathways 
rather than p53 immunohistochemistry expression alone could accurately determine clinical 
outcome in a large unselected series of Be and in a series of patients uniformly treated with 
adjuvant a n t ~ l i n e - b a s e d d chemotherapy. 
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Figure 6-1: p53 network illustrating the interaction between p53 and MDM2: murine double 
minute 2 (MDM2), murine double minute 4 (MDM4), ataxia telangiectasia mutated (ATM), p21 and 
Be12. 
In response to celluL'll" stress (such as DNA dam.1ge, oncogenes or hypoxia), p53 is 
phosphorylated at specific serinelthreonine residues which prevents the MDM2-pS3 
interaction, and thus pS3 is stabilized and activated. Therefore oncogene stress signals 
result in increased proliferation and eventually malignant transformation if upstream 
activators of p53 (such as ARF, Q-fK2, or ATIv1), p53 itself (e.g. mutation), regulators of 
p53 (e.g. MDM2 or MDM4) or p53 downstream signalling components (pS3 target genes: 
Bcl2, Pum.'1, Noxa, Bax, p21, p48) are inactivated. It should be noted that pS3 controls 
apoptosis by induction of prcrapoptotic genes such as Puma, Noxa and Bax and by 
suppressing anti-apoptotic genes such as Bel2. 
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Table 6·1: Hypothesis and theories of immunohistochemistry detection of the functional status of 

















Positive (+) .:. 
Positive (+) .:. 
Theory 
Wild t}pe (WI) p53 protein is short lived as 
activated wr p53 induces the transcription 
of MDM2, v.hich binds to p53 and leads to 
its destruction 
Null mutations or deletion of p53 result in 
absence, or premature stop codons and 
shortened protein products that often may 
not be detectable by IHC 
Inactivation of wr p53 rather than mutation 
e.g.; upstream and/or down stream 
regulator.; e.g., MDM2, MDM4, A1M, 
BRCAL.etc. 
O:>ntinuous exposure to stress such as DNA 
damage, resulting in stabilization and 
intracellular accumulation of wr TP53 
point missense mutations of TPS3 produce 
abnormal proteins v.hich are resistant to 
degradation leading to intrace llular 
accumulation of abnormal p53 
Through an auto-regulatory leedback loop 
'lVith MDM2, activated TP53 induces the 
transcription of MDM2, which binds to and 
inactivates wr TP53 
Overexpression of MDM2 due to ER 
dependent transactivation of MDM2 
inactivate TP53 apoptotic pathway 
ER and TPS3 independent transactivation of 
MDM2 e.g., MDM2 gene amplification, 
overexpression of MDM2 mRNA splice 
variant 
~ w n n regulation of TP53-p21 cell grov-th 
axIS 
Up regulation of TP53 apoptotic activity 
pathway 
Bc12 is a direct downstream responsive gene 
of ER and p53. Retention of BcJ..2 
expression inhibits apoptosis, inhibit cell 
C}de progression at GO/Gl, extends cell 
survival but does not promote cell 
proliferation. 
P21 protein expressIon is increased by 
normal TPS3 activity leading to cell C}l:Ie 
arrest and tumour gromh inhibition 
TPS3 independent expressed p21 
concomitantly prevent apoptosis, promotes 
gromh "cell survival promoter', and induces 
differentiation by direct interaction 'lVith ER-
(1.. 
II IC: immunohistochemistry 
Clinical outcome: Hypothesis 
.. Good prognosis: active wr p53 
transcriptional pathwa}5 
.. Poor prognosis: completely 
inactive p53 transcriptional 
pathwa}5 due to null mutant TP53 
.. Good prognos is: partially inactive 
p53 transcriptional pathwa}5 
.. Poor prognosis: completely 
inactive p53 transcriptional 
pathways 
.. Good prognosis: active pS3 
transcriptional pathwa}5 
.. Good prognosis: partially inactive 
pS3 transcriptional pathwa}5 
.. Poor prognos is: completely 
inactive pS3 transcriptional 
pathwa}5 due to point missense 
mutantTPS3 
.. Good prognosis: partially inactive 
p53 transcriptional pathwa}5 
.. Poor prognosis: completely 
inactive p53 transcriptional 
pathwa}5 due to inappropriate pS3 
degradation 
.. Good prognosis: partially inactive 
p53 transcriptional pathwa}5 
.. Good prognosis: partially inactive 
p53 transcriptional pathway -Mth 
cell C}l:Ie progression delay 
.. Good prognosis: actIve TP53 
mediated cell C}l:Ie arrest pathway 
.. Poor prognosis: completely 
inactive p53 pathway -Mth TP53-
independent, inappropriate 
activation of p21 axis 
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6.3 Material and Methods 
6.3.1 Nottingham/Tenovus population study 
We studied a series of primary operable invasive BC derived from the Noningh.un Tenovus 
(NottinghamlTenovus) Primary Breast Carcinoma Series of women age :90 years, 
Nottingham Gty Hospital (1989-1999). Out of 1100 twnours consecutivelyaccmed, 990 
cases were included in this study based on the following inclusion criten.'1: ~ ~ complete 
clinical and therapeutic data available and n) successful analysis for all markers required for 
this study. The clinicopathological characteristics of our cohort are summarised in (Table 
6-2). Median follow up was 111 months (range 1 to 233). 
All patients received a standardised approach for diagnosis and treatment. Adjuvant 
systemic therapies (A 1) were scheduled on the basis of prognostic and predictive factor 
status including Nottingham Prognostic index (NPI) 137, oestrogen receptor-IX (ER-oc) status, 
and menopausal status. Patients within the good prognostic group (NPI :::;3.4) did not 
receive AT. Hormonal therapy (HI) was prescribed to patients with ER-IX+ tumours and 
NPI scores of >3.4 (moderate and poor prognostic groups). Pre-menopausal patients 
within the moderate and poor prognostic groups were candidates for CMF 
(Cyclophosphamide, Methotrexate, and S-FlourouraciI) chemotherapy; and patients with 
ER-IX + tumour were also offered Hr. Conversely, postmenopausal patients with moderate 
or poor NPI and ER-IX + were offered Hr, while ER-IX- patients received CMF if fit. 
Exploratory subgroup analysis of the p53 pathway surrogates was also performed in LN 
negative cases vs. LN positive cases, AT untreated cases vs. AT-treated cases and in ER+ 
high risk patients (NPI >3.4) who received Hr vs. Hr naive cases. 
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Table 6-2: Oinicopathological characteristics of the NottinghamlTenovus and 
RMHIBreakthrough series 
Variable NottinghamlTenovus Series RMH/Breakthmugh Series 
n=990 n.245 
nit Cases (%) nit Cases (%) 
Menopausal status 984 
Pre-menopausal 388 (39) NA 
Postmenopausal 596(61) NA 
Iwnoyr h i s t o l o ~ i c a l l ~ m ! k k 983 240 
Gl 150 (15) 23 (10) 
G2 294 (30) 69 (29) 
G3 539 (55) 148 (62) 
Lymph node stage 984 237 
Negative 601(61) 38 (35) 
Positive 383(39) 154(65) 
Survival·· 949 244 
Alive and ~ n n 567 (60) 179 
Dead from disease 297 (31) 42 
Dead from other causes 85 (9)· NA ...... 
Adjyvant ~ l ' J t e m i ! ; ; themI'>: (AD 973 245 
No AT 377 (39) 0(0) 
Honnone therapy (HI) alone 382 (39) 0(0) 
Cl1emotherapyalone 182 (19) 53 (22) 
Honnone + chemotherapy 32 (3) 192 (78) 
Iwnoursize (!;m) 983 243 
II (:5 2) 576 (59) 127 (52) 
1'2 (>2.0-5) 394 (40) 100 (41) 
TI(>5) 13 '(1) 16 M 
.. Number of cases for which data were available . 
.... Survival data for NottinghamlTenovus senes were available for up to 20 years and for 
RMH'Breakthrough series for up to 10 years • 
........ : Deaths of causes other than breast cancer were censored at last follow up. 
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6.3.2 Validation study 
We used a series of 245 invasive breast carcinomas diagnosed and In.'Ulaged at the Royal 
Marsden Hospital and Breakthrough breast cancer research centre (IUvU-J/Breakthrough) 
between 1994 and 2000. Patients were selected on the basis of being eligible for therapeutic 
surgery and receiving standard anthracyt:line-based AT. All patients were prim.1rily treated 
with surgery followed by anthracyt:line-based chemotherapy. Hf was prescribed for 
patients with ER+ tumours (tamoxifen alone in 96.4% of the patients for the available 
follow-up period). Complete follow-up was avaibble for 244 patients, ranging from 0.5 to 
125 months (median ,. 67 months, mean - 67 months). The characteristics of this cohort 
are described elsewhere 107 and summarised in (Table 6-2). 
6.3.3 Survival data 
Survival data including breast cancer specific survival (BCSS) time, disease-free survival 
(DFS), development of loco-regional and distant metastases (OM) was maintained on a 
prospective basis. BesS was expressed as the number of months from diagnosis to the 
occurrence of Be rebted-death. DFS was defined as the number of months from diagnosis 
to the occurrence of local recurrence (LR), local LN reL'lpse or DM rebpse. DM-free 
survival (MFS) was defined the number of months from diagnosis to the occurrence of OM 
relapse. 
6.3.4 Immunohistochemical assay 
In both series, tumours were arrayed in tissue micro arrays (IMAs) constructed with 2 
replicate 0.6 mm cores from the centre and periphery of the tumours for each In.1rker 
which were considered to be sufficiently representative. The 1MAs were 
immunohistochemically profiled for a panel of antibodies including p53 and some of its 
transcriptional targets {e.g. MDM2, MDM4, Bcl2 and p21}. Details of antibodies, antigen 
231 
0upter6 
retrieval, immunohistochemical methods and some results of the above 
immunohistochemical analyses have already been reported elsewhere 87,104,106, 107, 138 and are 
summarised in (Table 6-3). A cut-off value for each marker was selected as previous 
published 87, 100, 102, 104, 105, 106, 107, 138, \39 and was confinned by testing the different values 
against outcome at 10 years using Cox regression. Positive and negative (omission of the 
primary antibody and IgG-matched serum) controls were included in each nul. 
In NottinghamlTenovus series, HER-2 expression was assessed according to the new 
/\SeDl CAP guidelines 109 by using IHC and fluorescence in situ hybridisation ( F I S ~ ; ;
FISH was performed for HER-2 IHC score 2 + cases using a HER-2 and a centromere 17 
(CEPl7) specific probe {Vysis, 11, USA}, according to the supplier's instructions as 
previously described in chapter 3. 
For the 1MA constructed with cases from RMHIBreakthrough, immunohistochemistry 
was performed with antibodies raised against the following markers: ER, progesterone 
receptor (PR) , HER-2, EGFR, G. 5/6, Ck 14, Ck 17, Cyt:lin D1, KI67, p53, and 
topoisomerase II IX, as reported elsewhere 107, 138. 1MA sections were also subjected to 
chromogenic in situ hybridisation ( a S ~ ~ with SpotLight probes for COlD!, M Y ~ ~
HER2, TOP2A, and chromosome 8-centromere as previously reported 138. The 
immunohistochemical and aSH scoring was performed by at least 2 observers who were 
blinded to the results of the patients' outcome in two different settings for each marker. 
There was substantial to excellent intra-observer and inter-observer agreements (k :>0.6; 
Cohen's kappa and multi-rater kappa tests, respectivel0 
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Table 6-3: Primary antibodies, clone, source, optimal dilution and scoring system used for each 
immunohistochemical marker 
Antibody Oone Soun:e Dilution Distribution Cut-offs R I : ~ ~
Mouse MAb D07 Novocastra 1: 50 Nuclear >10% (neg.uive) 87, 102, 
anti p53 1 ( ) " 2 0 0 o ~ ~ 104-107 
>20% (High) 
Aftinity pwlfied IHGOOI08 Beth}i Labs 1:250 Nuclear 0% (negative) 183 
rabbit anti- < I - 2 0 % 0 0 ~ ~
HdrnXIMDM4 >20% 
( o v e ~ x p ~ s s i o n ) )
Mouse MAb IBIO Novocastra 1:50 Nuclear 2:10% 182 
anti-MDM2 ( o v e ~ x p ~ s i o n ) )
Mouse MAb 124 Dako-C)tomation 1:100 C)topIasm >10% (positive 87, 104, 
anti-Bc12 106, 107 
BRCAI MSllO Oncogen Research 1:150 Nuclear <25% (negative) 87, 102, 
104, 
106, 107 
Rabbit MAb Y170 Abeam 1:100 Nuclear <25% (negative) 102,104 
anti-AlM >75% 
Mouse MAb EAI0 Abeam 1:25 Nuclear 2: 10% (positive) 104, 
anti-21 106, 
107,139 
Mouse MAb SX53G8 Dako-C)tomarion 1:50 Nuclear 2: 10% (positive) 104, 
anti-27 106. 107 
Mouse MAb Vim3B4 Dako-C)tomation 1:250 C)toplasm 2: 10% (positive) 104,106 
anti-vimentin 
Rabbit anti-Bax Pol)Clonal Abeam 1:1000 C)toplasm 2: 10% (positive) 106 
Mouse MAb 105 Dako-C)tomarion 1:200 Nuclear 2:3 (positive) 87, 104, 
anti-ER-IX 107 
Mouse MAb PgR Dako-C)tomarion 1:150 Nuclear 2:3 (positive) 87, 104, 
anti-PR 107 
Mouse MAb 31G7 Zymed 1:50 Membrane o or + 1 (negative) 104,107 
anti-EGFR +2 or +3 
(positive) 
Mouse MAb 1lO02 Novocastra 1:40 C)toplasm 2:10% (positive) 87. 104, 
anti-CXl4 107 
Mouse MAb DS/161B4 Cl1emicon 1:60 C)toplasm 2: 10% (positive) 87, 104, 
anti-CXS/6 107 
Mouse MAb E3 Dako-C)tomarion 1:100 C)toplasm 2: 10% (positive) 107 
anti-CXl7 
Mouse MAb OCIO Dako-C)tomation 1:100 C)toplasm 2: 10% (positive) 87,104 
anti-CXla 
Rabbit pol)Clonai Dako-C)tomation 1:100 Membrane See text 104, 
antihuman 107,109 
HER-2 




MouseMAb KiSl D Dako- 1:150 Nuclear! >25% (positive) 107,138 
TOP2A C}1:omation ~ o p l a s m m
All sections were pre-treated with microwave antigen retrieval using 0.1% citrate buffer (PH 6) except 
for HER-2 (no pre-treatment) and EGFR (pre-treated with protease for 10 minutes). 
MDM2: mwine double minute 2, MDM4: murine double minute 4, A1M: ataxia telangiectasia 
mutated; BRCAl: Breast cancer 1, ER: oestrogen receptor, PR; progesterone receptor, Ck 
cytokeratin, EGFR; epidermal growth factor, TOP2A; Topoisomerase II alpha, MAb: Monoclonal 
antibody. 
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6.3.5 Statistical analysis 
Data management and analysis were perfOlmed using both SPSS software (SPSS, version16 
OUcago, IL) and STATA software (STATA, version 10, StataCOlp LP, Texas, USA). 
Where appropriate, Pearson's Chi-square, Fisher's exact, x2 for trend, Student's t and 
ANOV As one way tests were used.. Gunulative swvival probabilities were estimated using 
the Kaplan-Meier method and differences between survival rates were tested for 
significance using the log-rank test. Multivariate analysis for swvival was performed using 
the Cox hazard modeL The proportional hazards assumption was tested using standard log-
log plots. When appropriate, variables were assessed in univariate analysis as a continuous 
and categorical variable and the two models were compared using an appropriate likelihood 
ratio test. Hazard ratios (HR) and 95% confidence intervals (95% a) were estimated for 




6.4.1 Clinical significance of p53 protein expression 
Only 220/990 (22%) and 33/180 (18%) of NottingharnlTenovus and RMHIBreakthrough 
cases; respectively, showed positive p53 protein expression (p53 +) which was strongly 
associated (p <!l.OOl) with unfavourable clinicopathological parameters including high LN 
stage, high grade, large tumour size, HER-2 overexpressionl HER·2 gene amplification, 
basal-like phenotype (ER-/HER-2- with 00+ or Ck14+ or EGFR+), and triple-negative 
phenotype (ER-/PgR-/HER-2-). Moreover, in both NottingharnlTenovus and 
RMHIBreakthrough series, p53 + was associated with reduced BCSS, DFS and MFS Oog-
rank test; p<D.OOOl; (Figure 6-2). However, in multivariate Cox regression analysis 
including validated markers associated with outcome, p53 was no longer an independent 
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Figure 6·2: Kaplan-Meier survival curves of cases from both the NoninghamiTenovus (left 
upper and lower) and the RMHIBreakthrough series (right upper and lower) stratified according 
to negative and positive p53 expression. . 
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Table 6-4: Multivariate analysis using Cox regression in NottinghamlTenovus patients' whole 
cohort 




Nottingham/Tenovus' whole cohort (n=990) 
L ) I D ~ h h no!k stag; 3.3E-15* 6.2E-15* 
Negative 1 1 
Positive (1-3 nodes) 1.7 (1.3-2.3) 1.3 (1.1-1.7) 
Positive (>3 nodes) 4.7 (3.3-6.8) 3.9 (2.8-5.5) 
H i s t o I Q g i ~ a l l : r : l d e e 0.001* 
Grnde1 1 1 0.298 
Grade 2 1.4 (0.76-1.6) 1.02 (0.7-1.5) 
Grade 3 2.3 1.2-3.9 1.25 0.8-1.9) 
Size 1.2 1.1-1.4 0.007* 1.2 ( 1.1-1.3 0.01* 
p53( +) 1.3 0.9-1.7 0.105 1.3 1.0-1.7 0.091 
Bcl2 (-) 1.5 1.1-2.0 0.010" 1.3 1.1-0' 0.01* 
MDM4(-) 3.8 2.1-6.6 4.7E-6* 2.7 1.8-4.0 1.3E-S* 
MDM2{-) 1.0 1.0-1.1 0.365 1.0 1.0-1.1 0.263 
Oestrogen receptor(-) 1.4 0.9-2.0 0.110 1.6 1.1-2.2 0.007* 
Progesterone receptor{-) 1.1 0.8-1.6 0.513 1.0 0.8-1.6 0.841 
HER-2( +) 1.9 1.4-2.7 2.0E-4* 1.9 1.4-2.6 1.6E-4* 
CkS/6( +) 1.3 0.9-1.8 0.159 1.6 1.2-2.3 0.002* 
"Statistically significant 
MDM2: murine double minute 2; MDM4: murine double minute; HER-2; Human epidennal growth 
factor receptor 2; Ck cytokeratin 
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6.4.2 Clinical outcome of p53 transcription pathway status 
By exploring clinicopathological significance of the main p53 transcription pathways 
(MDM4, MDM2, Bcll and p21) with regard to p53 protein expression, BC patients were 
stratified into 6 statistically prognostic groups (BesS: log rank 135, p- 1.4E-27 and DFS: 
log-rank test 102.7, p-1.4E-20) that ranged from excellent to extremely poor {Figures 6-3, 
6-4 and 6-5). The robustness of this model was further confinned in RMHIBreakthrough 
series Oog-rank test; BesS: p<o.00009, DFS: p=O.00003 and MFS: p-o.00002). Our 
exploratory a n a l ~ e s s revealed that the subclassification of BC according to p53 pathway six 
prognostic subgroups was proven to be significant in LN-negative patients (BesS: log rank 
79.5, p-l.lE-15 and DFS: log rank 60.1, p=4.6E-12), in LN-positive patients [BesS: log 
rank 60.9, p-7.9E-12 and DFS: log rank 4.3, p-3.0E-81 patients who received no AT 
(BesS: log rank 59.7, p-1.4E-ll andDFS: log rank 47.3, p= 4.9E-9) and those with ER+ 
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Figure 6-5: Kaplan- Meier survival curves of breast carcinoma specific survival of p53 positive 
breast carcinoma patients stratified according to the p53 transcription pathways. 
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6.4.3 Prognostic independence of functional p53 
transcription pathway phenotypes 
To assess the prognostic importance of these phenotypes, a multivariate Cox regression 
model was used to compare their perfOlmance to the validated prognostic indicators 
assessed in NottingharnlTenovus whole patient cohort (Table 6-5) and in patients who 
had not received any AT subgroup (data not shown). We found the functional status of pS3 
transcription pathways remained significantly associated with BesS, DFS (Table 6-5) and 
:MFS (data not shown). A similar analysis of the RMHIBreakthrough cohort revealed 
similar results for BesS (p=o.002), DFS (p==o.003) and MFS (p-Q.OOOS). 
Table 6-5: O>x regression model showing independence of p53 transcription pathways as a 
prognostic factor in Nottingham/Tenovus whole breast carcinoma series 
Breast Can:inoma Specific Disease Free survival 
Factor Survival (Bess) (DFS) 
10 yealS 10 yealS 
HR (095%) P HR (095%) P 
~ ~ r i p t i o n n opathwayys 7.6E-12* 2.4E-9* 
P53±/MDM4+/MDM2±/Bc12±/p21± 1.0 1.0 
P53-/MDM4-/MDM2+Bc12+/p21± 2.7 (1.3-5.4) 2.4 (1.4-3.9) 
P53 ±/MDM4-/MDM2-/Bc12 +p21 ± 3.3 (1.S-5.9) 2.2 (1.>3.4) 
P53±/MDM4-/MDM2-/Bc12-/p21- 3.6 (2.0-6.7) 2.8 (1.S-4.3) 
P53-/MDM4-/MDM2+/Bc12-/p21- 4.6 (21-10.0) 2.5 (1.3-4.7) 
P53+/MDM4-/MDM2+/Bc12-/p21- 8.5 (3.9-18.4) 5.9 (3.0-11.2) 
P53-/MDM4-/MDM2-/BcI2-/p21- 6.1 (3.0-12.4) 3.7 (2.1-6.5) 
P53 +/MDM4-/MDM2-/Bc12-1 p21- 14.7 (6.6-32.n 8.6 (U-168) 
LWJph node (L!S)stag\: 1.6E-15* 8.4E-15* 
Negative 1.0 1.0 1 
1-3 INs + 1.8 (1.4-2.4) 1.3 (1.1-1.7) 
>3lNs+ 4.9 (3.4-7.0) 3.9 (2.S-5.4) 
Histological gm<k; 0.001* 0.272 
Gradel 1.0 1.0 
Grade 2 1.3 (0.7-2.5) 1.0 (0.7-1.6) 
Grade 3 2.2 11.2-3.9 1.2 0.S-1.9 
Size 1.3 (1.1-1.54) 0.001* 1.2 1.1-1.4 0.003* 
HER-2overexpression 1.8 1.3-2.6 0.001* 1.9 1.3-2.6 2.5E-4* 
Ck5/6+ 1.3 0.9-1.9 0.108 1.6 1.2-2.2 0.001* 
Eostrogen receptor(-) 1.2 a.S-1.S 0.273 1.6 1.2-2.3 0.009* 
Progesterone receptor(-) 1.1 0.S-1.6 0.476 0.9 0.7-1.2 0.772 
.. Statistically significant 
MOM2: murine double minute 2; MDM4: murine double minute; HER-2: Human epidermal growth 
factor receptor 2; Ck: c}'tokeratin 
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To examine the prognostic significance of functional status of p53 transcriptional status, the 
p53 transcription pathway phenotypes were reduced into 2 groups according to the status 
of p53 transcriptional activity a) active/partially inactive p53 transcription pathway 
including p53 ±/MDM4 +/MDM2 ±/Bc12 ±I p21 ±, p53 +/MDM4-/MDM2 +/Bc12 +/ 
p21± and p53±/MDM4-/MDM2-/Bc12+/p21± and b) completely inactive p53 
transcriptional p a t h w a ~ ~ (two or more inactive p53 transcriptional pathways) including 
p53 ±/MDM4-/MDM2-/Bc12-/ p21-, p53-/MDM4-/MDM2 +/Bc12-/p21-, p53 ±I 
MDM4-/MDM2-/Bc12-/p21+ and p53+/MDM4-/MDM2+/Bcl2-/p21-. In both 
NottinghamlTenovus and RMHIBreakthrough series, the completely inactive p53 
pathways showed a worse clinical outcome (Figure 6-6). Our exploratory a n a l ~ e s s
revealed that the function status of p53 transcription pathway i.e. active/partially inactive 
vs. completely inactive pathway status, was proven to be significant in LN-negative patients 
(BesS: log rank 5.4, p-2.3E-13 and DFS: log rank 36.5, p-1.5E-9), in LNpositive patients 
[BesS: log rank 311, p-2.3E-8 and DFS: log rank 192, p ~ 1 . 3 E - 5 ] , , patients who received 
no AT (BesS: log rank 40.9, p- 1.7E-10 and DFS: log rank 32.7, po. 1.9E-8) and those 
with ER+ tumours who received lIT (p<o.0001) (BesS: log rank 13.6, po. 22E-4 and 
DFS: log rank 1422, p- 1.6E-4). 
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Figure 6·6: Kaplan-Meier survival curves (breast cancer specific survival and disease free survival) 
of both NottinghamlTenovus (left upper and lower) and RMHIBreakthrough series (right upper 
and lower) stratified according to partially inactive and completely inactive p53 pathways. 
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In Multivariate Cox regression a n a l ~ i s s of NottinghamlTenovus series, the completely 
inactive p53 transcriptional status was an independent predictor of outcome and more 
powerful than NPI for BesS: HR 2.64,95% (0) 1.61-4.32, p<!l.OOOl vs. HR 1.71, 95% 
(0) 1.36-2.15, p <0.0001, respectively, and for DFS: HR 1.93, 95% (0) 1.33-2.81, p ... O.OOl 
vs. HR 1.46, 95% (0) 1.22-1J5, P <0.0001, respectively. These profiles were also shown to 
be independent predictors of BesS, DFS and MFS in the RMHIBreakthrough series 
(Table 6-6). 
Table 6-6: Cox regression model showing independence of the status of p53 transcription 
activity as a prognostic factor in RMHIBreakthrough series 
Breast Can:inoma Specific Surviv.tl (BesS) Disease Free surviv.tl 
Factor 10 )'tars (OFS) 
10 )'tars 
HR (095%) P HR (095%) P 
f53 tr.lmiption activity 0.001* 0.007* 
Aaivel paniaJly inactioc 1 1 
Completely inactive 4.5 (1.856-11.017) 2.5 (1.286-
4.806) 
l,)'!!!ph node (LN) stage 0.008* 0.002* 
Negative (LN-) 1 1 
Positive (l.N+) 4.2 (1.457-12.275) 3.4 (1.539-
7.317) 
Histolo2ical2rnde 0.5 0.161 
Gradel 1 1 
Grade 2 1.04 (0.114-9.455) 2.7 (0.337-
21.749) 
Grade 3 1.9 (0.23S-15.281) 4.8 (0.62S-
36.140) 
Size 1.01 (0.997-1.035) 0.096 1.02 (1.002- 0.0261 
1.028) 
II- Statistically significant 
We investigated the clinical outcome of 274 early stage small ttunours Oymph node negative 
with primary tumour size :5 2cm) from NottinghamlTenovus patients who did not receive 
any AT. Consistent with the findings in the other groups, patients with partially inactive p53 
p a t h w a ~ ~ had a longer BesS and DFS than cases with completely inactive p53 pathways 
[(HR 3.97, 95% (0) 2.2-7.2, p<o.OOOl) and (HR 2.5, 95% (0) 1.6-3.9, P <0.0001), 
respectively], (Figure 6-7). 
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Figure 6-7: Kaplan- Meier survival curves of disease-free survival of breast small early stage 
breast cancer patients who received no systemic adjuvant therapy stratified according to pS3 
transcription pathways. 
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6.4.4 Clinicopathological features of different TP53 
transcription pathway phenotypes 
MDM4 overexpression phenotypes 
It was fOWld that 182/990 (18%) of NottinghamlTenovus cohort showed MDM4-
overexpression which was associated with favot.I.rnble clinicopathological features: ER +, 
PR +, AR +, small tumour size, and low grade with longer BCSS and DFS (data not shown). 
Tumours with MDM4-overexpression displayed high expression of MDM2, Bc12, p21 and 
low Bax indicating partially inactive p53 transcription pathways. BCSS, DSF and MFS of 
cases with concomitant expression of p53 and MDM4 (pS3 +/MDM4 +/MDM2 ±/Bc12 ±I 
p21±) were similar to those with a p53-/MDM4+ phenotype, despite the fact that the latter 
group included a higher percentage of ER+ (p<!),0001) and low grade cancers (p<o.0001). 
MDM2 overexpression phenotrPes 
MDM2-overexpression was fOWld in 26% (253/990) and 37% (661180) of Nottingham! 
Tenovus and RMHIBreakthrough patients; respectively and according to co-expression of 
p53, MDM4, Bc12 and p21, it comprised a blend of 4 different phenotypes with statistically 
significant different clinical outcomes ranging from excellent to very poor prognosis 
(p <0.0001): 
a) Patients with tumours displaying a concomitant MDM4+ and MDM2+ phenotype 
(p53-/MDM4+/MDM2+/Bc12±/p21±) showed both excellent prognosis and 
favot.I.rnble clinicopathological characteristics indistinguishable from those with 
exclusive MDM4-overexpression (p53 ±/MDM4 +/MDM2-/Bc12 ±I p21 ±). 
b) Patients with tumours harbouring p53-/MDM4-/MDM2+/Bc12+1 ±p21 had a 
relatively good outcome, however compared with those from the p53-/MDM4+ 
247 
p53 trancriptiorul ~ ~ in /must wrer 
IMDM2 +/Bc12 ±I p21 ± subt}pe, these patients showed a relatively worse prognosis 
(HR. ... 2.5, p=O.Ol), higherfrequencyof ATM- (p-o.004) and ER+ (p-o.OOl) 
c) Patients with p53-/MDM4-/MDM2+/bc12-/p21- tumours displayed a shorter BCSS 
and DFS (Fig 3) and more aggressive clinicopathological features compared to the p53-
IMDM4-/MDM2 +/Bc12 +1 p21 ± subgroup. 
d) Patients with p53+/MDM4-/MDM2+/Bc12-/p21- tumours showed clinico-
pathological features identical to those with (p53+/MDM4-/MDM2-/Bc12-/p21-) and 
those (p53-/MDM4-/MDM2+/Bc12-/p21-). 
Negative MDM4 and MDM2 phenotypes 
When Nottingham/renovus cases with concomitant negative expression of MDM4 and 
MDM2 were stratified according to p53, Bc12 and p21 co-expressions, 6 phenot}pes with 4 
clinical outcomes ranged from moderate to extremely poor prognosis were identified: 
a) Patients with p53-/MDM4-/MDM2-/Bc12 +1 p21 ± tumours were characterised by 
moderate prognosis and favourable clinicopathological features. Compared to patients 
with tumours displaying a p53-IMDM4-/MDM2-/Bc12-/p21- phenotype, they were 
associated with slightly better prognosis (HR.=1.47, p-o.035), lower histological grade 
(p<o.OOOl), higher frequency of ER+ (p4l0001), PR+ (p<O.OOOl), and lower 
frequency of basal-like (p<O.OOOl) and triple-negative phenot}pes (P<o.OOOl). 
However compared to those with p53-/MDM4-/MDM2+/Bc12+/p21± tumours, 
these cases displa;ed shorter BCSS, DFS, and OM fonnation times (data not shown), 
higher grade (p<O.OOOl), and higherfrequencyof Bax- (p=o.OOl). 
b) Patients with p53 +IMDM4-/MDM2-/Bc12 +1 p21 ± cancers showed clinical outcomes 
and pathological features similar to those with p53-/MDM4-/MDM2-/Bc12+/p21± 
tumours. 
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c) Patients with tumours displaying a p53-/MDM4-/MDM2-/Bcl2-/p21- phenotype 
were associated with poor prognosis and unfavow-able clirUcopathological features, 
similar to those with p53-/MDM4-/MDM2+/Bcl2-/p21- tumours. 
d) Patients with p53+/MDM4-/MDM2-/Bcl2-/p21- tumours, apart from the 
clinicopathological features of high p53 protein expression (i.e. higher grade, ER-, 
basal-like and triple negative phenotypes), showed poor clinical outcome and 
clinicopathological features similar to those present in subjects with p53-/MDM4-
IMDM2+/Bcl2-/p21- tumours. 
MDM4-/MDM2-/Bc12- phenotype with high p21 
Patients with p53-/MDM4-/MDM2-/Bcl2-1 p21 + tumours, compared to those with a p53-
IMDM4-/MDM2-/Bcl2-/p21- phenotype, showed shorter BQ;S, DFS and MFS (HR; 1.6, 
95% Q; 1.04-2.56, p...o.03) but a higher frequency of ER+ (p..a.009). On the other hand, 
patients with p53+/MDM4-/MDM2-/Bcl2-/p21+ tumours, compared to those with a 
p53+/MDM4-/MDM2-/Bcl2-/p21- phenotype, showed a shorter BQ;S: HR 3.0,95% a 
1.7-5.5, p-1.6E-4; DFS: HR 2.4,95% a 1.4-42, p==O.002 and MSF: HR 2.4,95% a 1. 4-
4.3, p-o.003 and higher frequency of HER-2 overexpression (p=().Q04). On the other 
hand, when compared to those with a p53-/MDM4-/MDM2-/Bcl2-/p21+ phenotype, 
patients with p53+/MDM4-/MDM2-/Bcl2-/p21+ tumours were significantly more 
frequently ER- (p=O.OOl). 
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6.4.5 Clinicopathological features of completely inactive p53 
transcription pathway 
In both NottinghamlTenovus and RMHIBreakthrough series, a completely inactive p53 
transcription pathway was strongly associated with aggressive clinicopathological features, 
active progressive cell cycle and more genetic instability including: higher grade, Bcl2-, p2i-
, p27-, ER-, PR-, p53+, HER·2 gene amplification, EGFR+, basal 0+, higher 
proliferation index (MIB1), basal-like phenotype and triple negative (Tables 6-7 and 6-8). 
In the NottinghamlTenovus series completely inactive p53 transcription pathways were 
associated with larger tumour size and higher LN stage as well; it should be noted that 
similar associations were not expected to be found in the RMHIBreakthrough series, given 
that it is composed solely of patients who received AT. 
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Table 6-7: The clinicopathological features of p53 transcription pathways status in 
NottinghamlTenovus series 
P53 tr.tnscrietion status 
ktive/partiaUy inactive Completely inactive 
Yari1lhk (N=608) (N-382) )(2 
n(%) n(%) 
Pvalut 
~ ~ 3.7E-I0" 
~ 2 c m m 391 (65) 185 (48) 
>2cm 213 (34.5) 186(49) 
>5cm 3 (0.5) 10 (3) 
Lll!JI1h nod!: Stag!: 
Negative 376 (63) 225 (59) 1.2E-S" 
Positive (1-3 nodes) 






Gradel 134 (21) 16 (4) 
Grade 2 224 (37) 70 (18) 
Grade 3 244 41 295 '(78) 
Bax( +) 186 34 76 26 0.024 
p27( +) 169 36 45 IS 1.5E-IO" 
BRCAI -) 113 14 127 27 2.8E-9* 
ATM - 243 40 229 60 0.01· 
MIBI +) 274 45 302 79 1.2E-14" 
ER(+ 503 86 155 42 2.2E-14* 
PgR( +) 423 (72 159 28 3.2E-14* 
0<18(- 295 81 23 2.0E-14* 
CO/6( +) 55 9) 111 29) 1.4E-14* 
EGFR(+) 92 16 96 27 1.0E-04· 
Vimentin 23 5 79 25 1.7E-14* 
HER-2(+) 28 5 85 12 5.0E-7" 
Basal like phenotype 37 6 110 (31) 1.6E-14* 
Triple negative phenotype 47 8 161 44 UE-14* 
,. Statistically significant .. MDM2: murine double minute 2; MDM4: murine double minute 4; ATM: 
ataxia telangiectasia mutated; BRCA1: Breast cancer 1; ER: oestrogen receptor; PgR; progesterone 
receptor; G: cytokeratin; EGFR: epidermal growth factor; TOP2A: Topoisomerase II alpha. 
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Table 6-8: The clinicopathological features of p53 transcription p a t h w a ~ ~ status in 
RMHIBreakthrough series 
P53 trnnsc r i ~ t i o n n status 
Active! partiaUy inactive G>mpletely 
~ ~ (N .. 124) inactive }(1 
n(%) (N-56) 
n(%) p 
~ ~ 0.310 
::;2cm 68 (55) 27 (48) 
>2cm 46 (37) 27 (49) 
>Scm 9 (7), 2 (4) 
L):IDl"!h OOd!; Stag!; 
Negative 44 (37) 23 (42) 0.616 
Positive 74 (63) 32 (38) 
~ ~ 0.002* 
Gradel 15 (12) 3 (6) 
Grade 2 42 (35) 7 (13) 
Grade 3 65 (53 44 81 
MIBI( +) 52 (49 25 79 5E-4* 
ER(+) 115 (93) 3359 1.7E-7* 
PgR( +) 105 (85) 30 54 2.6E-5" 
Ck5/6( +) 5 4) 13 25 0.00017* 
EGFR +) 43) 13 23 7.0E-04* 
HER-Z( +) 13 10) 13 25 0.036 
HER-2 aSH ( +) 119 15 28 0.002* 
TOP2A(+) 58 481 35 66 0.032 
TOP2AaSH 7 6 10 11 0.012 
Basal like phenotype 5 4 15 ?Z <0.0001* 
Triple negative phenotype 6 5 14 25 0.0002* 
* Statistically significant. MDM2: murine double minute 2; MDM4: murine double minute 4; ATM: 
ataxia telangiectasia mutated; BRCA1: Breast cancer 1; ER: oestrogen receptor; PR: progesterone 
receptor; G: cytokeratin; EGFR: epidennal growth factor; TOP2A: Topoisomerase II alpha. 
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6.4.6 P53 status and clinical outcome in specific AT settings 
To evaluate whether the status of p53 transcription pathways had different clinical 
outcomes in specific AT settings, we investigated the clinical outcome and survival ,of 
NottingharnlTenovus high risk patients (n ... 309; N P I ~ 3 . 4 4 and ER+) and (n-152; NPI 
~ 3 . 4 4 and pre-menopausal) who had received fIT and CMT-chemotherapy, respectively. 
We found that patients with phenotypes (p53±/MDM4-/MDM2±/Bcl2-/p21-) and 
(P53±/MDM4-/MDM2-/Bcl-/p21±) had the w o ~ t t outcomes in both fIT and CMT-
chemotherapy treated patients (data not shown). Completely inactive p53 pathways in Hf 
or CMF-chemotherapy treated patients had shorter B ~ S : : HR 2.1, 95% a 1.4-3.1, 
p-2.5E-4 and HR 1.8,95% a Ll-2.9, p=O.026, respectively; DFS: HR 2.0, 95% a 1.4-
2.8, p-2.0E-4 and HR 1.8, 95% a Ll-2.6, p=O.Ol, respectively and MFS: HR 2.0,95% a 
1.4-2.9, p ... 3E-4 and HR 1.7,95% a 1.03-2.8, p=O.036, respectively. 
Poor outcome of completely inactive p53 pathways was confirmed in the 
RMHIBreakthrough series which comprised patients that were unifonnly treated with 
anthracydine-based chemotherapy (Figure 6-7) 
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6.5 Discussion 
Almost half of human cancers retain the wild-type TP53, indicating that the p53 pathway is 
inactivated by alterations other than mutation of TP53 itself 102 177-181,227-228-232. Specific post-
translational modifications of p53 18, 225, 234 and p53-independent pathways, e_g., ER-oc, can 
modulate the activity of p53 transcription pathways 230-232, 234, 235. Depending on which 
upstream or downstream components within the p53 transcription pathway have been 
inactivated 177-180, variable patterns of association between p53 and a number of other co-
regulatory and effectors proteins have been documented 177-180. In our study we identified 
two main groups of p53 transcription pathways regardless of the expression level of p53: (a) 
Low risk, with active or partially inactive p53 transcription pathway, which was associated 
with tumours displaying favourable clinical parameters, good prognosis and had 
significantly longer BCSS and DFS after AT. (b) High risk, with completely inactive p53 
pathway, which was characterised by aggressive clinicopathological features, and poor 
prognosis and worse outcome even in AT treated patients. 
6.5.1 Completely inactive p53 transcription pathways 
As we have shown, regardless of p53 levels, patients with a completely inactive p53 pathway 
exhibited unfavourable clinicopathological features, bad prognosis and poor outcome even 
after receiving AT. In a high proportion of cancers lacking point missense TP53 mutation, 
p53 function could be inactivated by other recognised mechanisms including null 
mutations, MDM2 overexpression, and! or alteration of p53 upstream regulators or co-
activator (e.g. ATM) 102,177-180,228-231. For instance, 11'53 null mutations destabilise p53 and 
are associated with absence of p53, MDM2, Bcl2 and p21 228. In leukaemia, A1M has been 
shown to represent an alternative regulatory mechanism of p53 inactivation 102, 177-180. In 
agreement with others 102,177-180, we found 60% of tumours with completely inactive p53 
were associated with loss of A1M expression suggesting that A1M in Be may be a 
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mechanism by which a subset of BC escape tumour suppressor effect of p53 237, 238. 
Another transcriptional co-activator for p53 is BRCAl which stimulates transcription from 
p53-resposive promoters 102,88,180. We found down-regulation of BRCA1 was statistically 
significant (p <0.0001) associated with the completely inactive p53 transcription pathways 
implying a further mechanism wherebyp53 function can be inhibited in Be 
Genetic changes at chromosome 17, where the TP53 gene is located, have been reported in 
more than half of high grade BC 225. We found complete inactivation of TP53 was 
associated with HER-2 amplification. 
6.5.2 Qinical outcome diversity of MDM2/MDM4 over-
expression and TP53/ER crosstalk networks 
The significance of MDM2/MDM4 with respect to cancer diagnosis and prognosis is 
unclear, as MDM2-overexpression has been reported to correlate with poor prognosis in 
some studies, however with good prognosis in others 179-180,234,235,238. Indeed we found that 
MDM2-overexpression is associated with both good and poor prognosis depending on co-
expression of p53, MDM4, Bcl2 and on p53 dependent and independent trans activation of 
MDM2 177-180, 234, 235, 238. In Be, overexpression of multip1e-MDM2-mRNA variants has 
been shown to correlate with absence of ER and worse outcome, while MDM2 
overexpression occurred only in ER-cx positive tumour, and was associated with a 
favourable prognosis 234. In addition, in tissue culture model systems, it was shown that ER-
dependent p53- independent trans activation of MDM2 in Be cells could only occur in cell 
lines that were ER-cx positive 234,235. Moreover, it has been suggested that Bcl2, 'p21 and 
MDM2 could be p53-independent direct transcriptional regulators of ER 179,180,230,231,234,235, 
238. In accord with these observations, we found MDM2-overexpression subgroups with 
better prognosis were associated with normal expression of p53 and strongly correlated to 
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the presence of Bc12 and ER, while those with poor prognosis were strongly correL'lted to 
presence of abnonnal p53 protein expression and absence of Bc12, p21, and ER. 
6.5.3 P21 expression and worst prognosis and poorest 
outcome after AT treatment 
We found that p21+ expression is not significantly associated with clinical outcome in Be 
although p21 + was statistically associated with recognised favourable clinical parameters, 
However, tumours with p53-/MDM4-/MDM2-/p21 + and p53 +/MDM4-/MDM2-/Bc12-
/ p21 + phenotypes, despite showing ER + and HER-2 overexpression, respectively, had a 
very poor prognosis and the shortest BesS and DFS after receiving AT, in agreement with 
previous reports on p21 239-242, In fact, data from colorectal cancer cell lines and mouse 
model studies showed that the growth and proliferation of tumour cells with intact 
checkpoint functions (P21 +1 +) was not inhibited by y-irradiation and chemotherapeutic 
agents, whereas y-irradiation and chemotherapeutic agents successfully inhibited 
checkpoint-deficient cells (P21-1-) 240-242, In addition, recent anti-sense studies for p21 gene 
suppression reported increased radio- and chemo-responsiveness by enhancing apoptosis 
243, Moreover, critical roles of p21 in concomitantly preventing apoptosis, promoting 
growth "cell swvival promoter", and inducing differentiation through direct interaction 
with ER, have been recently proposed 243, 
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6.5.4 p53 transcriptional pathways, clinical outcome and 
management of Be 
In BO, only a minority of patients « 20% of those receiving AT fully benefit from the 
different AT regimens currently in use) 178. 180.227.232.235. There is evidence to support a 
critical role of wild-type p53 in modulating response to AT by triggering either apoptosis or 
cell-cycle arrest 177·227.232, 233 .However, it is also obvious that AT may also induce apoptosis 
via a p53-independent pathway 239 and mutant TP53 has been claimed to interlere with pS3-
independent apoptosis 239. In agreement with other studies 177·227. 230. 232. 233 we have 
demonstrated a significantly worse BesS and DFS in completely inactive p53 transcription 
pathways with either high or low p53 expression patients even after receiving AT compared 
with patients with active or partially inactive 1P53 pathways. Moreover, we fotmd that 
patients with p53-independent p21 and MDM2 expression given AT had the shortest BesS 
and DFS especially ER-oc+ patients. This studywas not designed to address the associations 
between p53 transcriptional pathways and response to adjuvant endocrine or chemo-
endocrine therapies. However, our results provide evidence to suggest that the ftmctional 
status of p53 transcriptional pathways may predict the clinical outcome in both adjuvant 
systemic therapy naive patients and those treated with endocrine and! or chemotherapy 
(both CMF and anthracydine-based regimens). In fact, interlering with p53 itself or its 
downstream transcriptional targets may provide interesting therapeutic avenues. Preclinical 
gene therapy studies have demonstrated that TP53 correction results in an increase in radio-
and chemotherapy sensitivity and anti-tumourigenic effects in several types of cancer 177.180, 
224-232.233.235.243 • 
In conclusion, we have shown that the phenotypic patterns of pS3 ftmctional 
transcriptional pathways rather than its expression alone provide important infonnation 
about Be behaviour. 11Us infonnation may assist routine clinical decision-making. Future 
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studies testing the prognostlC and predictive infonnation provided by the p53 







Frequently, pathologists observe a collection of co-existing subtle pathological changes in 
breast tissue samples representing 'precursor' lesions. These are challenging to identify, 
classify and manage and currently, we cannot predict which precursors will progress into 
cancer but studies suggest that between 1-30% lesions develop a subsequent tumour event 
within a decade 66-67, In contrast to the 'stochastic' model of ontogenesis where 
transfonnation results from random mutations and subsequent clonal selection, tumours 
nowadays are considered as a multi-step clonal disease and its progression is dependent on 
acquiring funher genetic and epigenetic changes in stern or progenitor cells that lead to 
activation of oncogenes and inactivation of tumour suppressor genes 27-30, 62-65, In this 
m o d e ~ ~ cancer originates in tissue stern or progenitor cells probably through dysregulation 
of self-renewal pathways and this leads to expansion of this cell population that may 
undergo additional genetic and epigenetic change 62, The nature of these genetic and 
epigenetic changes, and the type of progenitor they target, probably contribute to the 
cellular heterogeneity found in tumours 27-30,62-65. The transfonnation of progenitor cells 
into neoplastic cells may be due to deregulation of self-renewal, differentiation, membrane 
transport activity, telomerase activity and anti-apoptotic pathways, contributing to the ability 
to migrate and metastasis 27-30, 62-65, Currently the precise cell lineages involved in the 
earliest oncogenic events involving progenitor transformation and formation of precursor 
lesions en route to invasive cancer development is not known. 
In this study, we noticed that some columnar cell lesions associated with ADH and! or 
/ ALH progressed into invasive special types of breast cancer: TC, 1LC and! or classic ILC, 
within 5-15 years of the initial diagnosis, This led us to conduct a comprehensive 
morphological study to determine the morphological features and frequency of putative 
precursor lesions involved in the development of some pure forms of special types of 
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breast carcinoma. Subsequently, we identified the LNGBN family that included low 
nuclear grade breast carcinoma (LNGBC; tubular, cribrifonn, low grade invasive ductal 
carcinoma, classical lobular and tubulolobular carcinoma) and their putative precursor 
lesions; low nuclear grade intraepithelial neoplasia (flat epithelial atypia (FE A) , atypical 
ductal hyperplasia (ADH), low/intermediate ductal carcinoma in situ (DOS), and lobular 
neoplasia (LN), (Figure 7-1). 
Low Nuclear Grade Breast Neoplasia Family (LNGBN) 
. - - - - - - - - - - - . . : : - - - - . . . . : : : . . . . ~ _ _L L L - - , L . L . L . . . ~ G G
Invasive low nuclear grad 
carcinoma __ 
CCL; columnar cell lesions, LN; Lobular neoplasia; ADH, atypical ductal hyperplasia; 
ICC; invasive cribriform carcinoma, TC; tubular carcinoma; TLC; tubulolobular carcinoma; IDC; 
invasive ductal carcinoma, ,ILC; ; invasive lobular carcinoma 
Figure 7-1: Evolutionary pathways of low grade breast neoplasia. 
Our proposal of the LNGBN family was based on a) remarkable similarity of nuclear and 
cytoplasmic morphological features between putative precursor lesions and either co-
existing or consequent invasive carcinoma, b) intimate topographic distribution of putative 
precursor lesion and either co-existing or consequent invasive carcinoma, c) the significant 
coexistence of colwnnar cell lesions (CCLs), lobular neoplasia (LN) and atypical ductal 
hyperplasia/low grade ductal carcinoma in situ (ADHIlow grade DOS) with invasive 
tubular carcinoma (to, tubulolobular carcinoma (flO and classic invasive lobular 
carcinoma (ILO. 
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In addition, we proposed an evolutionary and biological pathway for the development of 
this LNGBN family in which FEA was considered as the very early non obligate common 
precursor (Figures 7-2 and 7-3). 
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Figure 7-2: The proposed e ~ o l u t i o n a r y y pathway of tubular carcinoma based on histological 
evidence and the reported genenc changes for each stage 
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Reported Genetic Changes Reference 
Lesions Loss Gain 
CCC -16q -llq +16p +19 71 
! -19q +7 +20 +15q 
CCH -16q -17p -llq +11p 71 
! -22 -lp +7 -12q 
-17p +llp +Iq 71 
-22 +7 
-12q 
-17p -llq +17q lq +12q 60 
-22q 
-lp Iq +Iq 81 12q -13q +3q 
-llq +2p 82 
ILC -17p -19p +lSp +lq +19 60 
-22q -11q +7p Iq +2Oq 
-12q - 1 ~ ~ 17q +3q 81 
-1 82 17q 
Figu re 7-3: The proposed evolutionary pathway of ILC through CCLs based on histological 
evidence and the reponed genetic changes for each stage 
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Moreover, we have used custom-made tissue m i c r o a r r a ~ ~ (1MA) with high throughput 
immWlohistochemistry (IHq to investigate a panel of biological markers including cell 
cyt:le, proliferation, apoptosis, differentiation and hormone receptor regulator proteins and 
a number of putative tumour suppressor and oncogenes. We fOWld that CXl.., ADHilow 
grade DOS, LN and invasive low grade breast cancers have remarkably similar 
immWlophenotype and that this phenotype is very similar to the immWlophenotype of the 
luminal "N' BC subclass and is distinct from that have seen in high grade breast cancers. 
The luminal "N' BC subclass is characterised by high expression of oestrogen and 
progesterone receptors, MUC1, ESA, and luminal 0<. (0<.18/19). 
Interestingly, we fOWld the low nuclear grade breast neoplasia family have a similar 
immWlohistochemistry profile to the ER + luminal restricted progenitor cell of normal 
terminal duct lobular units and we speculated that the LNGBN family may arise from the 
luminal restricted progenitors cell (ER +/MUG 1 +) which might further acquire stochastic 
genetic and epigenetic hits that lead to the activation of the luminal 'A' pathway. This 
finding supports our proposal of FEA as a common non-obligate precursor of TC and 
ILC Furthermore, the similarity in the genomic profiles of CCl..s and matched co-existing 
DOS, LN and invasive carcinoma supports a common cell of origin of this family and 
gives substantial evidence that cx::::r...s are the early non-obligate precursor lesions of tubular 
and invasive lobular carcinoma. 
We fOWld one of the remarkable features of the LNGBN family is low mitotic index and 
positive expression of cell cyt:le/ apoptosis regulator Bel2. Subsequently, we hypothesised 
that a grading system based on balance between "M" as a proliferation marker and "Bc12" 
as a cell cyt:le/ apoptosis regulator would be capable of accurately discriminating between 
low and high-grade tumours and providing a more objective and clinically valuable measure 
of tumour grade with prognostic significance for invasive Be in general and particularly in 
moderately differentiated, small and ER negative (ER-) cancers. Moreover, we fOWld the 




outcome in a population based cohort and accurately reclassified most patients with NGS-
G2 including (97%) of ILC into low grade like risk group. In addition, we showed the 
WBc12 balance identified prognostically significant subgroups in a cohort of patients 
treated with adjuvant anthracydine-based chemotherapy. The use of this simple and 
objective grading system instead of NGS may help improve on the prognostic ability of 
current a1goritluns for clinical decision making (e.g. NPI). We further substantiate our 
proposal of LNGBN by exploring the genomic profiles of matched coexisting different 
members of LNGBN family which exhibit remarkable genetic similarity. 
Whether the LNGBN family is a continuum through which BC progresses or merely the 
end point of distinct genetic pathways has been debated 140 and it is not clear whether BC 
develops along two (low versus high) or three (grades 1 versus 2 versus 3) distinct pathways. 
In our study, the large majority of BC cases exhibited one of the two predominant fonus 
comprising either LNGBC (NGS-Gl-like) or high (NGS-G3-like) grade biological 
characteristics, supporting the view that genetic pathways model of grade origin. Tumours 
with intermediate prognosis (NGS-G2-like) may arise as homogenous tumours that are 
truly border-line between low and high grade, or could rather reflect a heterogeneous 
composition of both low and high grade cell types. Genetic analysis of LNGBC suggests 
the majority of these tumours constitute the end of the spectrum of low grade cancers as 
they often harbour deletion of 16q and gains of lq 56,60,81. 
Interestingly, we found that LNGBN tumours were either arrested in GO/ G 1 or out-of-cell 
cycle state. On the contnuy, most basal-like and HER-2+ tumours were NGS G3-like 
phenotypes with actively progressive cell cycle suggesting that once BC committed to a 
specific evolutionary/molecular pathway, progression or cross over to other high grade 
pathways would be an unlikely biological phenomenon. However, the progression of a 
subset of low nuclear grade with luminal phenotype to luminal BC of a higher grade would 
be a possibility 140 and could be due to acquisition of additional genetic or epigenetic 
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aberrations (e.g., p53 mutation, gene amplifications), which lead to more active cell cycle 
progression and increased proliferation. 
Meta-analysis of publicly available gene expression data 176-191 demonstrated that most of 
the genes associated with histological grade are involved in cell cycle regulation, 
proliferation, apoptosis, p53 and ER signalling networks. In agreement with these studies, 
we found that most candidate genes associated with the progression of LNGBN family are 
involved in cell cycle regulation, proliferation, apoptosis, p53 and ER signalling networks. 
Among these genes was MDM4 which demonstrated independent prognostic and 
predictive power. In addition our results showed that these markers faithfully identified 
women who were at high risk and who would benefit from different protocols of adjuvant 
therapy. Given that most of the LNGBN family have wild type p53, and both functional 
MDM4 and Bcl2 expression among p53 network led us to hypothesise that the functional 
status of p53 transcriptional pathways rather than p53 immunohistochemistry expression 
alone could accurately determine clinical outcome in a large unselected series of Be and in a 
series of patients uniformly treated with adjuvant anthracycline-based chemotherapy. 
Depending on which upstream or downstream components within the p53 transcription 
pathway have been inactivated. We recognized variable patterns of association between 
p53 and a number of other co-regulatory and effectors proteins. Subsequently, we 
identified two main groups of p53 transcription pathways regardless of the expression level 
of p53: (a) Low risk, with active or partially inactive p53 transcription pathway, which was 
associated with tumours displaying favourable clinical parameters, good prognosis and had 
significantly longer BesS and DFS after AT; (b) High risk, with completely inactive p53 
pathway, which was characterised by aggressive clinicopathological features, poor prognosis 





Conclusions, Key Points an Future Directions 
The co-localisation of lobular neoplasia (ALH and LaS) with columnar cell lesions, and 
ADH and low grade Das has been described with or without coexisting low grade or 
lobular invasive breast cancer. The concept of a low grade Owninal A type) family of 
invasive, in situ and their precursors is emerging which includes colwnnar cell lesions, 
ADHI low grade DOS, lobular neoplasia, classical lobular carcinoma and tubular 
carcmoma 
In sununaxy, our results suggest that 1) Tubular and lobular breast carcinoma arise as 
members of a low nuclear grade breast neoplasia (lNGBN) family, 2) <Xl..s are early 
non-obligate precursor components of the LNGBN family, 3) The common cell of origin 
of the LNGBN family may be the oestrogen receptor-alpha (ER IX) positive luminal 
restricted progenitor cell (ER+/MUC1 + cells) of the terminal duct lobular unit that might 
acquire stochastic genetic and epigenetic changes that eventually lead to activation of the 
luminal "N' pathway, 4) Cydin D1 and MDM4 are oncogenes that potentially lead to 
activation of the luminal pathway and progression of the LNGBN family,S) An alteration 
of E-cadherin (CDH1) appears to be a secondary event resulting in the characteristic 
morphology of both in situ and invasive lobular lesions, 6) A biological grading s ~ t e m m
dependent on the baL'Ulce between Bcl2 protein expression and mitotic figures could 
accurately reclassify patients with intennediately differentiated, small early stage or ER IX 
negative breast cancers into two groups of low versus high risk of death and recurrence, 
and 7) The functional status of p53 transcriptional p a t h w a ~ ~ can be assessed using 
immunohistochemistry protein expression of p53 downstream! regulator genes to 




The future goals should focus on the development of a rapid, inexpensive prognostic 
clinical test that will provide individual risk infonnation for all women diagnosed with 
precursor lesions. 
This goal could be achieved bytransbting our genomic findings into a series of actions: 
a) Substantiate our study findings of genomic change, using aCGH, in LNGBN by 
including additional candidate precursor lesions in a larger patient cohort with and 
without invasive cancer 
b) Validate our genomic findings by detecting gene amplification/loss usmg 
fluorescence in situ hybridisation (FISH) and chromogenic in situ hybridisation 
(asH) techniques, with emphasis on ERI p53 cross-talk network and cell cycle 
regulator genes 
c) Investigate the prone chromosomal sites on lq and 16q; other molecum 
techniques such as spectral karyotyping (SKY), muti-colour chromosome painting, 
second generation sequencing or methylation strategies could be used to 
investigate reciprocal translocation, subtle rearrangements or demethylation. 
d) Develop a biological mouse model to investigate how human breast cells acquire 
cancer properties and to provide insights for predicting the development of 
tumour fonnation. A transplantable human-mouse (HIM) xenograft model could 
be generated from patients' precursor lesions before treatment as described by 
Ding et al 2010 244. Cells from precursor lesions could be implanted into the 
mamrruuy fat pad and be followed up to detect further host-tumour pathological 
changes using histologic technique. Full genome sequencing could be perfonned 
on precursor lesions, early passage xenograft (harvested 101 days after initial 
engrafting into the mouse host) and for any new pathological lesions. DNA 
samples could be prepared from the aforementioned stages for sequence coverage 
and mutation analysis. In addition, these xenografts could be used to knockout 
one or more of the suppressor genes e.g. E-cadherin, p53 etc and! or to induce 
overexpression of one of the oncogenes to examine their role in the progression of 
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breast cancer. In addition, we can use one of the breast cancer transgenic mouse 
models whose oncogenesis is induced by expression of the polyoma virus middle T 
oncoprotein (PyMf mice) to analyze a series of biomarkers that are associ .. lted with 
the progression of human breast cancers especially cell proliferation, 
differentiation, and apoptosis markers. Previously, this mouse model of mammary 
carcinogenesis proved to represent a powerful model to study the causal events 
associated with tumour progression to malignancy and metastasis245 
e) Clinical follow up of cases diagnosed with exclusive CXl..s without ADHI ALH to 
estimate the risk of progression 
f) Develop routine immunohistochemical (IHq techniques to identify candidate 
markers which would assist in decision-making regarding the clinical management 
of preinvasive lesions and would tell a woman diagnosed with one of the precursor 
lesions about her risk of future breast cancer. 
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